U.S. patent application number 11/289656 was filed with the patent office on 2006-06-01 for ppar active compounds.
Invention is credited to Dean R. Artis, Ryan Bremer, Prabha N. Ibrahim, Byunghun Lee, Jack Lin, Shenghua Shi, Chao Zhang, Rebecca Zuckerman.
Application Number | 20060116416 11/289656 |
Document ID | / |
Family ID | 36565676 |
Filed Date | 2006-06-01 |
United States Patent
Application |
20060116416 |
Kind Code |
A1 |
Lin; Jack ; et al. |
June 1, 2006 |
PPAR active compounds
Abstract
Compounds are described that are active on at least one of
PPAR.alpha., PPAR.delta., and PPAR.gamma., which are useful for
therapeutic and/or prophylactic methods involving modulation of at
least one of PPAR.alpha., PPAR.delta., and PPAR.gamma..
Inventors: |
Lin; Jack; (Hercules,
CA) ; Artis; Dean R.; (Kensington, CA) ;
Ibrahim; Prabha N.; (Mountain View, CA) ; Zhang;
Chao; (Moraga, CA) ; Zuckerman; Rebecca;
(Alameda, CA) ; Bremer; Ryan; (Albany, CA)
; Shi; Shenghua; (San Diego, CA) ; Lee;
Byunghun; (Marina, CA) |
Correspondence
Address: |
FOLEY & LARDNER LLP
P.O. BOX 80278
SAN DIEGO
CA
92138-0278
US
|
Family ID: |
36565676 |
Appl. No.: |
11/289656 |
Filed: |
November 29, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60631746 |
Nov 30, 2004 |
|
|
|
60715312 |
Sep 7, 2005 |
|
|
|
Current U.S.
Class: |
514/414 ;
514/419; 548/465; 548/495 |
Current CPC
Class: |
A61P 9/12 20180101; A61P
9/10 20180101; A61P 25/02 20180101; A61P 27/12 20180101; C07D
209/36 20130101; A61P 1/04 20180101; C07D 209/40 20130101; A61P
15/08 20180101; A61P 9/04 20180101; A61P 43/00 20180101; A61P 17/06
20180101; A61P 35/00 20180101; A61P 37/06 20180101; A61P 3/04
20180101; A61P 3/10 20180101; A61P 11/06 20180101; A61P 25/16
20180101; A61P 3/06 20180101; A61P 27/02 20180101; C07D 209/30
20130101; A61P 17/00 20180101; A61P 25/28 20180101; A61P 11/00
20180101; A61P 29/00 20180101 |
Class at
Publication: |
514/414 ;
514/419; 548/465; 548/495 |
International
Class: |
A61K 31/405 20060101
A61K031/405; C07D 403/02 20060101 C07D403/02 |
Claims
1. A compound having the chemical structure ##STR30## all salts,
prodrugs, tautomers and stereoisomers thereof, where in: U, V, W,
X, and Y are independently N or CR.sup.5, wherein no more than two
of U, V, W, and Y are N; Q is --O--, --S--, or --NR.sup.51--;
R.sup.1 is selected from the group consisting of optionally
substituted carboxyl and a carboxylic acid isostere; R.sup.2 is
selected from the group consisting of hydrogen, optionally
substituted lower alkyl, optionally substituted lower alkenyl,
optionally substituted lower alkynyl, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.2R.sup.9; R.sup.3 and
R.sup.4 are independently selected from the group consisting of
hydrogen, optionally substituted lower alkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl, or R.sup.3 and R.sup.4 may
combine to form a 3-7-membered optionally substituted
mono-cycloalkyl or 3-7-membered optionally substituted
mono-heterocycloalkyl; R.sup.5at each occurrence is independently
selected from the group consisting of hydrogen, halo, optionally
substituted lower alkyl, optionally substituted lower alkenyl,
optionally substituted lower alkynyl, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --OR.sup.10, --SR.sup.11,
--NR.sup.12R.sup.13, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.nR.sup.9; R.sup.6 and
R.sup.7 at each occurrence are independently selected from the
group consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted lower alkenyl, provided, however, that when
R.sup.6 and/or R.sup.7 are optionally substituted lower alkenyl, no
alkene carbon thereof is bound to nitrogen, optionally substituted
lower alkynyl, provided, however, that when R.sup.6 and/or R.sup.7
are optionally substituted lower alkynyl, no alkyne carbon thereof
is bound to nitrogen, optionally substituted cycloalkyl, optionally
substituted cycloalkylalkyl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkylalkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, and optionally substituted
heteroaralkyl, or R.sup.6 and R.sup.7 together with the nitrogen to
which they are attached form a 5-7 membered optionally substituted
heterocycloalkyl or 5-7 membered optionally substituted heteroaryl;
R.sup.8 at each occurrence is independently selected from the group
consisting of optionally substituted lower alkyl, optionally
substituted lower alkenyl, provided, however, that when R.sup.8 is
optionally substituted lower alkenyl, no alkene carbon thereof is
bound to --C(Z)-, optionally substituted lower alkynyl, provided,
however, that when R.sup.8 is optionally substituted lower alkynyl,
no alkyne carbon thereof is bound to --C(Z)-, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, and --OR.sup.11; R.sup.9 at each
occurrence is independently selected from the group consisting of
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.9 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
--S(O).sub.n--, optionally substituted lower alkynyl, provided,
however, that when R.sup.9 is optionally substituted lower alkynyl,
no alkyne carbon thereof is bound to --S(O).sub.n--, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl; R.sup.10 at each occurrence
is independently selected from the group consisting of hydrogen,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.10 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
oxygen, optionally substituted lower alkynyl, provided, however,
that when R.sup.10 is optionally substituted lower alkynyl, no
alkyne carbon thereof is bound to oxygen, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --C(Z)R.sup.8, and
--C(Z)NR.sup.6R.sup.7; R.sup.11 at each occurrence is independently
selected from the group consisting of hydrogen, optionally
substituted lower alkyl, optionally substituted lower alkenyl,
provided, however, that when R.sup.11 is optionally substituted
lower alkenyl, no alkene carbon thereof is bound to S or O,
optionally substituted lower alkynyl, provided, however, that when
R.sup.11 is optionally substituted lower alkynyl, no alkyne carbon
thereof is bound to S or O, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkylalkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, and optionally substituted
heteroaralkyl; R.sup.12 and R.sup.13 at each occurrence are
independently selected from the group consisting of hydrogen,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.12 and/or R.sup.13 are
optionally substituted lower alkenyl, no alkene carbon thereof is
bound to nitrogen, optionally substituted lower alkynyl, provided,
however, that when R.sup.12 and/or R.sup.13 are optionally
substituted lower alkynyl, no alkyne carbon thereof is bound to
nitrogen, optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl,
--C(Z)R.sup.8, --C(Z)NR.sup.6R.sup.7, --S(O).sub.2R.sup.9, and
--S(O).sub.2NR.sup.6R.sup.7, or R.sup.12 and R.sup.13 together with
the nitrogen to which they are attached form a 5-7 membered
optionally substituted heterocycloalkyl or 5-7 membered optionally
substituted heteroaryl; R.sup.51 is selected from the group
consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted lower alkenyl, provided, however, that when
R.sup.51 is optionally substituted lower alkenyl, no alkene carbon
thereof is bound to nitrogen, optionally substituted lower alkynyl,
provided, however, that when R.sup.51 is optionally substituted
lower alkynyl, no alkyne carbon thereof is bound to nitrogen,
optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl,
--C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8, --S(O).sub.2NR.sup.6R.sup.7,
and --S(O).sub.2R.sup.9; n is 1 or 2; and Z is O or S.
2. The compound of claim 1, wherein U, W, X, and Y are CH, and V is
CR.sup.5.
3. The compound of claim 2, wherein R.sup.5 is selected from the
group consisting of hydrogen, halo, lower alkyl optionally
substituted with 1-3 fluoro, lower alkylthio optionally substituted
with 1-3 fluoro, and lower alkoxy optionally substituted with 1-3
fluoro.
4. A compound having the chemical structure ##STR31## all salts,
prodrugs, tautomers and stereoisomers thereof, wherein: Q is --O--,
--S--, or --NR.sup.51--; R.sup.1 is selected from the group
consisting of optionally substituted carboxyl and a carboxylic acid
isostere; R.sup.3 and R.sup.4 are independently selected from the
group consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, and optionally substituted heteroaralkyl,
or R.sup.3 and R.sup.4 may combine to form a 3-7 membered
optionally substituted mono-cycloalkyl or 3-7 membered optionally
substituted mono-heterocycloalkyl; R.sup.5 is independently
selected from the group consisting of hydrogen, halo, optionally
substituted lower alkyl, optionally substituted lower alkenyl,
optionally substituted lower alkynyl, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --OR.sup.10, --SR.sup.11,
--NR.sup.12R.sup.13, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.nR.sup.9; R.sup.6 and
R.sup.7 at each occurrence are independently selected from the
group consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted lower alkenyl, provided, however, that when
R.sup.6 and/or R.sup.7 are optionally substituted lower alkenyl, no
alkene carbon thereof is bound to nitrogen, optionally substituted
lower alkynyl, provided, however, that when R.sup.6 and/or R.sup.7
are optionally substituted lower alkynyl, no alkyne carbon thereof
is bound to nitrogen, optionally substituted cycloalkyl, optionally
substituted cycloalkylalkyl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkylalkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, and optionally substituted
heteroaralkyl, or R.sup.6 and R.sup.7 together with the nitrogen to
which they are attached form a 5-7 membered optionally substituted
heterocycloalkyl or 5-7 membered optionally substituted heteroaryl;
R.sup.8 at each occurrence is independently selected from the group
consisting of optionally substituted lower alkyl, optionally
substituted lower alkenyl, provided, however, that when R.sup.8 is
optionally substituted lower alkenyl, no alkene carbon thereof is
bound to --C(Z)-, optionally substituted lower alkynyl, provided,
however, that when R.sup.8 is optionally substituted lower alkynyl,
no alkyne carbon thereof is bound to --C(Z)-, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, and --OR.sup.11; R.sup.9 at each
occurrence is independently selected from the group consisting of
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.9 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
--S(O).sub.n--, optionally substituted lower alkynyl, provided,
however, that when R.sup.9 is optionally substituted lower alkynyl,
no alkyne carbon thereof is bound to --S(O).sub.n--, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl; R.sup.10 at each occurrence
is independently selected from the group consisting of hydrogen,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.10 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
oxygen, optionally substituted lower alkynyl, provided, however,
that when R.sup.10 is optionally substituted lower alkynyl, no
alkyne carbon thereof is bound to oxygen, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --C(Z)R.sup.8, and --C(Z)NR.sup.6
R.sup.7; R.sup.11 at each occurrence is independently selected from
the group consisting of hydrogen, optionally substituted lower
alkyl, optionally substituted lower alkenyl, provided, _however,
that when R.sup.11 is optionally substituted lower alkenyl, no
alkene carbon thereof is bound to S or O, optionally substituted
lower alkynyl, provided, however, that when R.sup.11 is optionally
substituted lower alkynyl, no alkyne carbon thereof is bound to S
or O, optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, and optionally substituted heteroaralkyl;
R.sup.12 and R.sup.13 at each occurrence are independently selected
from the group consisting of hydrogen, optionally substituted lower
alkyl, optionally substituted lower alkenyl, provided, however,
that when R.sup.12 and/or R.sup.13 are optionally substituted lower
alkenyl, no alkene carbon thereof is bound to nitrogen, optionally
substituted lower alkynyl, provided, however, that when R.sup.12
and/or R.sup.13 are optionally substituted lower alkynyl, no alkyne
carbon thereof is bound to nitrogen, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --C(Z)R.sup.8, --C(Z)NR.sup.6R.sup.7,
--S(O).sub.2R.sup.9, and --S(O).sub.2NR.sup.6R.sup.7, or R.sup.12
and R.sup.13 together with the nitrogen to which they are attached
form a 5-7 membered optionally substituted heterocycloalkyl or 5-7
membered optionally substituted heteroaryl; R.sup.15 is selected
from the group consisting of hydrogen, halo, cyano, nitro,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, optionally substituted lower alkynyl, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--OR.sup.10, --SR.sup.11, --NR.sup.12R.sup.13,
--C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8, --S(O).sub.2NR.sup.6R.sup.7,
and --S(O).sub.nR.sup.9, attached to A at any available atom to
produce a stable compound; R.sup.16 at each occurrence is
independently selected from the group consisting of halo, lower
alkyl, hydroxyl, lower alkoxy, thiol, and lower alkylthio, wherein
lower alkyl and the lower alkyl chains of lower alkoxy and lower
alkylthio are optionally substituted with fluoro, hydroxyl, lower
alkoxy, thiol, or lower alkylthio, provided, however, that any
substitution on lower alkoxy or lower alkylthio does not result in
O or S bound to the carbon that is bound to the alkoxy oxygen of
substituted lower alkoxy or the alkylthio sulfur of substituted
lower alkylthio; A is a monocyclic or bicyclic ring selected from
the group consisting of cycloalkyl, heterocycloalkyl, aryl or
heteroaryl; L is selected from the group consisting of
--CR.sup.52R.sup.53--, --C(Z)NR.sup.56--, --C(Z)-,
--S(O).sub.2NR.sup.56--; and --S(O).sub.2--, attached to A at any
available atom to produce a stable compound; R.sup.51 is selected
from the group consisting of hydrogen, optionally substituted lower
alkyl, optionally substituted lower alkenyl, provided, however,
that when R.sup.51 is optionally substituted lower alkenyl, no
alkene carbon thereof is bound to nitrogen, optionally substituted
lower alkynyl, provided, however, that when R.sup.51 is optionally
substituted lower alkynyl, no alkyne carbon thereof is bound to
nitrogen, optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl,
--C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8, --S(O).sub.2NR.sup.6R.sup.7,
and --S(O).sub.2R.sup.9; R.sup.52 and R.sup.53 are independently
selected from the group consisting of hydrogen, halo, lower alkyl,
hydroxyl, lower alkoxy, thiol, and lower alkylthio, wherein lower
alkyl and the lower alkyl chains of lower alkoxy and lower
alkylthio are optionally substituted with fluoro, hydroxyl, lower
alkoxy, thiol, lower alkylthio or --NR.sup.54R.sup.55, provided,
however, that the substitution of lower alkoxy or lower alkylthio
does not result in O, N, or S bound to the carbon that is bound to
the lower alkoxy oxygen or the lower alkylthio sulfur; R.sup.54 and
R.sup.55 are independently lower alkyl or combine with the nitrogen
to which they are attached to form a 5-7 membered heterocycloalkyl
or 5-7 membered heterocycloalkyl substituted with halo, hydroxyl,
lower alkoxy, or lower alkyl; R.sup.56 is selected from the group
consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted lower alkenyl, provided, however, that when
R.sup.56 is optionally substituted lower alkenyl, no alkene carbon
thereof is bound to nitrogen, optionally substituted lower alkynyl,
provided, however, that when R.sup.56 is optionally substituted
lower alkynyl, no alkyne carbon thereof is bound to nitrogen,
optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, and optionally substituted heteroaralkyl; m
is 0, 1, or 2; n is 1 or 2; and Z is O or S.
5. The compound of claim 4, wherein A is monocyclic aryl or
monocyclic heteroaryl.
6. The compound of claim 5, wherein: R.sup.15 is selected from the
group consisting of optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, --OR.sup.10, --SR.sup.11,
--NR.sup.12R.sup.13, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.nR.sup.9.
7. The compound of claim 6, wherein: one of R.sup.6 and R.sup.7,
one of R.sup.12 and R.sup.13, R.sup.8, R.sup.9, R.sup.10, and
R.sup.11 are selected from the group consisting of optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, and optionally substituted
heteroaryl.
8. The compound of claim 7, wherein R.sup.3 and R.sup.4 are H, and
Q is O.
9. A method for treating a subject suffering from or at risk of a
disease or condition for which PPAR modulation provides a
therapeutic benefit, comprising administering to said subject an
effective amount of a PPAR modulator according to claim 1.
10. The method of claim 9 wherein said compound is approved for
administration to a human.
11. The method of claim 9 wherein said disease or condition is a
PPAR-mediated disease or condition.
12. The method of claim 9 wherein said disease or condition is
selected from the group consisting of obesity,-overweight
condition, hyperlipidemia, associated diabetic dyslipidemia and
mixed dyslipidemia, mixed dyslipidemia, hypoalphalipoproteinemia,
Syndrome X, Type II diabetes mellitus, Type I diabetes,
hyperinsulinemia, impaired glucose tolerance, insulin resistance, a
diabetic complication of neuropathy, nephropathy, retinopathy or
cataracts, hypertension, coronary heart disease, heart failure,
hypercholesterolemia, inflammation, thrombosis, congestive heart
failure, cardiovascular disease, atherosclerosis, arteriosclerosis,
hypertriglyceridemia, eczema, psoriasis, cancer, pain, conditions
associated with the lung and gut, regulation of appetite and food
intake in subjects suffering from disorders such as obesity,
anorexia bulimia and anorexia nervosa, neurodegenerative diseases,
Alzheimer's disease, Parkinson's disease, amyotrophic lateral
sclerosis, vitiligo, uveitis, Sjogren's disease, pemphigus
foliaceus, inclusion body myositis, polymyositis, dermatomyositis,
scleroderma, Grave's disease, Hashimoto's disease, chronic
graft-versus host disease, rheumatoid arthritis, inflammatory bowel
syndrome, Crohn's disease, multiple sclerosis, infertility, asthma,
chronic obstructive pulmonary disease, and macular
degeneration.
13. A method for treating a subject suffering from or at risk of a
disease or condition for which PPAR modulation provides a
therapeutic benefit, comprising administering to said subject an
effective amount of a PPAR modulator according to claim 4.
14. The method of claim 13 wherein said compound is approved for
administration to a human.
15. The method of claim 13 wherein said disease or condition is a
PPAR-mediated disease or condition.
16. The method of claim 13 wherein said disease or condition is
selected from the group consisting of obesity, overweight
condition, hyperlipidemia, associated diabetic dyslipidemia and
mixed dyslipidemia, mixed dyslipidemia, hypoalphalipoproteinemia,
Syndrome X, Type II diabetes mellitus, Type I diabetes,
hyperinsulinemia, impaired glucose tolerance, insulin resistance, a
diabetic complication of neuropathy, nephropathy, retinopathy or
cataracts, hypertension, coronary heart disease, heart failure,
hypercholesterolemia, inflammation, thrombosis, congestive heart
failure, cardiovascular disease, atherosclerosis, arteriosclerosis,
hypertriglyceridemia, eczema, psoriasis, cancer, pain, conditions
associated with the lung and gut, regulatino of appetite and food
intake in subjects suffering from disorders such as obesity,
anorexia bulimia and anorexia nervosa, neurodegenerative diseases,
Alzheimer's disease, Parkinson's disease, amyotrophic lateral
sclerosis, vitiligo, uveitis, Sjogren's disease, pemphigus
foliaceus, inclusion body myositis, polymyositis, dermatomyositis,
scleroderma, Grave's disease, Hashimoto's disease, chronic
graft-versus host disease, rheumatoid arthritis, inflammatory bowel
syndrome, Crohn's disease, multiple sclerosis, infertility, asthma,
chronic obstructive pulmonary disease, and macular
degeneration.
17. A composition comprising: a pharmaceutically acceptable
carrier; and a compound according to claim 1.
18. A kit comprising a composition according to claim 17.
19. The kit of claim 18, further comprising a written indication
that said composition is approved for administering to a human.
20. The kit of claim 18, wherein said composition is approved for a
medical indication selected from the group consisting of obesity,
overweight condition, hyperlipidemia, associated diabetic
dyslipidemia and mixed dyslipidemia, mixed dyslipidemia,
hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus,
Type I diabetes, hyperinsulinemia, impaired glucose tolerance,
insulin resistance, a diabetic complication of neuropathy,
nephropathy, retinopathy or cataracts, hypertension, coronary heart
disease, heart failure, hypercholesterolemia, inflammation,
thrombosis, congestive heart failure, cardiovascular disease,
atherosclerosis, arteriosclerosis, hypertriglyceridemia, eczema,
psoriasis, cancer, pain, conditions associated with the lung and
gut, regulation of appetite and food intake in subjects suffering
from disorders such as obesity, anorexia bulimia and anorexia
nervosa, neurodegenerative diseases, Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, vitiligo,
uveitis, Sjogren's disease, pemphigus foliaceus, inclusion body
myositis, polymyositis, dermatomyositis, scleroderma, Grave's
disease, Hashimoto's disease, chronic graft-versus host disease,
rheumatoid arthritis, inflammatory bowel syndrome, Crohn's disease,
multiple sclerosis, infertility, asthma, chronic obstructive
pulmonary disease, and macular degeneration.
21. A composition comprising: a pharmaceutically acceptable
carrier; and a compound according to claim 4.
22. A kit comprising a composition according to claim 21.
23. The kit of claim 22, further comprising a written indication
that said composition is approved for administering to a human.
24. The kit of claim 22, wherein said composition is approved for a
medical indication selected from the group consisting of obesity,
overweight condition, hyperlipidemia, associated diabetic
dyslipidemia and mixed dyslipidemia, mixed dyslipidemia,
hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus,
Type I diabetes, hyperinsulinemia, impaired glucose tolerance,
insulin resistance, a diabetic complication of neuropathy,
nephropathy, retinopathy or cataracts, hypertension, coronary heart
disease, heart failure, hypercholesterolemia, inflammation,
thrombosis, congestive heart failure, cardiovascular disease,
atherosclerosis, arteriosclerosis, hypertriglyceridemia, eczema,
psoriasis, cancer, pain, conditions associated with the lung and
gut, regulation of appetite and food intake in subjects suffering
from disorders such as obesity, anorexia bulimia and anorexia
nervosa, neurodegenerative diseases, Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, vitiligo,
uveitis, Sjogren's disease, pemphigus foliaceus, inclusion body
myositis, polymyositis, dermatomyositis, scleroderma, Grave's
disease, Hashimoto's disease, chronic graft-versus host disease,
rheumatoid arthritis, inflammatory bowel syndrome, Crohn's disease,
multiple sclerosis, infertility, asthma, chronic obstructive
pulmonary disease, and macular degeneration.
Description
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional App.
No. 60/631,746, filed Nov. 30, 2004, and U.S. Provisional App. No.
60/715,312, filed Sep. 7, 2005, both entitled PPAR Active
Compounds, and both of which are incorporated herein by reference
in their entireties and for all purposes.
BACKGROUND OF THE INVENTION
[0002] The present invention relates to the field of modulators for
the family of nuclear receptors identified as peroxisome
proliferator-activated receptors.
[0003] The following description is provided solely to assist the
understanding of the reader. None of the references cited or
information provided is admitted to be prior art to the present
invention. Each of the references cited herein is incorporated by
reference in its entirety, to the same extent as if each reference
were individually indicated to be incorporated herein in its
entirety.
[0004] The peroxisome proliferator-activated receptors (PPARs) form
a subfamily in the nuclear receptor superfamily. Three isoforms,
encoded by separate genes, have been identified thus far:
PPAR.gamma., PPAR.alpha., and PPAR.delta..
[0005] There are two PPAR.gamma. isoforms expressed at the protein
level in mouse and human, .gamma.1 and .gamma.2. They differ only
in that the latter has 30 additional amino acids at its N terminus
due to differential promoter usage within the same gene, and
subsequent alternative RNA processing. PPAR.gamma.2 is expressed
primarily in adipose tissue, while PPAR.gamma.1 is expressed in a
broad range of tissues.
[0006] Murine PPAR.alpha. was the first member of this nuclear
receptor subclass to be cloned; it has since been cloned from
humans. PPAR.alpha. is expressed in numerous metabolically active
tissues, including liver, kidney, heart, skeletal muscle, and brown
fat. It is also present in monocytes, vascular endothelium, and
vascular smooth muscle cells. Activation of PPAR.alpha. induces
hepatic peroxisome proliferation, hepatomegaly, and
hepatocarcinogenesis in rodents. These toxic effects are not
observed in humans, although the same compounds activate
PPAR.alpha. across species.
[0007] Human PPAR.delta. was cloned in the early 1990s and
subsequently cloned from rodents. PPAR.delta. is expressed in a
wide range of tissues and cells with the highest levels of
expression found in digestive tract, heart, kidney, liver, adipose,
and brain. Thus far, no PPAR.delta.-specific gene targets have been
identified.
[0008] The PPARs are ligand-dependent transcription factors that
regulate target gene expression by binding to specific peroxisome
proliferator response elements (PPREs) in enhancer sites of
regulated genes. PPARs possess a modular structure composed of
functional domains that include a DNA binding domain (DBD) and a
ligand binding domain (LBD). The DBD specifically binds PPREs in
the regulatory region of PPAR-responsive genes. The DBD, located in
the C-terminal half of the receptor, contains the ligand-dependent
activation domain, AF-2. Each receptor binds to its PPRE as a
heterodimer with a retinoid X receptor (RXR). Upon binding an
agonist, the conformation of a PPAR is altered and stabilized such
that a binding cleft, made up in part of the AF-2 domain, is
created and recruitment of transcriptional coactivators occurs.
Coactivators augment the ability of nuclear receptors to initiate
the transcription process. The result of the agonist-induced
PPAR-coactivator interaction at the PPRE is an increase in gene
transcription. Downregulation of gene expression by PPARs appears
to occur through indirect mechanisms. (Bergen & Wagner, 2002,
Diabetes Tech. & Ther., 4:163-174).
[0009] The first cloning of a PPAR (PPAR.alpha.) occurred in the
course of the search for the molecular target of rodent hepatic
peroxisome proliferating agents. Since then, numerous fatty acids
and their derivatives, including a variety of eicosanoids and
prostaglandins, have been shown to serve as ligands of the PPARs.
Thus, these receptors may play a central role in the sensing of
nutrient levels and in the modulation of their metabolism. In
addition, PPARs are the primary targets of selected classes of
synthetic compounds that have been used in the successful treatment
of diabetes and dyslipidemia. As such, an understanding of the
molecular and physiological characteristics of these receptors has
become extremely important to the development and utilization of
drugs used to treat metabolic disorders.
[0010] Kota et al., 2005, Pharmacological Research 51: 85-94,
provides a review of biological mechanisms involving PPARs that
includes a discussion of the possibility of using PPAR modulators
for treating a variety of conditions, including chronic
inflammatory disorders such as atherosclerosis, arthritis and
inflammatory bowel syndrome, retinal disorders associated with
angiogenesis, increased fertility, and neurodegenerative
diseases.
[0011] Yousefet al., 2004, Journal of Biomedicine and Biotechnology
2004(3):156-166, discusses the anti-inflammatory effects of PPAR
.alpha., .gamma. and .delta. agonists, suggesting that PPAR
agonists may have a role in treating neuronal diseases such as
Alzheimer's disease, and autoimmune diseases such as inflammatory
bowel disease and multiple sclerosis. A potential role for PPAR
agonists in the treatment of Alzheimer's disease has been described
in Combs et al., 2000, Journal of Neuroscience 20(2): 558, and such
a role for PPAR agonists in Parkinson's disease is discussed in
Breidert et al. 2002, Journal of Neurochemistry, 82: 615. A
potential related function of PPAR agonists in treatment of
Alzheimer's disease, that of regulation of the APP-processing
enzyme BACE, has been discussed in Sastre et al. 2003, Journal of
Neuroscience 23(30):9796. These studies collectively indicate PPAR
agonists may provide advantages in treating a variety of
neurodegenerative diseases by acting through complementary
mechanisms.
[0012] Discussion of the anti-inflammatory effects of PPAR agonists
is also available in Feinstein, 2004, Drug Discovery Today.
Therapeutic Strategies 1(1):29-34 in relation to multiple sclerosis
and Alzheimer's disease; Patel et al., 2003, The Journal of
Immunology, 170:2663-2669 in relation to chronic obstructive
pulmonary disease (COPD) and asthma; Lovett-Racke et al., 2004, The
Journal of Immunology, 172:5790-5798 in relation to autoimmune
disease; Malhotra et al., 2005, Expert Opinions in Pharmacotherapy,
6(9):1455-1461 in relation to psoriasis; and Storer et al., 2005,
Journal of Neuroimmunology, 161:113-122 in relation to multiple
sclerosis.
[0013] This wide range of roles for the PPARs that have been
discovered suggest that PPAR.alpha., PPAR.gamma. and PPAR.delta.
may play a role in a wide range of events involving the
vasculature, including atherosclerotic plaque formation and
stability, thrombosis, vascular tone, angiogenesis, cancer,
pregnancy, pulmonary disease, autoimmune disease, and neurological
disorders.
[0014] Among the synthetic ligands identified for PPARs are
Thiazolidinediones (TZDs). These compounds were originally
developed on the basis of their insulin-sensitizing effects in
animal pharmacology studies. Subsequently, it was found that TZDs
induced adipocyte differentiation and increased expression of
adipocyte genes, including the adipocyte fatty acid-binding protein
aP2. Independently, it was discovered that PPAR.gamma. interacted
with a regulatory element of the aP2 gene that controlled its
adipocyte-specific expression. On the basis of these seminal
observations, experiments were performed that determined that TZDs
were PPAR.gamma. ligands and agonists and demonstrate a definite
correlation between their in vitro PPAR.gamma. activities and their
in vivo insulin-sensitizing actions. (Bergen &
Wagner,supra).
[0015] Several TZDs, including troglitazone, rosiglitazone, and
pioglitazone, have insulin-sensitizing and anti-diabetic activity
in humans with type 2 diabetes and impaired glucose tolerance.
Farglitazar is a very potent non-TZD PPAR-.gamma.-selective agonist
that was recently shown to have antidiabetic as well as
lipid-altering efficacy in humans. In addition to these potent
PPAR.gamma. ligands, a subset of the non-steroidal antiinflammatory
drugs (NSAIDs), including indomethacin, fenoprofen, and ibuprofen,
have displayed weak PPAR.gamma. and PPAR.alpha. activities. (Bergen
& Wagner, supra).
[0016] The fibrates, amphipathic carboxylic acids that have been
proven useful in the treatment of hypertriglyceridemia, are
PPAR.alpha. ligands. The prototypical member of this compound
class, clofibrate, was developed prior to the identification of
PPARs, using in vivo assays in rodents to assess lipid-lowering
efficacy. (Bergen & Wagner, supra).
[0017] Fu et al., Nature, 2003, 425:9093, demonstrated that the
PPAR.alpha. binding compound, oleylethanolamide, produces satiety
and reduces body weight gain in mice.
[0018] Clofibrate and fenofibrate have been shown to activate
PPAR.alpha. with a 10-fold selectivity over PPAR.gamma..
Bezafibrate acted as a pan-agonist that showed similar potency on
all three PPAR isoforms. Wy-14643, the 2-arylthioacetic acid
analogue of clofibrate, was a potent murine PPAR.alpha. agonist as
well as a weak PPAR.gamma. agonist. In humans, all of the fibrates
must be used at high doses (200-1,200 mg/day) to achieve
efficacious lipid-lowering activity.
[0019] TZDs and non-TZDs have also been identified that are dual
PPAR.gamma./.alpha. agonists. By virtue of the additional
PPAR.alpha. agonist activity, this class of compounds has potent
lipid-altering efficacy in addition to antihyperglycemic activity
in animal models of diabetes and lipid disorders. KRP-297 is an
example of a TZD dual PPAR.gamma./.alpha. agonist (Fajas, J. Biol.
Chem., 1997,272:18779-18789); furthermore, DRF-2725 and AZ-242 are
non-TZD dual PPAR.gamma./.alpha. agonists. (Lohray, et al., J. Med.
Chem., 2001, 44:2675-2678; Cronet, et al., Structure (Camb.), 2001,
9:699-706).
[0020] In order to define the physiological role of PPAR.delta.,
efforts have been made to develop novel compounds that activate
this receptor in a selective manner. Amongst the
.alpha.-substituted carboxylic acids previously described, the
potent PPAR.delta. ligand L-165041 demonstrated approximately
30-fold agonist selectivity for this receptor over PPAR.gamma.; it
was inactive on murine PPAR.alpha. (Liebowitz, et al., FEBS Lett.,
2000, 473:333-336). This compound was found to increase
high-density lipoprotein levels in rodents. It was also reported
that GW501516 was a potent, highly-selective PPAR.delta. agonist
that produced beneficial changes in serum lipid parameters in
obese, insulin-resistant rhesus monkeys. (Oliver et al., Proc.
Natl. Acad. Sci., 2001, 98:5306-5311).
[0021] In addition to the compounds discussed above, certain
thiazole derivatives active on PPARs have been described. (Cadilla
et al., Internat. Appl. PCT/US01/149320, Internat. Publ. WO
02/062774, incorporated herein by reference in its entirety.)
[0022] Some tricyclic-.alpha.-alkyloxyphenylpropionic acids were
described as dual PPAR.alpha./.gamma. agonists in Sauerberg et al.,
J. Med. Chem. 2002, 45:789-804.
[0023] A group of compounds that were stated to have equal activity
on PPAR.alpha./.gamma./.delta. was described in Morgensen et al.,
Bioorg. & Med. Chem. Lett. 2002, 13:257-260.
[0024] Oliver et al., described a selective PPAR.delta. agonist
that promotes reverse cholesterol transport. (Oliver et al.,
supra.)
[0025] Yamamoto et al., U.S. Pat. No. 3,489,767 describes
1-(phenylsulfonyl)-indolyl aliphatic acid derivatives that are
stated to have "antiphlogistic, analgesic and antipyretic actions."
(Col. 1, lines 16-19.)
[0026] Kato et al., European patent application 94101551.3,
Publication No. 0 610 793 Al, describes the use of
3-(5-methoxy-1-p-toluenesulfonylindol-3-yl)propionic acid (page 6)
and 1-(2,3,6-triisopropylphenylsulfonyl)-indole-3-propionic acid
(page 9) as intermediates in the synthesis of particular
tetracyclic morpholine derivatives useful as analgesics.
[0027] Accordingly, there is a need for safer, more effective PPAR
agonists for the treatment of a variety of diseases, including
PPAR.alpha., PPAR.gamma. or PPAR.delta. selective agonists as well
agonists selective for any two or all three of PPAR.alpha.,
PPAR.gamma. and PPAR.delta..
[0028] This application incorporates herein by reference and for
all purposes the entire disclosures of each of the following
applications: U.S. application Ser. No. 10/937,791, filed Sep. 8,
2004, U.S. application Ser. No. 10/893,134, filed Jul. 16, 2004,
U.S. Provisional App. No. 60/488,523, filed Jul. 17, 2003, U.S.
Provisional App. No. 60/552,994, filed Mar. 12, 2004, U.S.
Provisional App. No. 60/631,893, filed Nov. 11, 2004, and U.S.
Provisional App. No. 60/715,258, filed Sep. 7, 2005, all entitled
PPAR Active Compounds.
SUMMARY OF THE INVENTION
[0029] The present invention involves compounds active on PPARs,
which are useful for therapeutic and/or prophylactic methods
involving modulation of at least one of PPAR.alpha., PPAR.delta.,
and PPAR.gamma.. Included are compounds that have pan-activity
across the PPAR family (i.e., PPAR.alpha., PPAR.delta., and
PPAR.gamma.), as well as compounds that have significant
specificity (at least 5-, 10-, 20-, 50-, or 100-fold greater
activity) on a single PPAR, or on two of the three PPARs.
[0030] In one aspect, the invention provides compounds of Formula I
as follows: ##STR1## wherein: [0031] U, V, W, X, and Y are
independently N or CR.sup.5, wherein at most two of U, V, W, and Y
are N, and preferably no more than two of U, V, W, X, and Y are N;
[0032] Q is --O--, --S--, or --NR.sup.51--; [0033] R.sup.1 is
selected from the group consisting of optionally substituted
carboxyl and a carboxylic acid isostere; [0034] R.sup.2 is selected
from the group consisting of hydrogen, optionally substituted lower
alkyl, optionally substituted lower alkenyl, optionally substituted
lower alkynyl, optionally substituted cycloalkyl, optionally
substituted cycloalkylalkyl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkylalkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, optionally substituted
heteroaralkyl, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.2R.sup.9; [0035]
R.sup.3 and R.sup.4 are independently selected from the group
consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, and optionally substituted heteroaralkyl,
or R.sup.3 and R.sup.4 may combine to form a 3-7 membered
optionally substituted mono-cycloalkyl or 3-7 membered optionally
substituted mono-heterocycloalkyl; [0036] R.sup.5at each occurrence
is independently selected from the group consisting of hydrogen,
halo, optionally substituted lower alkyl, optionally substituted
lower alkenyl, optionally substituted lower alkynyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --OR.sup.10, --SR.sup.11,
--NR.sup.12R.sup.13, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.nR.sup.9; [0037]
R.sup.6 and R.sup.7 at each occurrence are independently selected
from the group consisting of hydrogen, optionally substituted lower
alkyl, optionally substituted lower alkenyl, provided, however,
that when R.sup.6 and/or R.sup.7 are optionally substituted lower
alkenyl, no alkene carbon thereof is bound to nitrogen, optionally
substituted lower alkynyl, provided, however, that when R.sup.6
and/or R.sup.7 are optionally substituted lower alkynyl, no alkyne
carbon thereof is bound to nitrogen, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl, or R.sup.6 and R.sup.7
together with the nitrogen to which they are attached form a 5-7
membered optionally substituted heterocycloalkyl or 5-7 membered
optionally substituted heteroaryl; [0038] R.sup.8 at each
occurrence is independently selected from the group consisting of
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.8 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
--C(Z)-, optionally substituted lower alkynyl, provided, however,
that when R.sup.8 is optionally substituted lower alkynyl, no
alkyne carbon thereof is bound to --C(Z)-, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, and --OR.sup.11; [0039] R.sup.9 at each
occurrence is independently selected from the group consisting of
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.9 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to
--S(O).sub.n--, optionally substituted lower alkynyl, provided,
however, that when R.sup.9 is optionally substituted lower alkynyl,
no alkyne carbon thereof is bound to --S(O).sub.n--, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl; [0040] R.sup.10 at each
occurrence is independently selected from the group consisting of
hydrogen, optionally substituted lower alkyl, optionally
substituted lower alkenyl, provided, however, that when R.sup.10 is
optionally substituted lower alkenyl, no alkene carbon thereof is
bound to oxygen, optionally substituted lower alkynyl, provided,
however, that when R.sup.10 is optionally substituted lower
alkynyl, no alkyne carbon thereof is bound to oxygen, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, --C(Z)R.sup.8, and
--C(Z)NR.sup.6R.sup.7; [0041] R.sup.11 at each occurrence is
independently selected from the group consisting of hydrogen,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, provided, however, that when R.sup.11 is optionally
substituted lower alkenyl, no alkene carbon thereof is bound to S
or O, optionally substituted lower alkynyl, provided, however, that
when R.sup.11 is optionally substituted lower alkynyl, no alkyne
carbon thereof is bound to S or O, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl; [0042] R.sup.12 and R.sup.13
at each occurrence are independently selected from the group
consisting of hydrogen, optionally substituted lower alkyl,
optionally substituted lower alkenyl, provided, however, that when
R.sup.12 and/or R.sup.13 are optionally substituted lower alkenyl,
no alkene carbon thereof is bound to nitrogen, optionally
substituted lower alkynyl, provided, however, that when R.sup.12
and/or R.sup.13 are optionally substituted lower alkynyl, no alkyne
carbon thereof is bound to nitrogen, optionally substituted
cycloalkyl, optionally substituted cycloalkylalkyl, optionally
substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted-heteroaryl, optionally
substituted heteroaralkyl, --C(Z)R.sup.8, --C(Z)NR.sup.6R.sup.7,
--S(O).sub.2R.sup.9, and --S(O).sub.2NR.sup.6R.sup.7, or R.sup.12
and R.sup.13 together with the nitrogen to which they are attached
form a 5-7 membered optionally substituted heterocycloalkyl or 5-7
membered optionally substituted heteroaryl; [0043] R.sup.51 is
selected from the group consisting of hydrogen, optionally
substituted lower alkyl, optionally substituted lower alkenyl,
provided, however, that when R.sup.51 is optionally substituted
lower alkenyl, no alkene carbon thereof is bound to nitrogen,
optionally substituted lower alkynyl, provided, however, that when
R.sup.51 is optionally substituted lower alkynyl, no alkyne carbon
thereof is bound to nitrogen, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkylalkyl,
optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, optionally substituted
heteroaralkyl, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.2R.sup.9; [0044] n is 1
or 2; [0045] Z is O or S; and all salts, prodrugs, tautomers and
stereoisomers thereof
[0046] In one embodiment of compounds of Formula I, R.sup.5 is
selected from the group consisting of hydrogen, halo, optionally
fluoro substituted lower alkyl, optionally fluoro substituted lower
alkylthio, and optionally fluoro substituted lower alkoxy. In one
embodiment, when Q is --NR.sup.51--, then R.sup.51 is hydrogen or
optionally substituted lower alkyl, where lower alkyl is preferably
optionally substituted with halo, hydroxyl, lower alkoxy, thiol, or
lower alkylthio, provided that hydroxy, lower alkoxy, thiol, or
lower alkylthio are not substituted at the carbon that is bound to
the nitrogen of --NR.sup.51--. In one embodiment, U, W, X and Y are
CH, and V is CR.sup.5. In one embodiment, U, W, X and Y are CH, and
V is CR.sup.5, where R.sup.5 is selected from the group consisting
of hydrogen, halo, optionally fluoro substituted lower alkyl,
optionally fluoro substituted lower alkylthio, and optionally
fluoro substituted lower alkoxy.
[0047] In certain embodiments involving compounds of Formula I, the
compounds have a structure of Formula I in which the bicyclic core
shown for Formula I has one of the following structures:
##STR2##
[0048] Thus, in particular embodiments involving compounds of
Formula I, the compound includes a bicyclic core as shown above.
Such compounds can include substitutents as described for Formula
I, with the understanding that ring nitrogens other than the
nitrogen corresponding to position 1 of the indole structure are
unsubstituted. In particular embodiments, the compounds have one of
the bicyclic cores shown above and substitution pattern as shown
herein for compounds having an indolyl or other bicyclic core.
[0049] In certain embodiments, compounds of Formula I have a
structure of Formula Ia as shown below: ##STR3## wherein: [0050] X,
Y, Q, R.sup.1, R.sup.3, and R.sup.4 are as defined in Formula I
above; [0051] R.sup.2 is selected from the group consisting of
--CR.sup.52R.sup.53R.sup.14, --C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.2R.sup.9; [0052]
R.sup.14 is selected from the group consisting of optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl and optionally substituted heteroaryl;
[0053] R.sup.52 and R.sup.53 are independently selected from the
group consisting of hydrogen, halo, lower alkyl, hydroxyl, lower
alkoxy, thiol, and lower alkylthio, wherein lower alkyl and the
lower alkyl chains of lower alkoxy and lower alkylthio are
optionally substituted with fluoro, hydroxyl, lower alkoxy, thiol,
lower alkylthio or --NR.sup.54R.sup.55, provided, however, that the
substitution of lower alkoxy or lower alkylthio does not result in
O, N, or S bound to the carbon that is bound to the lower alkoxy
oxygen or the lower alkylthio sulfur; [0054] R.sup.54 and R.sup.55
are independently lower alkyl, or R.sup.54 and R.sup.55 combine
with the nitrogen to which they are attached to form a 5-7 membered
heterocycloalkyl or 5-7 membered heterocycloalkyl substituted with
halo, hydroxyl, lower alkoxy, or lower alkyl; [0055] R.sup.24,
R.sup.25 and R.sup.26 are independently selected from the group
consisting of hydrogen, halo, optionally substituted lower alkyl,
optionally substituted lower alkenyl, optionally substituted lower
alkynyl, optionally substituted cycloalkyl, optionally substituted
cycloalkylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heterocycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl,
--OR.sup.10, --SR.sup.11, --NR.sup.12R.sup.13,
--C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8, --S(O).sub.2NR.sup.6R.sup.7,
and --S(O).sub.nR.sup.9; [0056] n, Z, R.sup.6, R.sup.7, R.sup.8,
R.sup.9, R.sup.10, R.sup.11, R.sup.12, and R.sup.13 are as defined
for Formula I above; and all salts, prodrugs, tautomers and
stereoisomers thereof.
[0057] In one embodiment of compounds of Formula Ia, R.sup.2 is
--S(O).sub.2R.sup.9. In another embodiment, X and Y are CH, and
R.sup.24 and R.sup.26 are hydrogen. In another embodiment, X and Y
are CH, and R.sup.24 and R.sup.25 are hydrogen. In another
embodiment, X and Y are CH, and R.sup.25 and R.sup.26 are hydrogen.
In another embodiment, R.sup.24, R.sup.25, and R.sup.26 are
independently selected from the group consisting of hydrogen, halo,
optionally fluoro substituted lower alkyl, optionally fluoro
substituted lower alkylthio, and optionally fluoro substituted
lower alkoxy. In another embodiment, X and Y are CH, R.sup.24 and
R.sup.26 are hydrogen, and R.sup.25 is selected from the group
consisting of hydrogen, halo, optionally fluoro substituted lower
alkyl, optionally fluoro substituted lower alkylthio, and
optionally fluoro substituted lower alkoxy. In another embodiment,
when Q is --NR.sup.51--, R.sup.51 is hydrogen or optionally
substituted lower alkyl, where lower alkyl is preferably optionally
substituted with halo, hydroxyl, lower alkoxy, thiol, or lower
alkylthio, provided that hydroxy, alkoxy, thiol, or alkylthio are
not substituted at the carbon that is bound to the nitrogen of
--NR.sup.51--.
[0058] In certain embodiments, compounds of Formula I have a
structure of Formula Ib as shown below: ##STR4## wherein n,
R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8,
R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, Z, and Q are as
defined in Formula I above. In one embodiment of compounds of
Formula Ib, R.sup.5 is selected from the group consisting of halo,
optionally fluoro substituted lower alkyl, optionally fluoro
substituted lower alkylthio, and optionally fluoro substituted
lower alkoxy. In another embodiment, R.sup.3 and R.sup.4 are H, Q
is O, and R.sup.5 is selected from the group consisting of halo,
optionally fluoro substituted lower alkyl, optionally fluoro
substituted lower alkylthio, and optionally fluoro substituted
lower alkoxy. In another embodiment, when Q is --O--, then R.sup.5
is halo, preferably Br. In another embodiment, when Q is --S--,
then R.sup.5 is optionally fluoro substituted lower alkoxy, also
lower alkoxy, preferably methoxy. In another embodiment, when Q is
--NR.sup.51--, then R.sup.51 is hydrogen or optionally substituted
lower alkyl, where lower alkyl is preferably optionally substituted
with halo, hydroxyl, lower alkoxy, thiol, or lower alkylthio,
provided that hydroxy, alkoxy, thiol, or alkylthio are not
substituted at the carbon that is bound to the nitrogen of
--NR.sup.51--.
[0059] In certain embodiments, compounds of Formula I have a
structure of Formula Ic as shown below: ##STR5## wherein: [0060]
R.sup.1, R.sup.3, R.sup.4, R.sup.5, and Q are as defined in Formula
I above; [0061] A is a monocyclic or bicyclic ring selected from
the group consisting of cycloalkyl, heterocycloalkyl, aryl, and
heteroaryl; [0062] L is selected from the group consisting of
--CR.sup.52R.sup.53--, --C(Z)NR.sup.56--, --C(Z)-,
--S(O).sub.2NR.sup.56--; and --S(O).sub.2--, attached to A at any
available atom to produce a stable compound; [0063] R.sup.52,
R.sup.53, R.sup.54, and R.sup.55 are as defined for Formula Ib
above; [0064] R.sup.56 is selected from the group consisting of
hydrogen, optionally substituted lower alkyl, optionally
substituted lower alkenyl, provided, however, that when R.sup.56 is
optionally substituted lower alkenyl, no alkene carbon thereof is
bound to nitrogen, optionally substituted lower alkynyl, provided,
however, that when R.sup.56 is optionally substituted lower
alkynyl, no alkyne carbon thereof is bound to nitrogen, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, and
optionally substituted heteroaralkyl; [0065] R.sup.15 is selected
from the group consisting of hydrogen, halo, cyano, nitro,
optionally substituted lower alkyl, optionally substituted lower
alkenyl, optionally substituted lower alkynyl, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
--OR.sup.10, --SR.sup.11, --NR.sup.12R.sup.13,
--C(Z)NR.sup.6R.sup.7, --C(Z)R.sup.8, --S(O).sub.2NR.sup.6R.sup.7,
and --S(O).sub.nR.sup.9, attached to A at any available atom to
produce a stable compound; [0066] n, Z, R.sup.6, R.sup.7, R.sup.8,
R.sup.9, R.sup.10, R.sup.11, R.sup.12, and R.sup.13 are as defined
in Formula I above; [0067] R.sup.16 at each occurrence is
independently selected from the group consisting of halo, lower
alkyl, hydroxyl, lower alkoxy, thiol, and lower alkylthio, wherein
lower alkyl and the lower alkyl chains of lower alkoxy and lower
alkylthio are optionally substituted with fluoro, hydroxyl, lower
alkoxy, thiol, or lower alkylthio, provided, however, that any
substitution on lower alkoxy or lower alkylthio does not result in
O or S bound to the carbon that is bound to the alkoxy oxygen of
substituted lower alkoxy or the alkylthio sulfur of substituted
lower alkylthio; [0068] m is 0, 1, or2; and [0069] all salts,
prodrugs, tautomers and stereoisomers thereof.
[0070] In one embodiment of compounds of Formula Ic, A is a
monocyclic aryl or monocyclic heteroaryl. In one embodiment, A is a
monocyclic heteroaryl. In one embodiment, R.sup.15 is selected from
the group consisting of optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, optionally substituted
aryl, optionally substituted heteroaryl, --OR.sup.10, --SR.sup.11,
--NR.sup.12R.sup.13, --C(Z)NR.sup.6 R.sup.7, --C(Z)R.sup.8,
--S(O).sub.2NR.sup.6R.sup.7, and --S(O).sub.nR.sup.9, further
wherein one of R.sup.6 and R.sup.7, one of R.sup.12, and R.sup.13,
R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are selected from the group
consisting of optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, optionally substituted aryl, and
optionally substituted heteroaryl. In one embodiment, R.sup.5 is
selected from the group consisting of halo, optionally fluoro
substituted lower alkyl, optionally fluoro substituted lower
alkylthio, and optionally fluoro substituted lower alkoxy. In
another embodiment, R.sup.3 and R.sup.4 are H, Q is O, and R.sup.5
is selected from the group consisting of halo, optionally fluoro
substituted lower alkyl, optionally fluoro substituted lower
alkylthio, and optionally fluoro substituted lower alkoxy. In
another embodiment, when Q is --O--, then R.sup.5 is halo,
preferably Br. In another embodiment, when Q is --S--, then R.sup.5
is optionally fluoro substituted lower alkoxy, also lower alkoxy,
preferably methoxy. In another embodiment, when Q is --NR.sup.51--,
then R.sup.51 is hydrogen or optionally substituted lower alkyl,
where lower alkyl is preferably optionally substituted with halo,
hydroxyl, lower alkoxy, thiol, or lower alkylthio, provided that
hydroxy, alkoxy, thiol, or alkylthio are not substituted at the
carbon that is bound to the nitrogen of --NR.sup.51--.
[0071] In specifying a compound or compounds of Formula I, Ia, Ib,
or Ic, unless clearly indicated to the contrary, specification of
such compound(s) includes pharmaceutically acceptable salts of the
compound(s).
[0072] In certain embodiments of the above compounds, compounds are
excluded where N, O, S or C(Z) would be bound to a carbon that is
also bound to N, O, S, or C(Z) or is bound to an alkene carbon atom
of an alkenyl group or bound to an alkyne atom of an alkynyl group.
Accordingly, in certain embodiments compounds are excluded from the
present invention in which there are included linkages such as
--NR--CH.sub.2--NR--, --O--CH.sub.2--NR--,
--S(O).sub.0-2--CH.sub.2--NR--, --C(Z)-CH.sub.2--NR--,
--O--CH.sub.2--O--, --S(O).sub.0-2--CH.sub.2--O--,
--C(Z)-CH.sub.2--O--, --S(O).sub.0-2--CH.sub.2--S(O).sub.0-2--,
--C(Z)-CH.sub.2--S(O).sub.0-2--, --C(Z)--CH.sub.2--C(Z)-,
--NR--CH.dbd.CH--, --NR--C.ident.C--, --O--CH.ident.CH--,
--O--C.ident.C--, --S(O).sub.0-2--CH.dbd.CH--,
--S(O).sub.0-2--C.ident.C--, --C(Z)-CH.dbd.CH--, or
--C(Z)-C.ident.C--.
[0073] Reference to compounds of Formula I, Ia, Ib, or Ic herein
includes specific reference to sub-groups and species of compounds
of Formula I, Ia, Ib, or Ic described herein (e.g., particular
embodiments as described above) unless indicated to the
contrary.
[0074] Another aspect of the invention concerns novel use of
compounds of Formula I, Ia, Ib, or Ic for the treatment of diseases
associated with PPARs. Another aspect of the invention concerns
novel compounds of Formula I, Ia, Ib, or Ic.
[0075] Another aspect of this invention provides compositions that
include a therapeutically effective amount of a compound of Formula
I, Ia, Ib, or Ic and at least one pharmaceutically acceptable
carrier, excipient, and/or diluent. The composition can include a
plurality of different pharmacalogically active compounds,
including one or more compounds of Formula I, Ia, Ib, or Ic. An
"effective amount" of a compound or composition, as used herein,
includes within its meaning a non-toxic but sufficient amount of
the particular compound or composition to which it is referring to
provide the desired therapeutic effect.
[0076] In another aspect, compounds of Formula I, Ia, Ib, or Ic can
be used in the preparation of a medicament for the treatment of a
PPAR-mediated disease or condition or a disease or condition in
which modulation of a PPAR provides a therapeutic benefit.
[0077] In another aspect, the invention provides kits that include
a composition as described herein. In particular embodiments, the
composition is packaged, e.g., in a vial, bottle, flask, which may
be further packaged, e.g., within a box, envelope, or bag; the
composition is approved by the U.S. Food and Drug Administration or
similar regulatory agency for administration to a mammal, e.g., a
human; the composition is approved for administration to a mammal,
e.g., a human, for a PPAR-mediated disease or condition; the kit
includes written instructions or other indication that the
composition is suitable or approved for administration to a mammal,
e.g., a human, for a PPAR-mediated disease or condition; the
composition is packaged in unit dose or single dose form, e.g.,
single dose pills, capsules, or the like.
[0078] In another aspect, the invention provides a method of
treating or prophylaxis of a disease or condition in a mammal,
e.g., a PPAR-mediated disease or condition or a disease or
condition in which modulation of a PPAR provides a therapeutic
benefit, by administering to the mammal a therapeutically effective
amount of a compound of Formula I, Ia, Ib, or Ic, a prodrug of such
compound, or a pharmaceutically acceptable salt of such compound or
prodrug. The compound can be administered alone or can be part of a
pharmaceutical composition.
[0079] In aspects and embodiments involving treatment or
prophylaxis of a disease or condition, the disease or condition is
selected from the group consisting of obesity, overweight
condition, hyperlipidemia, dyslipidemia including associated
diabetic dyslipidemia and mixed dyslipidemia,
hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus,
Type I diabetes, hyperinsulinemia, impaired glucose tolerance,
insulin resistance, a diabetic complication (e.g., neuropathy,
nephropathy, retinopathy or cataracts), hypertension, coronary
heart disease, heart failure, hypercholesterolemia, inflammation,
thrombosis, congestive heart failure, cardiovascular disease
(including atherosclerosis, arteriosclerosis, and
hypertriglyceridemia), epithelial hyperproliferative diseases (such
as-eczema and psoriasis), cancer, neuropathic or inflammatory pain,
conditions associated with the lung and gut, regulation of appetite
and food intake in subjects suffering from disorders such as
obesity, anorexia bulimia and anorexia nervosa, neurodegenerative
diseases, such as Alzheimer's disease, Parkinson's disease, and
amyotrophic lateral sclerosis, autoimmune diseases such as Type-1
diabetes mellitus, vitiligo, uveitis, Sjogren's disease, pemphigus
foliaceus, inclusion body myositis, polymyositis, dermatomyositis,
scleroderma, Grave's disease, Hashimoto's disease, chronic
graft-versus host disease, rheumatoid arthritis, inflammatory bowel
syndrome, Crohn's disease and multiple sclerosis, pregnancy (e.g.
fertility), diseases involving airway smooth muscle cells such as
asthma and COPD, and angiogenesis related conditions, such as
macular degeneration.
[0080] In certain embodiments of aspects involving compounds of
Formula I, Ia, Ib, or Ic, the compound is specific for any one or
any two of PPAR.alpha., PPAR.gamma. and PPAR.delta., e.g. specific
for PPAR.alpha.; specific for PPAR.delta.; specific for
PPAR.gamma.; specific for PPAR.alpha. and PPAR.delta.; specific for
PPAR.alpha. and PPAR.gamma.; specific for PPAR.delta. and
PPAR.gamma.. Such specificity means that the compound has at least
5-fold greater activity (preferably at least 5-, 10-, 20-, 50-, or
100-fold or more greater activity) on the specific PPAR(s) than on
the other PPAR(s), where the activity is determined using a
biochemical assay suitable for determining PPAR activity, e.g., any
assay known to one skilled in the art or as described herein. In
another embodiment, compounds have significant activity on all
three of PPAR.alpha., PPAR.delta., and PPAR.gamma..
[0081] In certain embodiments, a compound of the invention has an
EC.sub.50 of less than 100 nM, less than 50 nM, less than 20 nM,
less than 10 nM, less than 5 nM, or less than 1 nM with respect to
at least one of PPAR.alpha., PPAR.gamma. and PPAR.delta. as
determined in a generally accepted PPAR activity assay. In one
embodiment, a compound of Formula I, Ia, Ib, or Ic will have an
EC.sub.50 of less than 100 nM, less than 50 nM, less than 20 nM,
less than 10 nM, less than 5 nM, or less than 1 nM with respect to
at least any two of PPAR.alpha., PPAR.gamma. and PPAR.delta.. In
one embodiment, a compound of Formula I, Ia, Ib, or Ic will have an
EC.sub.50 of less than 100 nM, less than 50 nM, less than 20 nM,
less than 10 nM, less than 5 nM, or less than 1 nM with respect to
all three of PPAR.alpha., PPAR.gamma. and PPAR.delta.. Further to
any of the above embodiments, a compound of the invention will be a
specific agonist of any one of PPAR.alpha., PPAR.gamma. and
PPAR.delta., or any two of PPAR.alpha., PPAR.gamma. and
PPAR.delta.. A specific agonist of one of PPAR.alpha., PPAR.gamma.
and PPAR.delta. is such that the EC.sub.50 for one of PPAR.alpha.,
PPAR.gamma. and PPAR.delta. will be at least about 5-fold, also
10-fold, also 20-fold, also 50-fold, or at least about 100-fold
less than the EC.sub.50 for the other two of PPAR.alpha.,
PPAR.gamma. and PPAR.delta.. A specific agonist of two of
PPAR.alpha., PPAR.gamma. and PPAR.delta. is such that the EC.sub.50
for each of two of PPAR.alpha., PPAR.gamma. and PPAR.delta. will be
at least about 5-fold, also 10-fold, also 20-fold, also 50-fold, or
at least about 100-fold less than the EC.sub.50 for the other of
PPAR.alpha., PPAR.gamma. and PPAR.delta..
[0082] In certain embodiments of the invention, the compounds of
Formula I, Ia, Ib, or Ic active on PPARs also have desireable
pharmacologic properties. In particular embodiments the desired
pharmacologic property is PPAR pan-activity, PPAR selectivity for
any individual PPAR (PPAR.alpha., PPAR.delta., or PPAR.gamma.),
selectivity on any two PPARs (PPAR.alpha. and PPAR.delta.,
PPAR.alpha. and PPAR.gamma., or PPAR.delta. and PPAR.gamma.), or
any one or more of serum half-life longer than 2 hr, also longer
than 4 hr, also longer than 8 hr, aqueous solubility, and oral
bioavailability more than 10%, also more than 20%.
[0083] Additional embodiments will be apparent from the Detailed
Description and from the claims.
DETAILED DESCRIPTION OF THE INVENTION
[0084] As indicated in the Summary above, the present invention
concerns the peroxisome proliferator-activated receptors (PPARs),
which have been identified in humans and other mammals. A group of
compounds have been identified, corresponding to Formula I, Ia, Ib,
or Ic, that are active on one or more of the PPARs, in particular
compounds that are active on one or more human PPARs. The
identification of these compounds provides compounds that can be
used as modulators on PPARs, including agonists of at least one of
PPAR.alpha., PPAR.delta., and PPAR.gamma., as well as dual PPAR
agonists and pan-agonist, such as agonists of both PPAR.alpha. and
PPAR.gamma., both PPAR.alpha. and PPAR.delta., both PPAR.gamma. and
PPAR.delta., or agonists of PPAR.alpha., PPAR.gamma. and
PPAR.delta..
[0085] As used herein the following definitions apply unless
otherwise indicated:
[0086] "Halo" or "Halogen"--alone or in combination means all
halogens, that is, chloro (Cl), fluoro (F), bromo (Br), or iodo
(I).
[0087] "Hydroxyl" refers to the group --OH.
[0088] "Thiol" or "mercapto" refers to the group --SH.
[0089] "Alkyl"--alone or in combination means an alkane-derived
radical containing from 1 to 20, preferably 1 to 15, carbon atoms
(unless specifically defined). It is a straight chain alkyl or
branched alkyl, and includes a straight chain or branched alkyl
group that optionally contains or is interrupted by a cycloalkyl
portion. The straight chain or branched alkyl group is attached at
any available atom to produce a stable compound. Examples of this
include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or
2-methyl-cyclopropylpentyl. In many embodiments, an alkyl is a
straight or branched alkyl group containing from 1-15, 1-8, 1-6,
1-4, or 1-2, carbon atoms, such as methyl, ethyl, propyl,
isopropyl, butyl, t-butyl and the like. "Optionally substituted
alkyl" denotes unsubstituted alkyl or alkyl that is independently
substituted with 1 to 3 groups or substituents selected from the
group consisting of halo, hydroxy, optionally substituted lower
alkoxy, optionally substituted acyloxy, optionally substituted
aryloxy, optionally substituted heteroaryloxy, optionally
substituted cycloalkyloxy, optionally substituted
heterocycloalkyloxy, thiol, optionally substituted lower alkylthio,
optionally substituted arylthio, optionally substituted
heteroarylthio, optionally substituted cycloalkylthio, optionally
substituted heterocycloalkylthio, optionally substituted
alkylsulfinyl, optionally substituted arylsulfinyl, optionally
substituted heteroarylsulfinyl, optionally substituted
cycloalkylsulfinyl, optionally substituted
heterocycloalkylsulfinyl, optionally substituted alkylsulfonyl,
optionally substituted arylsulfonyl, optionally substituted
heteroarylsulfonyl, optionally substituted cycloalkylsulfonyl,
optionally substituted heterocycloalkylsulfonyl, optionally
substituted amino, optionally substituted amido, optionally
substituted amidino, optionally substituted urea, optionally
substituted aminosulfonyl, optionally substituted
alkylsulfonylamino, optionally substituted arylsulfonylamino,
optionally substituted heteroarylsulfonylamino, optionally
substituted cycloalkylsulfonylamino, optionally substituted
heterocycloalkylsulfonylamino, optionally substituted
alkylcarbonylamino, optionally substituted arylcarbonylamino,
optionally substituted heteroarylcarbonylamino, optionally
substituted cycloalkylcarbonylamino, optionally substituted
heterocycloalkylcarbonylamino, optionally substituted carboxyl,
optionally substituted acyl, optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, optionally substituted
aryl, optionally substituted heteroaryl, nitro, and cyano, attached
at any available atom to produce a stable compound.
[0090] "Lower alkyl" refers to an alkyl group having 1-6 carbon
atoms. "Optionally substituted lower alkyl" denotes lower alkyl or
lower alkyl that is independently substituted with 1 to 3 groups or
substituents as defined in [0057] attached at any available atom to
produce a stable compound.
[0091] "Lower alkylene" refers to a divalent alkane-derived radical
containing 1-6 carbon atoms, straight chain or branched, from which
two hydrogen atoms are taken from the same carbon atom or from
different carbon atoms. Examples of alkylene include, but are not
limited to, --CH.sub.2--, --CH.sub.2CH.sub.2--, and
--CH.sub.2CH(CH.sub.3)--.
[0092] "Alkenyl"--alone or in combination means a straight,
branched, or cyclic hydrocarbon containing 2-20, preferably 2-17,
more preferably 2-10, even more preferably 2-8, most preferably
2-4, carbon atoms and at least one, preferably 1-3, more preferably
1-2, most preferably one, carbon to carbon double bond. In the case
of a cycloalkenyl group, conjugation of more than one carbon to
carbon double bond is not such as to confer aromaticity to the
ring. Carbon to carbon double bonds may be either contained within
a cycloalkyl portion, with the exception of cyclopropyl, or within
a straight chain or branched portion. Examples of alkenyl groups
include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl,
cyclohexenylalkyl and the like. "Optionally substituted alkenyl"
denotes alkenyl or alkenyl that is independently substituted with 1
to 3 groups or substituents as defined in [0057] attached at any
available atom to produce a stable compound.
[0093] "Lower alkenyl" refers to an alkenyl group having 2-6 carbon
atoms. "Optionally substituted lower alkenyl" denotes lower alkenyl
or lower alkenyl that is substituted with 1 to 3 groups or
substituents as defined in [0057] attached at any available atom to
produce a stable compound.
[0094] "Alkynyl"--alone or in combination means a straight or
branched hydrocarbon containing 2-20, preferably
2-17,-more-preferably 2-10, even more-preferably 2-8, most
preferably 2-4, carbon atoms containing at least one, preferably
one, carbon to carbon triple bond. Examples of alkynyl groups
include ethynyl, propynyl, butynyl, and the like. "Optionally
substituted alkynyl" denotes alkynyl or alkynyl that is
independently substituted with 1 to 3 groups or substituents as
defined in [0057] attached at any available atom to produce a
stable compound.
[0095] "Lower alkynyl" refers to an alkynyl group having 2-6 carbon
atoms. "Optionally substituted lower alkynyl" denotes lower alkynyl
or lower alkynyl that is substituted with 1 to 3 groups or
substituents as defined in [0057] attached at any available atom to
produce a stable compound.
[0096] "Lower alkoxy" denotes the group --OR.sup.e, where R.sup.e
is lower alkyl. "Optionally substituted lower alkoxy" denotes lower
alkoxy in which R.sup.e is optionally substituted lower alkyl.
[0097] "Acyloxy" denotes the group --OC(O)R.sup.f, where R.sup.f is
hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl, or
heteroaryl. "Optionally substituted acyloxy" denotes acyloxy in
which R.sup.f is hydrogen, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl, or optionally
substituted heteroaryl.
[0098] "Aryloxy" denotes the group --OR.sup.g, where R.sup.g is
aryl. "Optionally substituted aryloxy" denotes aryloxy in which
R.sup.g is optionally substituted aryl.
[0099] "Heteroaryloxy" denotes the group --OR.sup.h, where R.sup.h
is heteroaryl. "Optionally substituted heteroaryloxy" denotes
heteroaryloxy in which R.sup.h is optionally substituted
heteroaryl.
[0100] "Cycloalkyloxy" denotes the group --OR.sup.i, where R.sup.i
is cycloalkyl. "Optionally substituted cycloalkyloxy" denotes
cycloalkyloxy in which R.sup.i is optionally substituted
cycloalkyl.
[0101] "Heterocycloalkyloxy" denotes the group --OR.sup.j, where
R.sup.j is heterocycloalkyl. "Optionally substituted
heterocycloalkyloxy" denotes heterocycloalkyloxy in which R.sup.j
is optionally substituted heterocycloalkyl.
[0102] "Lower alkylthio" denotes the group --SR.sup.k, where
R.sup.k is lower alkyl. "Optionally substituted lower alkylthio"
denotes lower alkylthio in which R.sup.k is optionally substituted
lower alkyl.
[0103] "Arylthio" denotes the group --SR.sup.L, where R.sup.L is
aryl. "Optionally substituted arylthio" denotes arylthio in which
R.sup.L is optionally substituted aryl.
[0104] "Heteroarylthio" denotes the group --SR.sup.m, where R.sup.m
is heteroaryl. "Optionally substituted heteroarylthio" denotes
heteroarylthio in which R.sup.m is optionally substituted
heteroaryl.
[0105] "Cycloalkylthio" denotes the group --SR.sup.n, where R.sup.n
is cycloalkyl. "Optionally substituted cycloalkylthio" denotes
cycloalkylthio in which R.sup.n is optionally substituted
cycloalkyl.
[0106] "Heterocycloalkylthio" denotes the group --SR.sup.o, where
R.sup.o is heterocycloalkyl. "Optionally substituted
heterocycloalkylthio" denotes heterocycloalkylthio in which R.sup.o
is optionally substituted heterocycloalkyl.
[0107] "Acyl" denotes groups --C(O)R.sup.p, where R.sup.p is
hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl, or
heteroaryl. "Optionally substituted acyl" denotes acyl in which
R.sup.p is hydrogen, optionally substituted lower alkyl, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, or optionally substituted
heteroaryl.
[0108] "Optionally substituted amino" denotes the group
--NR.sup.qR.sup.r, where R.sup.q and R.sup.r may independently be
hydrogen, optionally substituted lower alkyl, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted acyl or optionally substituted sulfonyl, or
R.sup.q and R.sup.r together with the nitrogen to which they are
attached can form a 5-7 membered optionally substituted
heterocycloalkyl or 5-7 membered optionally substituted
heteroaryl.
[0109] "Optionally substituted amido" denotes the group
--C(O)NR.sup.sR.sup.t, where R.sup.s and R.sup.t may independently
be hydrogen, optionally substituted lower alkyl, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, or optionally substituted heteroaryl,
or R.sup.s and R.sup.t together with the nitrogen to which they are
attached can form a 5-7 membered optionally substituted
heterocycloalkyl or 5-7 membered optionally substituted
heteroaryl.
[0110] "Optionally substituted amidino" denotes the group
--C(.dbd.NR.sup.u)NR.sup.vR.sup.w, wherein R.sup.u, R.sup.v, and
R.sup.w are independently hydrogen or optionally substituted lower
alkyl.
[0111] "Optionally substituted urea" denotes the group
--NR.sup.xC(O)NR.sup.yR.sup.z, wherein R.sup.x is hydrogen or
optionally substituted lower alkyl, and R.sup.y and R.sup.z are
independently selected from hydrogen, optionally substituted lower
alkyl, optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl or optionally
substituted heteroaryl, or R.sup.y and R.sup.z together with the
nitrogen to which they are attached can form a 5-7 membered
optionally substituted heterocycloalkyl or 5-7 membered optionally
substituted heteroaryl.
[0112] "Optionally substituted sulfonyl" denotes the group
--S(O).sub.2R.sup.aa, wherein R.sup.aa is optionally substituted
lower alkyl, optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl.
[0113] "Optionally substituted aminosulfonyl" denotes the group
--S(O).sub.2NR.sup.bbR.sup.cc, where R.sup.bb and R.sup.cc may
independently be hydrogen, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl, or optionally
substituted heteroaryl, or R.sup.bb and R.sup.cc together with the
nitrogen to which they are attached can form a 5-7 membered
optionally substituted heterocycloalkyl or 5-7 membered optionally
substituted heteroaryl.
[0114] "Carboxyl" denotes the group --C(O)OR.sup.dd, where R.sup.dd
is hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl, or
heteroaryl. "Optionally substituted carboxyl" denotes carboxyl
wherein R.sup.dd is hydrogen, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl, or optionally
substituted heteroaryl.
[0115] "Carboxylic acid isostere" refers to a group selected from
thiazolidine dione, hydroxamic acid, acyl-cyanamide, tetrazole,
isoxazole, sulphonate, and sulfonamide. In functional terms,
carboxylic acid isosteres mimic carboxylic acids by virtue of
similar physical properties, including but not limited to molecular
size or molecular shape. Isoxazole may be optionally substituted
with lower alkyd lower alkyl substituted with 1-3 fluoro, aryl or
heteroaryl, and wherein aryl or heteroaryl may be optionally
substituted with 1-3 groups or substituents selected from halo,
lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro
substituted lower alkoxy, lower alkylthio, and fluoro substituted
lower alkylthio. Sulfonamide may be optionally substituted with
lower alkyl, fluoro substituted lower alkyl, acyl, aryl and
heteroaryl, wherein aryl or heteroaryl may be optionally
substituted with 1-3 groups or substituents selected from halo,
lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro
substituted lower alkoxy, lower alkylthio, and fluoro substituted
lower alkylthio.
[0116] "Aryl" refers to a ring system containing aromatic
hydrocarbons such as phenyl or naphthyl, which may be optionally
fused with a cycloalkyl of preferably 5-7, more preferably 5-6,
ring members. "Optionally substituted aryl" denotes aryl or aryl
that is substituted with with 1 to 3 groups or substituents as
defined in [0057], or optionally substituted lower alkyl,
optionally substituted lower alkenyl, or optionally substituted
lower alkynyl, attached at any available atom to produce a stable
compound.
[0117] "Aralkyl" refers to the group --R.sup.ee--Ar where Ar is an
aryl group and R.sup.ee is lower alkylene. "Optionally substituted
aralkyl" denotes aralkyl or aralkyl in which the alkylene group is
optionally substituted with 1 to 3 groups or substituents as
defined in [0057], attached at any available atom to produce a
stable compound, and in which the aryl group is optionally
substituted with 1 to 3 groups or substituents as defined in
[0057], or optionally substituted lower alkyl, optionally
substituted lower alkenyl, or optionally substituted lower alkynyl,
attached at any available atom to produce a stable compound.
[0118] "Heteroaryl"--alone or in combination means a monocyclic
aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic
aromatic group having 8 to 10 atoms, containing one or more,
preferably 1-4, more preferably 1-3, even more preferably 1-2,
heteroatoms independently selected from the group O, S, and N.
Heteroaryl is also intended to include oxidized S or N, such as
sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A
carbon or nitrogen atom is the point of attachment of the
heteroaryl ring structure such that a stable aromatic ring is
retained. Examples of heteroaryl groups include, but are not
limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl,
indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl,
quinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl,
isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl,
triazinyl, furanyl, benzofuryl, and indolyl. "Optionally
substituted heteroaryl" denotes heteroaryl or heteroaryl that is
substituted with with 1 to 3 groups or substituents as defined in
[0057], or optionally substituted lower alkyl, optionally
substituted lower alkenyl, or optionally substituted lower alkynyl,
attached at any available carbon or nitrogen to produce a stable
compound.
[0119] "Heteroaralkyl" refers to the group --R.sup.ff-HetAr where
HetAr is a heteroaryl group and R.sup.ff is lower alkylene.
"Optionally substituted heteroaralkyl" denotes heteroaralkyl or
heteroaralkyl in which the lower alkylene group is optionally
substituted with 1 to 3 groups or substituents as defined in
[0057], attached at any available atom to produce a stable
compound, and in which the heteroaryl group is optionally
substituted with 1 to 3 groups or substituents as defined in
[0057], or optionally substituted lower alkyl, optionally
substituted lower alkenyl, or optionally substituted lower alkynyl,
attached at any available carbon or nitrogen to produce a stable
compound.
[0120] "Cycloalkyl" refers to saturated or unsaturated,
non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems
of 3-8, more preferably 3-6, ring members per ring, such as
cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and the like.
"Optionally substituted cycloalkyl" denotes cycloalkyl or
cycloalkyl that is substituted with with 1 to 3 groups or
substituents as defined in [0057], or optionally substituted lower
alkyl, optionally substituted lower alkenyl, or optionally
substituted lower alkynyl, attached at any available atom to
produce a stable compound.
[0121] "Cycloalkylalkyl" refers to the group --R.sup.gg-Cyc where
Cyc is a cycloalkyl group and R.sup.gg is a lower alkylene group.
"Optionally substituted cycloalkylalkyl" denotes cycloalkylalkyl or
cycloalkylalkyl in which the alkylene group is optionally
substituted with 1 to 3 groups or substituents as defined in
[0057], attached at any available atom to produce a stable
compound, and in which the cycloalkyl group is optionally
substituted with 1 to 3 groups or substituents as defined in
[0057], or optionally substituted lower alkyl, optionally
substituted lower alkenyl, or optionally substituted lower alkynyl,
attached at any available atom to produce a stable compound.
[0122] "Heterocycloalkyl" means a saturated or unsaturated
non-aromatic cycloalkyl group having from 5 to 10 atoms in which
from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of
O, S or N, and are optionally fused with benzo or heteroaryl of 5-6
ring members. Heterocycloalkyl is also intended to include oxidized
S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring
nitrogen. The point of attachment of the heterocycloalkyl ring is
at a carbon or nitrogen atom such that a stable ring is retained.
Examples of heterocycloalkyl groups include, but are not limited
to, morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl,
pyrrolidinyl, piperazinyl, dihydrobenzofuryl, and dihydroindolyl.
"Optionally substituted heterocycloalkyl" denotes heterocycloalkyl
or heterocycloalkyl that is substituted with with 1 to 3 groups or
substituents as defined in [0057], or optionally substituted lower
alkyl, optionally substituted lower alkenyl, or optionally
substituted lower alkynyl, attached at any available carbon or
nitrogen to produce a stable compound.
[0123] "Heterocycloalkylalkyl" refers to the group --R.sup.hh-Het
where Het is a heterocycloalkyl group and R.sup.hh is a lower
alkylene group. "Optionally substituted heterocycloalkylalkyl"
denotes heterocycloalkylalkyl or heterocycloalkylalkyl in which the
alkylene group is optionally substituted with 1 to 3 groups or
substituents as defined in [0057], attached at any available atom
to produce a stable compound, and in which the heterocycloalkyl
group is optionally substituted with 1 to 3 groups or substituents
as defined in [0057], or optionally substituted lower alkyl,
optionally substituted lower alkenyl, or optionally substituted
lower alkynyl, attached at any available carbon or nitrogen to
produce a stable compound.
[0124] "Optionally substituted alkylsulfinyl" denotes the group
--S(O)R.sup.ii, wherein R.sup.ii is optionally substituted lower
alkyl.
[0125] "Optionally substituted arylsulfinyl" denotes the group
--S(O)R.sup.jj, wherein R.sup.jj is optionally substituted
aryl.
[0126] "Optionally substituted heteroarylsulfinyl" denotes the
group --S(O)R.sup.kk, wherein R.sup.kk is optionally substituted
heteroaryl.
[0127] "Optionally substituted cycloalkylsulfinyl" denotes the
group --S(O)R.sup.LL, wherein R.sup.LL is optionally substituted
cycloalkyl.
[0128] "Optionally substituted heterocycloalkylsulfinyl" denotes
the group --S(O)R.sup.mm, wherein R.sup.mm is optionally
substituted heterocycloalkyl.
[0129] "Optionally substituted alkylsulfonyl" denotes the group
--S(O).sub.2R.sup.nn, wherein R.sup.nn is optionally substituted
lower alkyl.
[0130] "Optionally substituted arylsulfonyl" denotes the group
--S(O).sub.2R.sup.oo, wherein R.sup.oo is optionally substituted
aryl.
[0131] "Optionally substituted heteroarylsulfonyl" denotes the
group --S(O).sub.2R.sup.pp, wherein R.sup.pp is optionally
substituted heteroaryl.
[0132] "Optionally substituted cycloalkylsulfonyl" denotes the
group --S(O).sub.2R.sup.qq, wherein R.sup.qq is optionally
substituted cycloalkyl.
[0133] "Optionally substituted heterocycloalkylsulfonyl" denotes
the group --S(O).sub.2R.sup.rr, wherein R.sup.rr is optionally
substituted heterocycloalkyl.
[0134] "Optionally substituted alkylsulfonylamino" denotes the
group --NR.sup.ssS(O).sub.2R.sup.tt, wherein R.sup.tt is optionally
substituted lower alkyl, and R.sup.ss is hydrogen or optionally
substituted lower alkyl.
[0135] "Optionally substituted arylsulfonylamino" denotes the group
--NR.sup.uuS(O).sub.2R.sup.vv, wherein R.sup.vv is optionally
substituted aryl, and R.sup.uu is hydrogen or optionally
substituted lower alkyl.
[0136] "Optionally substituted heteroarylsulfonylamino" denotes the
group --NR.sup.wwS(O).sub.2R.sup.xx, wherein R.sup.xx is optionally
substituted heteroaryl, and R.sup.ww is hydrogen or optionally
substituted lower alkyl.
[0137] "Optionally substituted cycloalkylsulfonylamino" denotes the
group --NR.sup.yyS(O).sub.2R.sup.zz, wherein R.sup.zz is optionally
substituted cycloalkyl, and R.sup.yy is hydrogen or optionally
substituted lower alkyl.
[0138] "Optionally substituted heterocycloalkylsulfonylamino"
denotes the group --NR.sup.baS(O).sub.2R.sup.bc, wherein R.sup.bc
is optionally substituted heterocycloalkyl, and R.sup.ba is
hydrogen or optionally substituted lower alkyl.
[0139] "Optionally substituted alkylcarbonylamino" denotes the
group --NR.sup.bdC(O)R.sup.be, wherein R.sup.be is optionally
substituted lower alkyl, and R.sup.bd is hydrogen or optionally
substituted lower alkyl.
[0140] "Optionally substituted arylcarbonylamino" denotes the group
--NR.sup.bfC(O)R.sup.bg, wherein R.sup.bg is optionally substituted
aryl, and R.sup.bf is hydrogen or optionally substituted lower
alkyl.
[0141] "Optionally substituted heteroarylcarbonylamino" denotes the
group --NR.sup.bhC(O)R.sup.bi, wherein R.sup.bi is optionally
substituted heteroaryl, and R.sup.bh is hydrogen or optionally
substituted lower alkyl.
[0142] "Optionally substituted cycloalkylcarbonylamino" denotes the
group --NR.sup.bjC(O)R.sup.bk, wherein R.sup.bk is optionally
substituted cycloalkyl, and R.sup.bj is hydrogen or optionally
substituted lower alkyl.
[0143] "Optionally substituted heterocycloalkylcarbonylamino"
denotes the group --NR.sup.blC(O)R.sup.bm, wherein R.sup.bm is
optionally substituted heterocycloalkyl, and R.sup.bl is hydrogen
or optionally substituted lower alkyl.
[0144] As used herein, the terms "ligand" and "modulator" are used
equivalently to refer to a compound that changes the activity of a
target biomolecule, e.g., a PPAR. Generally a ligand or modulator
will be a small molecule, where "small molecule" refers to a
compound with a molecular weight of 1500 daltons or less, or
preferably 1000 daltons or less, 800 daltons or less, or 600
daltons or less. The effects of a PPAR may be modulated by a
compound, for example, by increasing or decreasing the binding to
transcriptional coactivators or transcriptional corepressors,
resulting in changes in the expression levels of various target
proteins or the activity of other transcription factors. In one
instance, a PPAR agonist might function by enhancing the binding to
coactivators, in another an antagonist could result in an increase
in the binding to corepressors. In other cases, modulation might
occur through the interference or enhancement of the binding of an
agonist (natural or unnatural) to the PPAR. Upon binding an
agonist, the conformation of a PPAR is altered and stabilized such
that a binding cleft, made up in part of the AF-2 domain, is
created and recruitment of transcriptional coactivators can occur.
Coactivators enable nuclear receptors to initiate the transcription
process. The result of the agonist-induced PPAR-coactivator
interaction at the PPRE is an increase in gene transcription.
Further, in connection with ligands and modulators of PPAR, the
term "specific for PPAR" and terms of like import mean that a
particular compound binds to a PPAR to a statistically greater
extent than to other biomolecules that may be present in or
originally isolated from a particular organism, e.g., at least 2,
3, 4, 5, 10, 20, 50, 100, or 1000-fold. Also, where biological
activity other than binding is indicated, the term "specific for
PPAR" indicates that a particular compound has greater biological
effect on PPAR than do other biomolecules (e.g., at a level as
indicated for binding specificity). Similarly, the specificity can
be for a specific PPAR isoform with respect to other PPAR isoforms
that may be present in or originally isolated from a particular
organism. In the context of ligands interacting with PPARs, the
terms "activity on", "activity toward," and like terms mean that
such ligands have EC.sub.50 or IC.sub.50 less than 10 mM, less than
1 mM, less than 100 nM, less than 50 nM, less than 20 nM, less than
10 nM, less than 5 nM, or less than 1 nM with respect to at least
one PPAR as determined in a generally accepted PPAR activity
assay.
[0145] Also in the context of compounds binding to a biomolecular
target, the term "greater specificity" indicates that a compound
binds to a specified target to a greater extent than to another
biomolecule or biomolecules that may be present under relevant
binding conditions, where binding to such other biomolecules
produces a different biological activity than binding to the
specified target. In some cases, the specificity is with reference
to a limited set of other biomolecules, e.g., in the case of PPARs,
in some cases the reference may be to other receptors, or for a
particular PPAR, it may be other PPARs. In particular embodiments,
the greater specificity is at least 2, 3, 4, 5, 8, 10, 50, 100,
200, 400, 500, or 1000-fold greater specificity.
[0146] The term "pharmaceutical composition" refers to a
preparation that includes a therapeutically significant quantity of
an active agent, which is prepared in a form adapted for
administration to a subject. Thus, the preparation is
"pharmaceutically acceptable", indicating that it does not have
properties that would cause a reasonably prudent medical
practitioner to avoid administration of the material to a patient,
taking into consideration the disease or conditions to be treated
and the respective route of administration. In many cases, such a
pharmaceutical composition is a sterile preparation, e.g. for
injectibles.
[0147] The term "PPAR-mediated" disease or condition and like terms
refer to a disease or condition in which the biological function of
a PPAR affects the development and/or course of the disease or
condition, and/or in which modulation of PPAR alters the
development, course, and/or symptoms of the disease or condition.
Similarly, the phrase "PPAR modulation provides a therapeutic
benefit" indicates that modulation of the level of activity of PPAR
in a subject indicates that such modulation reduces the severity
and/or duration of the disease, reduces the likelihood or delays
the onset of the disease or condition, and/or causes an improvement
in one or more symptoms of the disease or condition. In some cases
the disease or condition may be mediated by any one or more of the
PPAR isoforms, e.g., PPAR.gamma., PPAR.alpha., PPAR.delta.,
PPAR.gamma. and PPAR.alpha., PPAR.gamma. and PPAR.delta.,
PPAR.alpha. and PPAR.delta., or PPAR.gamma., PPAR.alpha., and
PPAR.delta..
[0148] The term "composition" refers to a formulation suitable for
administration to an intended animal subject for therapeutic
purposes that contains at least one pharmaceutically active
compound.
[0149] The term "therapeutically effective" indicates that the
materials or amount of material is effective to prevent, alleviate,
or ameliorate one or more symptoms of a disease or medical
condition, and/or to prolong the survival of the subject being
treated.
[0150] A "pharmaceutically acceptable salt" is intended to mean a
salt that retains the biological effectiveness of the free acid and
base forms of the specified compound and that is not biologically
or otherwise unacceptable. A compound of the invention may possess
a sufficiently acidic, a sufficiently basic, or both functional
groups, and accordingly react with any of a number of inorganic or
organic bases, and inorganic and organic acids, to form a
pharmaceutically acceptable salt. Exemplary pharmaceutically
acceptable salts include those salts prepared by reaction of the
compounds of the present invention with a mineral or organic acid
or base, such as salts including sodium, chloride, sulfates,
pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,
monohydrogenphosphates, dihydrogenphosphates, metaphosphates,
pyrophosphates, chlorides, bromides, iodides, acetates,
propionates, decanoates, caprylates, acrylates, formates,
isobutyrates, caproates, heptanoates, propiolates, oxalates,
malonates, succinates, suberates, sebacates, ftimarates, maleates,
butyne-1,4 dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates,
methylbenzoates, dinitrobenzoates, hydroxybenzoates,
methoxybenzoates, phthalates, sulfonates, xylenesulfonates,
phenylacetates, phenylpropionates, phenylbutyrates, citrates,
lactates, .gamma.-hydroxybutyrates, glycollates, tartrates,
methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates,
naphthalene-2-sulfonates, and mandelates.
[0151] The term "pharmaceutically acceptable metabolite" refers to
a pharmacologically acceptable product, which may be an active
product, produced through metabolism of a specified compound (or
salt thereof) in the body of a subject or patient. Metabolites of a
compound may be identified using routine techniques known in the
art, and their activities determined using tests such as those
described herein. For example, in some compounds, one or more
alkoxy groups can be metabolized to hydroxyl groups while retaining
pharmacologic activity and/or carboxyl groups can be esterified,
e.g., glucuronidation. In some cases, there can be more than one
metabolite, where an intermediate metabolite(s) is further
metabolized to provide an active metabolite. For example, in some
cases a derivative compound resulting from metabolic
glucuronidation may be inactive or of low activity, and can be
further metabolized to provide an active metabolite.
[0152] The term "PPAR" refers to a peroxisome
proliferator-activated receptor as recognized in the art. As
indicated above, the PPAR family includes PPAR.alpha. (also
referred to as PPAR.alpha. or PPARalpha), PPAR.delta. (also
referred to as PPARd or PPARdelta), and PPAR.gamma. (also referred
to as PPARg or PPARgamma). The individual PPARs can be identified
by their sequences, where exemplary reference sequence accession
numbers are: NM.sub.--005036 (cDNA sequence for hPPARa) SEQ ID
NO:______, NP.sub.--005027 (protein sequence for hPPARa) SEQ ID
NO:______, NM.sub.--015869 (cDNA sequence for hPPARg isoform 2) SEQ
ID NO:______, NP.sub.--056953 (protein sequence for hPPARg isoform
2) SEQ ID NO:______, NM.sub.--006238 (cDNA sequence for hPPARd) SEQ
ID NO:______, and NP.sub.--006229 (protein sequence for hPPARd) SEQ
ID NO:______. One of ordinary skill in the art will recognize that
sequence differences will exist due to allelic variation, and will
also recognize that other animals, particularly other mammals, have
corresponding PPARs, which have been identified or can be readily
identified using sequence alignment and confirmation of activity,
can also be used. One of ordinary skill in the art will also
recognize that modifications can be introduced in a PPAR sequence
without destroying PPAR activity. Such modified PPARs can also be
used in the present invention, e.g., if the modifications do not
alter the binding site conformation to the extent that the modified
PPAR lacks substantially normal ligand binding.
[0153] As used herein in connection with the design or development
of ligands, the term "bind" and "binding" and like terms refer to a
non-covalent energetically favorable association between the
specified molecules (i.e., the bound state has a lower free energy
than the separated state, which can be measured calorimetrically).
For binding to a target, the binding is at least selective, that
is, the compound binds preferentially to a particular target or to
members of a target family at a binding site, as compared to
non-specific binding to unrelated proteins not having a similar
binding site. For example, BSA is often used for evaluating or
controlling for non-specific binding. In addition, for an
association to be regarded as binding, the decrease in free energy
going from a separated state to the bound state must be sufficient
so that the association is detectable in a biochemical assay
suitable for the molecules involved.
[0154] By "assaying" is meant the creation of experimental
conditions and the gathering of data regarding a particular result
of the experimental conditions. For example, enzymes can be assayed
based on their ability to act upon a detectable substrate.
Likewise, for example, a compound or ligand can be assayed based on
its ability to bind to a particular target molecule or molecules
and/or to modulate an activity of a target molecule.
[0155] By "background signal" in reference to a binding assay is
meant the signal that is recorded under standard conditions for the
particular assay in the absence of a test compound, molecular
scaffold, or ligand that binds to the target molecule. Persons of
ordinary skill in the art will realize that accepted methods exist
and are widely available for determining background signal.
[0156] By "binding site" is meant an area of a target molecule to
which a ligand can bind non-covalently. Binding sites embody
particular shapes and often contain multiple binding pockets
present within the binding site. The particular shapes are often
conserved within a class of molecules, such as a molecular family.
Binding sites within a class also can contain conserved structures
such as, for example, chemical moieties, the presence of a binding
pocket, and/or an electrostatic charge at the binding site or some
portion of the binding site, all of which can influence the shape
of the binding site.
[0157] By "binding pocket" is meant a specific volume within a
binding site. A binding pocket is a particular space within a
binding site at least partially bounded by target molecule atoms.
-Thus-a-binding-pocket-is-a-particular-shape; indentation, or
cavity-in the binding site. Binding pockets can contain particular
chemical groups or structures that are important in the
non-covalent binding of another molecule such as, for example,
groups that contribute to ionic, hydrogen bonding, van der Waals,
or hydrophobic interactions between the molecules.
[0158] By "chemical structure" or "chemical substructure" is meant
any definable atom or group of atoms that constitute a part of a
molecule. Normally, chemical substructures of a scaffold or ligand
can have a role in binding of the scaffold or ligand to a target
molecule, or can influence the three-dimensional shape,
electrostatic charge, and/or conformational properties of the
scaffold or ligand.
[0159] By "orientation", in reference to a binding compound bound
to a target molecule is meant the spatial relationship of the
binding compound and at least some of its consitituent atoms to the
binding pocket and/or atoms of the target molecule at least
partially defining the binding pocket.
[0160] By "clog P" is meant the calculated log P of a compound, "P"
referring to the partition coefficient of the compound between a
lipophilic and an aqueous phase, usually between octanol and
water.
[0161] In the context of compounds binding to a target, the term
"greater affinity" indicates that the compound binds more tightly
than a reference compound, or than the same compound in a reference
condition, i.e., with a lower dissociation constant. In particular
embodiments, the greater affinity is at least 2, 3, 4, 5, 8, 10,
50, 100, 200, 400, 500, 1000, or 10,000-fold greater affinity.
[0162] By binding with "moderate affinity" is meant binding with a
K.sub.D of from about 200 nM to about 1 .mu.M under standard
conditions. By "moderately high affinity" is meant binding at a
K.sub.D of from about 1 nM to about 200 nM. By binding at "high
affinity" is meant binding at a K.sub.D of below about 1 nM under
standard conditions. The standard conditions for binding are at pH
7.2 at 37.degree. C. for one hour. For example, typical binding
conditions in a volume of 100 .mu.l/well would comprise a PPAR, a
test compound, HEPES 50 mM buffer at pH 7.2, NaCl 15 mM, ATP 2
.mu.M, and bovine serum albumin (1 ug/well), at 37.degree. C. for
one hour.
[0163] Binding compounds can also be characterized by their effect
on the activity of the target molecule. Thus, a "low activity"
compound has an inhibitory concentration (IC.sub.50) (for
inhibitors or antagonists) or effective concentration (EC.sub.50)
(applicable to agonists) of greater than 1 .mu.M under standard
conditions. By "moderate activity" is meant an IC.sub.50 or
EC.sub.50 of 200 nM to 1 .mu.M under standard conditions. By
"moderately high activity" is meant an IC.sub.50 or EC.sub.50 of 1
nM to 200 nM. By "high activity" is meant an IC.sub.50 or EC.sub.50
of below 1 nM under standard conditions. The IC.sub.50 (or
EC.sub.50) is defined as the concentration of compound at which 50%
of the activity of the target molecule (e.g., enzyme or other
protein) activity being measured is lost (or gained) relative to
activity when no compound is present. Activity can be measured
using methods known to those of ordinary skill in the art, e.g., by
measuring any detectable product or signal produced by occurrence
of an enzymatic reaction, or other activity by a protein being
measured. For PPAR agonists, activities can be determined as
described in the Examples, or using other such assay methods known
in the art.
[0164] By "protein-ligand complex" or "co-complex" is meant a
protein and ligand bound non-covalently together.
[0165] By "protein" is meant a polymer of amino acids. The amino
acids can be naturally or non-naturally occurring. Proteins can
also contain modifications, such as being glycosylated,
phosphorylated, or other common modifications.
[0166] By "protein family" is meant a classification of proteins
based on structural and/or functional similarities. For example,
kinases, phosphatases, proteases, and similar groupings of proteins
are protein families. Proteins can be grouped into a protein family
based on having one or more protein folds in common, a substantial
similarity in shape among folds of the proteins, homology, or based
on having a common function. In many cases, smaller families will
be specified, e.g., the PPAR family.
[0167] By "specific biochemical effect" is meant a therapeutically
significant biochemical change in a biological system causing a
detectable result. This specific biochemical effect can be, for
example, the inhibition or activation of an enzyme, the inhibition
or activation of a protein that binds to a desired target, or
similar types of changes in the body's biochemistry. The specific
biochemical effect can cause alleviation of symptoms of a disease
or condition or-another desirable effect. The detectable result can
also be detected through an intermediate step.
[0168] By "standard conditions" is meant conditions under which an
assay is performed to obtain scientifically meaningful data.
Standard conditions are dependent on the particular assay, and can
be generally subjective. Normally the standard conditions of an
assay will be those conditions that are optimal for obtaining
useful data from the particular assay. The standard conditions will
generally minimize background signal and maximize the signal sought
to be detected.
[0169] By "standard deviation" is meant the square root of the
variance. The variance is a measure of how spread out a
distribution is. It is computed as the average squared deviation of
each number from its mean. For example, for the numbers 1, 2, and
3, the mean is 2 and the variance is: .sigma. 2 = ( 1 - 2 ) 2 + ( 2
- 2 ) 2 + ( 3 - 2 ) 2 3 = 0.667 . ##EQU1##
[0170] In the context of this invention, by "target molecule" is
meant a molecule that a compound, molecular scaffold, or ligand is
being assayed for binding to. The target molecule has an activity
that binding of the molecular scaffold or ligand to the target
molecule will alter or change. The binding of the compound,
scaffold, or ligand to the target molecule can preferably cause a
specific biochemical effect when it occurs in a biological system.
A "biological system" includes, but is not limited to, a living
system such as a human, animal, plant, or insect. In most but not
all cases, the target molecule will be a protein or nucleic acid
molecule.
[0171] By "pharmacophore" is meant a representation of molecular
features that are considered to be responsible for a desired
activity, such as interacting or binding with a receptor. A
pharmacophore can include 3-dimensional (hydrophobic groups,
charged/ionizable groups, hydrogen bond donors/acceptors), 2D
(substructures), and 1D (physical or biological) properties.
[0172] As used herein in connection with numerical values, the
terms "approximately" and "about" mean .+-.10% of the indicated
value.
I. Applications of PPAR Agonists
[0173] The PPARs have been recognized as suitable targets for a
number of different diseases and conditions. Some of those
applications are described briefly below. Additional applications
are known and the present compounds can also be used for those
diseases and conditions.
[0174] (a) Insulin resistance and diabetes: In connection with
insulin resistance and diabetes, PPAR.gamma. is necessary and
sufficient for the differentiation of adipocytes in vitro and in
vivo. In adipocytes, PPAR.gamma. increases the expression of
numerous genes involved in lipid metabolism and lipid uptake. In
contrast, PPAR.gamma. down-regulates leptin, a secreted,
adipocyte-selective protein that has been shown to inhibit feeding
and augment catabolic lipid metabolism. This receptor activity
could explain the increased caloric uptake and storage noted in
vivo upon treatment with PPAR.gamma. agonists. Clinically, TZDs,
including troglitazone, rosiglitazone, and pioglitazone, and
non-TZDs, including farglitazar, have insulin-sensitizing and
antidiabetic activity. (Bergen & Wagner, supra.)
[0175] PPAR.gamma. has been associated with several genes that
affect insulin action. TNF.alpha., a proinflammatory cytokine that
is expressed by adipocytes, has been associated with insulin
resistance. PPAR.gamma. agonists inhibited expression of TNF.alpha.
in adipose tissue of obese rodents, and ablated the actions of
TNF.alpha. in adipocytes in vitro. PPAR.gamma. agonists were shown
to inhibit expression of 11.beta.-hydroxysteroid dehydrogenase 1
(11.beta.-HSD-1), the enzyme that converts cortisone to the
glucocorticoid agonist cortisol, in adipocytes and adipose tissue
of type 2 diabetes mouse models. This is noteworthy since
hypercortico-steroidism exacerbates insulin resistance. Adipocyte
Complement-Related Protein of 30 kDa (Acrp30 or adiponectin) is a
secreted adipocyte-specific protein that decreases glucose,
triglycerides, and free fatty acids. In comparison to normal human
subjects, patients with type 2 diabetes have reduced plasma levels
of Acrp30. Treatment of diabetic mice and nondiabetic human
subjects with PPAR.gamma. agonists increased plasma levels of
Acrp30. Induction of Acrp30 by PPAR.gamma. agonists might therefore
also play a key role in the insulin-sensitizing mechanism of
PPAR.gamma. agonists in diabetes. (Bergen & Wagner, supra.)
[0176] PPAR.gamma. is expressed predominantly in adipose tissue.
Thus, it is believed that the net in vivo efficacy of PPAR.gamma.
agonists involves direct actions on adipose cells with secondary
effects in key insulin responsive tissues such as skeletal muscle
and liver. This is supported by the lack of glucose-lowering
efficacy of rosiglitazone in a mouse model of severe insulin
resistance where white adipose tissue was essentially absent.
Furthermore, in vivo treatment of insulin resistant rats produces
acute (<24 h) normalization of adipose tissue insulin action
whereas insulin-mediated glucose uptake in muscle was not improved
until several days after the initiation of therapy. This is
consistent with the fact that PPAR.gamma. agonists can produce an
increase in adipose tissue insulin action after direct in vitro
incubation, whereas no such effect could be demonstrated using
isolated in vitro incubated skeletal muscles. The beneficial
metabolic effects of PPAR.gamma. agonists on muscle and liver may
be mediated by their ability to (a) enhance insulin-mediated
adipose tissue uptake, storage (and potentially catabolism) of free
fatty acids; (b) induce the production of adipose-derived factors
with potential insulin sensitizing activity (e.g., Acrp30); and/or
(c) suppress the circulating levels and/or actions of insulin
resistance-causing adipose-derived factors such as TNF.alpha. or
resistin. (Bergen & Wagner, supra.)
[0177] (b) Dyslipidemia and atherosclerosis: In connection with
dyslipidemia and atherosclerosis, PPAR.alpha. has been shown to
play a critical role in the regulation of cellular uptake,
activation, and .beta.-oxidation of fatty acids. Activation of
PPAR.alpha. induces expression of fatty acid transport proteins and
enzymes in the peroxisomal .beta.-oxidation pathway. Several
mitochondrial enzymes involved in the energy-harvesting catabolism
of fatty acids are robustly upregulated by PPAR.alpha. agonists.
Peroxisome proliferators also activate expression of the CYP4As, a
subclass of cytochrome P450 enzymes that catalyze the
.omega.-hydroxylation of fatty acids, a pathway that is
particularly active in the fasted and diabetic states. In sum, it
is clear that PPAR.alpha. is an important lipid sensor and
regulator of cellular energy-harvesting metabolism. (Bergen &
Wagner, supra.)
[0178] Atherosclerosis is a very prevalent disease in Westernized
societies. In addition to a strong association with elevated LDL
cholesterol, "dyslipidemia" characterized by elevated
triglyceride-rich particles and low levels of HDL cholesterol is
commonly associated with other aspects of a metabolic syndrome that
includes obesity, insulin resistance, type 2 diabetes, and an
increased risk of coronary artery disease. Thus, in 8,500 men with
known coronary artery disease, 38% were found to have low HDL
(<35 mg/dL) and 33% had elevated triglycerides (>200 mg/dL).
In such patients, treatment with fibrates resulted in substantial
triglyceride lowering and modest HDL-raising efficacy.
More-importantly, a recent large prospective trial showed
that-treatment with gemfibrozil produced a 22% reduction in
cardiovascular events or death. Thus PPAR.alpha. agonists can
effectively improve cardiovascular risk factors and have a net
benefit to improve cardiovascular outcomes. In fact, fenofibrate
was recently approved in the United States for treatment of type
IIA and IIB hyper-lipidemia. Mechanisms by which PPAR.alpha.
activation cause triglyceride lowering are likely to include the
effects of agonists to suppress hepatic apo-CIII gene expression
while also stimulating lipoprotein lipase gene expression. Dual
PPAR.gamma./.alpha. agonists, including KRP-297 and DRF 2725,
possess potent lipid-altering efficacy in addition to
antihyperglycemic activity in animal models of diabetes and lipid
disorders.
[0179] The presence of PPAR.alpha. and/or PPAR.gamma. expression in
vascular cell types, including macrophages, endothelial cells, and
vascular smooth muscle cells, suggests that direct vascular effects
might contribute to potential antiatherosclerosis efficacy.
PPAR.alpha. and PPAR.alpha. activation have been shown to inhibit
cytokine-induced vascular cell adhesion and to suppress
monocyte-macrophage migration. Several additional studies have also
shown that PPAR.gamma.-selective compounds have the capacity to
reduce arterial lesion size and attenuate monocyte-macrophage
homing to arterial lesions in animal models of atherosclerosis.
PPAR.gamma. is present in macrophages in human atherosclerotic
lesions, and may play a role in regulation of expression of matrix
metalloproteinase-9 (MMP-9), which is implicated in atherosclerotic
plaque rupture (Marx et al., Am J Pathol. 1998, 153(1):17-23).
Downregulation of LPS induced secretion of MMP-9 was also observed
for both PPAR.alpha. and PPAR.gamma. agonists, which may account
for beneficial effects observed with PPAR agonists in animal models
of atherosclerosis (Shu et al., Biochem Biophys Res Commun. 2000,
267(1):345-9). PPAR.gamma. is also shown to have a role in
intercellular adhesion molecule-1 (ICAM-1) protein expression (Chen
et al., Biochem Biophys Res Commun. 2001, 282(3):717-22) and
vascular cell adhesion molecule-1 (VCAM-1) protein expression
(Jackson et al., Arterioscler Thromb Vasc Biol. 1999,
19(9):2094-104) in endothelial cells, both of which play a role in
the adhesion of monocytes to endothelial cells. In addition, two
recent studies have suggested that either PPAR.alpha. or
PPAR.gamma. activation in macrophages can induce the expression of
a cholesterol efflux "pump" protein.
[0180] It has been found that relatively selective PPAR.delta.
agonists produce minimal, if any, glucose- or triglyceride-lowering
activity in murine models of type 2 diabetes in comparison with
efficacious PPAR.gamma. or PPAR.alpha. agonists. Subsequently, a
modest increase in HDL-cholesterol levels was detected with
PPAR.delta. agonists in db/db mice. Recently, Oliver et al. (supra)
reported that a potent, selective PPAR.delta. agonist could induce
a substantial increase in HDL-cholesterol levels while reducing
triglyceride levels and insulin resistance in obese rhesus
monkeys.
[0181] Thus, via multifactor mechanisms that include improvements
in circulating lipids, systemic and local anti-inflammatory
effects, and, inhibition of vascular cell proliferation,
PPAR.alpha., PPAR.gamma., and PPAR.delta. agonists can be used in
the treatment or prevention of atherosclerosis. (Bergen &
Wagner, supra.)
[0182] (c) Inflammation: Monocytes and macrophages are known to
play an important part in the inflammatory process through the
release of inflammatory cytokines and the production of nitric
oxide by inducible nitric oxide synthase. Rosiglitazone has been
shown to induce apoptosis of macrophages at concentrations that
paralleled its affinity for PPAR.gamma.. This ligand has also been
shown to block inflammatory cytokine synthesis in colonic cell
lines. This latter observation suggests a mechanistic explanation
for the observed anti-inflammatory actions of TZDs in rodent models
of colitis. Additional studies have examined the relationship
between macrophages, cytokines and PPAR.gamma. and agonists thereof
(Jiang et al., Nature 1998, 391(6662):82-6., Ricote et al., Nature
1998, 391(6662):79-82, Hortelano et al., J. Immunol. 2000,
165(11):6525-31, and Chawla et al., Nat Med. 2001, 7(l):48-52)
suggesting a role for PPAR.gamma. agonists in treating inflammatory
responses, for example in autoimmune diseases.
[0183] The migration of monocytes and macrophages plays a role in
the development of inflammatory responses as well. PPAR ligands
have been shown to have an effect on a variety of chemokines.
Monocyte chemotactic protein-I (MCP-1) directed migration of
monocytes is attenuated by PPAR.gamma. and PPAR.alpha. ligands in a
monocytic leukemia cell line (Kintscher et al., Eur J Pharmacol.
2000, 401(3):259-70). MCP-1 gene expression was shown to be
suppressed by PPAR.gamma. ligand 15-deoxy-Delta(12,14)PGJ2
(15d-PGJ2) in two monocytic cell lines, which also showed induction
of IL-8 gene expression (Zhang et al., J Immunol. 2001,
166(12):7104-11).
[0184] Anti-inflammatory actions have been described for
PPAR.alpha. ligands that can be important in the maintenance of
vascular health. Treatment of cytokine-activated human macrophages
with PPAR.alpha. agonists induced apoptosis of the cells. It was
reported that PPAR.alpha. agonists inhibited activation of aortic
smooth muscle cells in response to inflammatory stimuli (Staels et
al., Nature 1998, 393:790-793.) In hyperlipidemic patients,
fenofibrate treatment decreased the plasma concentrations of the
inflammatory cytokine interleukin-6.
[0185] Anti-inflammatory pathways in airway smooth muscle cells
were investigated with respect to PPAR.alpha. and PPAR.gamma.
(Patel et al., The Journal of Immunology, 2003, 170:2663-2669).
This study demonstrated an anti-inflammatory effect of a
PPAR.gamma. ligand that may be useful in the treatment of COPD and
steroid-insensitive asthma.
[0186] (d) Hypertension: Hypertension is a complex disorder of the
cardiovascular system that has been shown to be associated with
insulin resistance. Type 2 diabetes patients demonstrate a
1.5-2-fold increase in hypertension in comparison with the general
population. Troglitazone, rosiglitazone, and pioglitazone therapy
have been shown to decrease blood pressure in diabetic patients as
well as troglitazone therapy in obese, insulin-resistant subjects.
Since such reductions in blood pressure were shown to correlate
with decreases in insulin levels, they can be mediated by an
improvement in insulin sensitivity. However, since TZDs also
lowered blood pressure in one-kidney one-clip Sprague Dawley rats,
which are not insulin resistant, it was proposed that the
hypotensive action of PPAR.gamma. agonists is not exerted solely
through their ability to improve insulin sensitivity. Other
mechanisms that have been invoked to explain the antihypertensive
effects of PPAR.gamma. agonists include their ability to (a)
downregulate expression of peptides that control vascular tone such
as PAI-I, endothelin, and type-c natriuretic peptide C or (b) alter
calcium concentrations and the calcium sensitivity of vascular
cells. (Bergen & Wagner, supra.)
[0187] (e) Cancer: PPAR modulation has also been correlated with
cancer treatment. (Burstein et al.; Breast Cancer Res. Treat. 2003,
79(3):391-7; Alderd et al.; Oncogene, 2003, 22(22):3412-6).
[0188] (f) weight Control: Administration of PPAR.alpha. agonists
can induce satiety, and thus are useful in weight loss or
maintenance. Such PPAR.alpha. agonists can act preferentially on
PPAR.alpha., or can also act on another PPAR, or can be PPAR
pan-agonists. Thus, the satiety inducing effect of PPAR.alpha.
agonists can be used for weight control or loss.
[0189] (g) Autoimmune diseases: PPAR agonists may provide benefits
in the treatment of autoimmune diseases. Agonists of PPAR isoforms
may be involved in T cell and B cell trafficking or activity, the
altering of oligodendrocyte function or differentiation, the
inhibition of macrophage activity, the reduction of inflammatory
responses, and neuroprotective effects, some or all of which may be
important in a variety of autoimmune diseases.
[0190] Multiple sclerosis (MS) is a neurodegenerative autoimmune
disease that involves the demyelination of axons and formation of
plaques. PPAR.delta. mRNA has been shown to be strongly expressed
in immature oligodendrocytes (Granneman et al., J Neurosci Res.
1998, 51 (5):563-73). PPAR.delta. selective agonists or
pan-agonists were shown to accelerate differentiation of
oligodendrocytes, with no effect on differentiation observed with a
PPAR.gamma. selective agonist. An alteration in the myelination of
corpus callosum was observed in PPAR.delta. null mice (Peters et
al., Mol Cell Biol. 2000, 20(14):5119-28). It was also shown that
PPAR.delta. mRNA and protein is expressed throughout the brain in
neurons and oligodendrocytes, but not in astrocytes (Woods et al.,
Brain Res. 2003, 975(1-2):10-21). These observations suggest that
PPAR.delta. has a role in myelination, where modulation of such a
role could be used to treat multiple sclerosis by altering the
differentiation of oligodendrocytes, which may result in slowing of
the demyelination, or even promoting the remyelination of axons. It
has also been shown that oligodendrocyte-like B12 cells, as well as
isolated spinal cord oligodendrocytes from rat, are affected by
PPAR.gamma. agonists. Alkyl-dihydroxyacetone phosphate synthase, a
key peroxisomal enzyme involved in the synthesis of plasmologens,
which are a key component of myelin, is increased in PPAR.gamma.
agonist treated B12 cells, while the number of mature cells in
isolated spinal cord oligodendrocytes increases with PPAR.gamma.
agonist treatment.
[0191] The role of PPARs in the regulation of B and T cells may
also provide therapeutic benefits in diseases such as MS. For
example, it has been shown that PPAR.gamma. agonists can inhibit
the secretion of IL-2 by T cells (Clark et al., J Immunol. 2000,
164(3):1364-71) or may induce apoptosis in T cells (Harris et al.,
Eur J Immunol. 2001, 31(4):1098-105), suggesting an important role
in cell-mediated immune responses. An antiproliferative and
cytotoxic effect on B cells by PPAR.gamma. agonists has also been
observed (Padilla et al., Clin Immunol. 2002, 103(1):22-33).
[0192] The anti-inflammatory effects of PPAR modulators, as
discussed herein, may also be useful in treating MS, as well as a
variety of other autoimmune diseases such as Type-1 diabetes
mellitus, psoriasis, vitiligo, uveitis, Sjogren's disease,
pemphigus foliaceus, inclusion body myositis, polymyositis,
dermatomyositis, scleroderma, Grave's disease, Hashimoto's disease,
chronic graft-versus host disease, rheumatoid arthritis,
inflammatory bowel syndrome, and Crohn's disease. Using a mouse
model, the PPAR.alpha. agonists gemfibrozil and fenofibrate were
shown to inhibit clinical signs of experimental autoimmune
encephalomyelitis, suggesting that PPAR.alpha. agonists may be
useful in treating inflammatory conditions such as multiple
sclerosis (Lovett-Racke et al., J Immunol. 2004,
172(9):5790-8).
[0193] Neuroprotective effects that appear to be associated with
PPARs may also aid in the treatment of MS. The effects of PPAR
agonists on LPS induced neuronal cell death were studied using
cortical neuron-glial co-cultures. PPAR.gamma. agonists 15d-PGJ2,
ciglitazone and troglitazone were shown to prevent the LPS-induced
neuronal cell death, as well as abolish NO and PGE2 release and a
reduction in iNOS and COX-2 expression (Kim et al., Brain Res.
2002, 941(1-2):1-10).
[0194] Rheumatoid arthritis (RA) is an autoimmune inflammatory
disease that results in the destruction of joints. In addition to
chronic inflammation and joint damage due in part to mediators such
as IL-6 and TNF-alpha, osteoclast differentiation is also
implicated in damage to the joints. PPAR agonists may regulate
these pathways, providing therapeutic benefits in treatment of RA.
In studies using PPAR.gamma. agonist troglitazone in
fibroblast-like synovial cells (FLS) isolated from patients with
rheumatoid arthritis, an inhibition of cytokine mediated
inflammatory responses was observed (Yamasaki et al., Clin Exp
Immunol., 2002, 129(2):379-84). PPAR.gamma. agonists have also
demonstrated beneficial effects in a rat or mouse model of RA
(Kawahito et al., J Clin Invest. 2000, 106(2):189-97; Cuzzocrea et
al., Arthritis Rheum. 2003, 48(12):3544-56). The effects of the
PPAR.alpha. ligand fenofibrate on rheumatoid synovial fibroblasts
from RA patients also showed inhibition of cytokine production, as
well as NF-KappaB activation and osteoclast differentiation.
Fenofibrate was also shown to inhibit the development of arthritis
in a rat model (Okamoto et al., Clin Exp Rheumatol. 2005,
23(3):323-30).
[0195] Psoriasis is a T cell mediated autoimmune disease, where T
cell activation leads to release of cytokines and resulting
proliferation of keratinocytes. In addition to anti-inflammatory
effects, the differentiation of keratinocytes may also be a
therapeutic target for PPAR agonists. Studies in a PPAR.delta. null
mouse model suggest using PPAR.delta. ligand to selectively induce
keratinocyte differentiation and inhibit cell proliferation (Kim et
al., Cell Death Differ. 2005). Thiazolidinedione ligands of
PPAR.gamma. have been shown to inhibit the proliferation of
psoriatic keratinocytes in monolayer and organ culture, and when
applied topically inhibit epidermal hyperplasia of human psoriatic
skin transplanted to SCID mice (Bhagavathula et al., J Pharmacol
Exp Ther. 2005,315(3):996-1004).
[0196] (h) Neurodegenerative diseases: The modulation of the PPARs
may provide benefits in the treatment of neuronal diseases. For
example, the anti-inflammatory effects of PPAR modulators discussed
herein have also been studied with respect to neuronal diseases
such as Alzheimer's disease and Parkinson's disease.
[0197] In addition to inflammatory processes, Alzheimer's disease
is characterized by deposits of amyloid-beta (Abeta) peptides and
neurofibrillary tangles. A decrease in the levels of Abeta peptide
in neuronal and non-neuronal cells was observed with induced
expression of PPAR.gamma., or by activation of PPAR.gamma. using a
thiazolidinedione (Camacho et al., J Neurosci. 2004,
24(48):10908-17). Treatment of APP717 mice with PPAR.gamma. agonist
pioglitazone showed several beneficial effects, including reduction
in activated microglia and reactive astrocytes in the hippocampus
and cortex, reduction in proinflammatory cyclooxygenase 2 and
inducible nitric oxide synthase, decreased .beta.-secretase-1 mRNA
and protein levels, and a reduction in the levels of soluble
Abeta1-42 peptide (Heneka et al., Brain. 2005, 128(Pt
6):1442-53).
[0198] Regions of degeneration of dopamine neurons in Parkinson's
disease have been associated with increased levels of inflammatory
cytokines (Nagatsu et al., J Neural Transm Suppl.
2000;(60):277-90). The effect of PPAR.gamma. agonist pioglitazone
on dopaminergic nerve cell death and glial activation was studied
in an MPTP mouse model of Parkinson's disease, wherein orally
administered pioglitazone resulted in reduced glial activation as
well as prevention of dopaminergic cell loss (Breidert et al.
Journal of Neurochemistry, 2002, 82: 615).
[0199] (i) Other indications: PPAR.gamma. modulators have shown
inhibition of VEGF-induced choroidal angiogenesis as well as
repression of choroidal neovascularization effects, suggesting
potential for treatment of retinal disorders. PPAR.delta. has been
shown to be expressed in implantation sites and in decidual cells
in rats, suggesting a role in pregnancy, such as to enhance
fertility. These studies were reviewed in Kota et al.,
Pharmacological Research, 2005, 51:85-94. The management of pain,
either neuropathic or inflammatory, is also suggested as a possible
target for PPAR modulators. Burstein, S., Life Sci. 2005,
77(14):1674-84, suggests that PPAR.gamma. provides a receptor
function for the activity of some cannabinoids. Lo Verme et al.,
Mol Pharmacol. 2005, 67(1):15-9, identifies PPAR.alpha. as a target
responsible for pain and inflammation reducing effects of
palmitoylethanolamide (PEA). PEA selectively activates PPAR.alpha.
in vitro, and induces expression of PPAR.alpha. mRNA when applied
topically to mice. In animal models of carrageenan-induced paw
edema and phorbol ester-induced ear edema, inflammation in wild
type mice is attenuated by PEA, which has no effect in PPAR.alpha.
deficient mice. PPAR.alpha. agonists OEA, GW7647 and Wy-14643
demonstrate similar effects. Benani et al., Neurosci Lett. 2004,
369(1):59-63, uses a model of inflammation in rats to assess the
PPAR response in the rat spinal cord following injection of
complete Freund's adjuvant into the hind paw. It was shown that
PPAR.alpha. was activated, suggesting a role in pain pathways.
[0200] In accordance with the description above, isoforms of the
PPAR family of nuclear receptors are clearly involved in the
systemic regulation of lipid metabolism and serve as "sensors" for
fatty acids, prostanoid metabolites, eicosanoids and related
molecules. These receptors function to regulate a broad array of
genes in a coordinate fashion. Important biochemical pathways that
regulate insulin action, lipid oxidation, lipid synthesis,
adipocyte differentiation, peroxisome function, cell apoptosis, and
inflammation can be modulated through the individual PPAR isoforms.
Strong therapeutic effects of PPAR.alpha. and PPAR.gamma. agonists
to favorably influence systemic lipid levels, glucose homeostasis,
and atherosclerosis risk (in the case of PPAR.alpha. activation in
humans) have recently been discovered. PPAR.alpha. and PPAR.gamma.
agonists are presently used clinically to favorably alter systemic
lipid levels and glucose homeostasis, respectively. Recent
observations made using PPARS ligands suggest that this isoform is
also an important therapeutic target for dyslipidemia and insulin
resistance, as well.
[0201] Thus, PPAR modulators, such as those described herein, can
be used in the prophylaxis and/or therapeutic treatment of a
variety of different disease and conditions, such as obesity,
overweight condition, hyperlipidemia, dyslipidemia including
associated diabetic dyslipidemia and mixed dyslipidemia,
hypoalphalipoproteinemia, Syndrome X, Type II diabetes mellitus,
Type I diabetes, hyperinsulinemia, impaired glucose tolerance,
insulin resistance, a diabetic complication (e.g., neuropathy,
nephropathy, retinopathy or cataracts), hypertension, coronary
heart disease, heart failure, hypercholesterolemia, inflammation,
thrombosis, congestive heart failure, cardiovascular disease
(including atherosclerosis, arteriosclerosis, and
hypertriglyceridemia), epithelial hyperproliferative diseases (such
as eczema and psoriasis), cancer, neuropathic or inflammatory pain,
conditions associated with the lung and gut, regulation of appetite
and food intake in subjects suffering from disorders such as
obesity, anorexia bulimia and anorexia nervosa, neurodegenerative
diseases, such as Alzheimer's disease, Parkinson's disease, and
amyotrophic lateral sclerosis, autoimmune diseases such as Type-1
diabetes mellitus, vitiligo, uveitis, Sjogren's disease, pemphigus
foliaceus, inclusion body myositis, polymyositis, dermatomyositis,
scleroderma, Grave's disease, Hashimoto's disease, chronic
graft-versus host disease, rheumatoid arthritis, inflammatory bowel
syndrome, Crohn's disease and multiple sclerosis, pregnancy (e.g.
fertility), diseases involving airway smooth muscle cells such as
asthma and COPD, and angiogenesis related conditions, such as
macular degeneration.
II. PPAR Active Compounds
[0202] As indicated in the Summary and in connection with
applicable diseases and conditions, a number of different PPAR
agonist compounds have been identified. In addition, the present
invention provides PPAR agonist compounds described by Formula I,
Ia, Ib, or Ic as provided in the Summary above. These compounds can
be used in the treatment or prophylaxis of a disease or condition
selected from obesity, overweight condition,
hyperlipidemia,-dyslipidemia including associated diabetic
dyslipidemia and mixed dyslipidemia, hypoalphalipoproteinemia,
Syndrome X, Type II diabetes mellitus, Type I diabetes,
hyperinsulinemia, impaired glucose tolerance, insulin resistance, a
diabetic complication (e.g., neuropathy, nephropathy, retinopathy
or cataracts), hypertension, coronary heart disease, heart failure,
hypercholesterolemia, inflammation, thrombosis, congestive heart
failure, cardiovascular disease (including atherosclerosis,
arteriosclerosis, and hypertriglyceridemia), epithelial
hyperproliferative diseases (such as eczema and psoriasis), cancer,
neuropathic or inflammatory pain, conditions associated with the
lung and gut, and regulation of appetite and food intake in
subjects suffering from disorders such as obesity, anorexia bulimia
and anorexia nervosa, neurodegenerative diseases, such as
Alzheimer's disease, Parkinson's disease, and amyotrophic lateral
sclerosis, autoimmune diseases such as Type-1 diabetes mellitus,
vitiligo, uveitis, Sjogren's disease, pemphigus foliaceus,
inclusion body myositis, polymyositis, dermatomyositis,
scleroderma, Grave's disease, Hashimoto's disease, chronic
graft-versus host disease, rheumatoid arthritis, inflammatory bowel
syndrome, Crohn's disease and multiple sclerosis, pregnancy (e.g.
fertility), diseases involving airway smooth muscle cells such as
asthma and COPD, and angiogenesis related conditions, such as
macular degeneration.
[0203] The activity of the compounds can be assessed using methods
known to those of skill in the art, as well as methods described
herein. Screening assays may include controls for purposes of
calibration and confirmation of proper manipulation of the
components of the assay. Blank wells that contain all of the
reactants but no member of the chemical library are usually
included. As another example, a known inhibitor (or activator) of
an enzyme for which modulators are sought, can be incubated with
one sample of the assay, and the resulting decrease (or increase)
in the enzyme activity used as a comparator or control. It will be
appreciated that modulators can also be combined with the enzyme
activators or inhibitors to find modulators which inhibit the
enzyme activation or repression that is otherwise caused by the
presence of the known enzyme modulator. Similarly, when ligands to
a target are sought, known ligands of the target can be present in
control/calibration assay wells.
[0204] Exemplary compounds described by Formula I are provided in
Table 1 as well as in the synthetic examples. Additional compounds
within Formula I, Ia, Ib, or Ic can be prepared and tested to
confirm activity using conventional methods and the guidance
provided herein. TABLE-US-00001 TABLE 1 Exemplary compounds of the
invention. Molecular weight Compound Number Structure Name Calc.
Measured 27 ##STR6## [5-Methoxy-1-(3,4-dichloro-
benzenesulfonyl)-1H-in- dol-3-ylsulfonyl]-acetic acid 444.96
MS(ESI)[M - H.sup.+].sup.- = 443.95 28 ##STR7## (5-Methoxy-1H-in-
dol-3-ylsulfanyl)-acetic acid 237.05 MS(ESI)[M - H.sup.+].sup.- =
238.15 23 ##STR8## [5-Bromo-1-(4-methoxy- benzenesulfonyl)-1H-in-
dol-3-yloxy]-acetic acid 440.27 MS(ESI)[M - H.sup.+].sup.- = 438.0;
440.0 24 ##STR9## 3-[5-Bromo-1-(4-methoxy- benzenesulfonyl)-1H-in-
dol-3-yloxy]-propionic acid 454.29 MS(ESI)[M - H.sup.+].sup.- =
452.0; 454.0 29 ##STR10## 3-[5-Bromo-1-(4-methoxy-
benzenesulfonyl)-1H-in- dol-3-yloxy]-propionic acid methyl ester
468.29 MS(ESI)[M - H.sup.+].sup.- = 466.0; 468.0
(a) Measuring Enzymatic and Binding Reactions During Screening
Assays
[0205] Techniques for measuring the progression of enzymatic and
binding reactions, e.g., in multicontainer carriers, are known in
the art and include, but are not limited to, the following.
[0206] Spectrophotometric and spectrofluorometric assays are well
known in the art. Examples of such assays include the use of
colorimetric assays for the detection of peroxides, as described in
Gordon, A. J. and Ford, R. A., The Chemist's Companion: A Handbook
Of Practical Data, Techniques And References, John Wiley and Sons,
N.Y., 1972, Page 437.
[0207] Fluorescence spectrometry may be used to monitor the
generation of reaction products. Fluorescence methodology is
generally more sensitive than absorption methodology. The use of
fluorescent probes is well known to those skilled in the art. For
reviews, see Bashford et al., Spectrophotometry and
Spectrofluorometry: A Practical Approach, pp. 91-114, IRL Press
Ltd. (1987); and Bell, Spectroscopy In Biochemistry, Vol. 1, pp.
155-194, CRC Press (1981).
[0208] In spectrofluorometric methods, enzymes are exposed to
substrates that change their intrinsic fluorescence when processed
by the target enzyme. Typically, the substrate is nonfluorescent
and is converted to a fluorophore through one or more reactions. As
a non-limiting example, SMase activity can be detected using the
Amplex.RTM. Red reagent (Molecular Probes, Eugene, Oreg.). In order
to measure sphingomyelinase activity using Amplex.RTM. Red, the
following reactions occur. First, SMase hydrolyzes sphingomyelin to
yield ceramide and phosphorylcholine. Second, alkaline phosphatase
hydrolyzes phosphorylcholine to yield choline. Third, choline is
oxidized by choline oxidase to betaine. Finally, H.sub.2O.sub.2, in
the presence of horseradish peroxidase, reacts with Amplex.RTM. Red
to produce the fluorescent product, Resorufin, and the signal
therefrom is detected using spectrofluorometry.
[0209] Fluorescence polarization (FP) is based on a decrease in the
speed of molecular rotation of a fluorophore that occurs upon
binding to a larger molecule, such as a receptor protein, allowing
for polarized fluorescent emission by the bound ligand. FP is
empirically determined by measuring the vertical and horizontal
components of fluorophore emission following excitation with plane
polarized light. Polarized emission is increased when the molecular
rotation of a fluorophore is reduced. A fluorophore produces a
larger polarized signal when it is bound to a larger molecule (i.e.
a receptor), slowing molecular rotation of the fluorophore. The
magnitude of the polarized signal relates quantitatively to the
extent of fluorescent ligand binding. Accordingly, polarization of
the "bound" signal depends on maintenance of high affinity
binding.
[0210] FP is a homogeneous technology and reactions are very rapid,
taking seconds to minutes to reach equilibrium. The reagents are
stable, and large batches may be prepared, resulting in high
reproducibility. Because of these properties, FP has proven to be
highly automatable, often performed with a single incubation with a
single, premixed, tracer-receptor reagent. For a review, see
Owickiet al., Genetic Engineering News, 1997, 17:27.
[0211] FP is particularly desirable since its readout is
independent of the emission intensity (Checovich, et al., Nature
1995, 375:254-256; Dandliker, et al., Methods in Enzymology 1981,
74:3-28) and is thus insensitive to the presence of colored
compounds that quench fluorescence emission. FP and FRET (see
below) are well-suited for identifying compounds that block
interactions between sphingolipid receptors and their ligands. See,
for example, Parker et al., J. Biomol. Screen., 2000, 5:77-88.
[0212] Fluorophores derived from sphingolipids that may be used in
FP assays are commercially available. For example, Molecular Probes
(Eugene, Oreg.) currently sells sphingomyelin and ceramide
fluorophores. These are, respectively,
N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)sp-
hingosyl phosphocholine (BODIPY.RTM. FL C5-sphingomyelin);
N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)s-
phingosyl phosphocholine (BODIPY.RTM. FL C12-sphingomyelin); and
N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)sp-
hingosine (BODIPY.RTM. FL C5-ceramide). U.S. Pat. No. 4,150,949,
(Immunoassay for gentamicin), discloses fluorescein-labelled
gentamicins, including fluoresceinthiocarbanyl gentamicin.
Additional fluorophores may be prepared using methods well known to
the skilled artisan.
[0213] Exemplary normal-and-polarized fluorescence readers include
the POLARION.RTM. fluorescence polarization system (Tecan AG,
Hombrechtikon, Switzerland). General multiwell plate readers for
other assays are available, such as the VERSAMAX.RTM. reader and
the SPECTRAMAX.RTM. multiwell plate spectrophotometer (both from
Molecular Devices).
[0214] Fluorescence resonance energy transfer (FRET) is another
useful assay for detecting interaction and has been described. See,
e.g., Heim et al., Curr. Biol. 1996, 6:178-182; Mitra et al., Gene
1996, 173:13-17; and Selvin et al., Meth. Enzymol. 1995,
246:300-345. FRET detects the transfer of energy between two
fluorescent substances in close proximity, having known excitation
and emission wavelengths. As an example, a protein can be expressed
as a fusion protein with green fluorescent protein (GFP). When two
fluorescent proteins are in proximity, such as when a protein
specifically interacts with a target molecule, the resonance energy
can be transferred from one excited molecule to the other. As a
result, the emission spectrum of the sample shifts, which can be
measured by a fluorometer, such as a fMAX multiwell fluorometer
(Molecular Devices, Sunnyvale Calif.).
[0215] Scintillation proximity assay (SPA) is a particularly useful
assay for detecting an interaction with the target molecule. SPA is
widely used in the pharmaceutical industry and has been described
(Hanselman et al., J. Lipid Res. 38:2365-2373 (1997); Kahl et al.,
Anal. Biochem. 243:282-283 (1996); Undenfriend et al., Anal.
Biochem. 161:494-500 (1987)). See also U.S. Pat. Nos. 4,626,513 and
4,568,649, and European Patent No. 0,154,734. One commercially
available system uses FLASHPLATE.RTM. scintillant-coated plates
(NEN Life Science Products, Boston, Mass.).
[0216] The target molecule can be bound to the scintillator plates
by a variety of well known means. Scintillant plates are available
that are derivatized to bind to fusion proteins such as GST, His6
or Flag fusion proteins. Where the target molecule is a protein
complex or a multimer, one protein or subunit can be attached to
the plate first, then the other components of the complex added
later under binding conditions, resulting in a bound complex.
[0217] In a typical SPA assay, the gene products in the expression
pool will have been radiolabeled and added to the wells, and
allowed to interact with the solid phase, which is the immobilized
target molecule and scintillant coating in the wells. The assay can
be measured immediately or allowed to reach equilibrium. Either
way, when a radiolabel becomes sufficiently close to the
scintillant coating, it produces a signal detectable by a device
such as a TOPCOUNT NXT.RTM. microplate scintillation counter
(Packard BioScience Co., Meriden Conn.). If a radiolabeled
expression product binds to the target molecule, the radiolabel
remains in proximity to the scintillant long enough to produce a
detectable signal.
[0218] In contrast, the labeled proteins that do not bind to the
target molecule, or bind only briefly, will not remain near the
scintillant long enough to produce a signal above background. Any
time spent near the scintillant caused by random Brownian motion
will also not result in a significant amount of signal. Likewise,
residual unincorporated radiolabel used during the expression step
may be present, but will not generate significant signal because it
will be in solution rather than interacting with the target
molecule. These non-binding interactions will therefore cause a
certain level of background signal that can be mathematically
removed. If too many signals are obtained, salt or other modifiers
can be added directly to the assay plates until the desired
specificity is obtained (Nichols et al., Anal. Biochem.
257:112-119, 1998).
[0219] Additionally, the assay can utilize AlphaScreen (amplified
luminescentproximity homogeneous assay) format, e.g.,
AlphaScreening system (Packard BioScience). AlphaScreen is
generally described in Seethala and Prabhavathi, Homogenous Assays:
AlphaScreen, Handbook of Drug Screening, Marcel Dekkar Pub. 2001,
pp. 106-110. Applications of the technique to PPAR receptor ligand
binding assays are described, for example, in Xu et al., 2002,
Nature 415:813-817.
(b) Assessment of Efficacy of Compounds in Disease Model
Systems.
[0220] The utility of compounds of Formula I, Ia, Ib, or Ic for the
treatment of diseases such as autoimmune disease and neurological
disease can be readily assessed using model systems known to those
of skill in the art. For example, efficacy of PPAR modulators in
models of Alzheimer's disease can be tested by mimicking
inflammatory injury to neuronal tissues and measuring recovery
using molecular and pharmacological markers (Heneka, M. T. et al.
(2000) J. Neurosci. 20, 6862-6867). Efficacy of PPAR modulators in
multiple sclerosis has been monitored using the accepted model of
experimental autoimmune encephalomyelitis (EAE, Storer et al (2004)
J. Neuroimmunol. 161, 113-122. See also: Niino, M. et al. (2001) J.
Neuroimmunol. 116, 40-48; Diab, A. et al. (2002) J. Immunol. 168,
2508-2515; Natarajan, C. and Bright, J. J. (2002) Genes Immun. 3,
59-70; Feinstein, D. L. et al. (2002) Ann. Neurol. 51,
694-702.)
(c) Isomers, Prodrugs, and Active Metabolites
[0221] Compounds contemplated herein are described with reference
to both generic formulae and specific compounds. In addition, the
invention compounds may exist in a number of different forms or
derivatives, all within the scope of the present invention. These
include, for example, tautomers, stereoisomers, racemic mixtures,
regioisomers, salts, prodrugs (e.g., carboxylic acid esters),
solvated forms, different crystal forms or polymorphs, and active
metabolites
(d) Tautomers, Stereoisomers, Regioisomers, and Solvated Forms
[0222] It is understood that certain compounds may exhibit
tautomerism. In such cases, the formulae provided herein expressly
depict only one of the possible tautomeric forms. It is therefore
to be understood that the formulae provided herein are intended to
represent any tautomeric form of the depicted compounds and are not
to be limited merely to the specific tautomeric form depicted by
the drawings of the formulae.
[0223] Likewise, some of the compounds according to the present
invention may exist as stereoisomers, i.e. they have the same
sequence of covalently bonded atoms and differ in the spatial
orientation of the atoms. For example, compounds may be optical
stereoisomers, which contain one or more chiral centers, and
therefore, may exist in two or more stereoisomeric forms (e.g.
enantiomers or diastereomers). Thus, such compounds may be present
as single stereoisomers (i.e., essentially free of other
stereoisomers), racemates, and/or mixtures of enantiomers and/or
diastereomers. As another example, stereoisomers include geometric
isomers, such as cis- or trans-orientation of substituents on
adjacent carbons of a double bond. All such single stereoisomers,
racemates and mixtures thereof are intended to be within the scope
of the present invention. Unless specified to the contrary, all
such steroisomeric forms are included within the formulae provided
herein.
[0224] In certain embodiments, a chiral compound of the present
invention is in a form that contains at least 80% of a single
isomer (60% enantiomeric excess ("e.e.") or diastereomeric excess
("d.e.")), or at least 85% (70% e.e. or d.e.), 90% (80% e.e. or
d.e.), 95% (90% e.e. or d.e.), 97.5% (95% e.e. or d.e.), or 99%
(98% e.e. or d.e.). As generally understood by those skilled in the
art, an optically pure compound having one chiral center is one
that consists essentially of one of the two possible enantiomers
(i.e., is enantiomerically pure), and an optically pure compound
having more than one chiral center is one that is both
diastereomerically pure and enantiomerically pure. In certain
embodiments, the compound is present in optically pure form.
[0225] For compounds in which synthesis involves addition of a
single group at a double bond, particularly a carbon-carbon double
bond, the addition may occur at either of the double bond-linked
atoms. For such compounds, the present invention includes both such
regioisomers.
[0226] Additionally, the formulae are intended to cover solvated as
well as unsolvated forms of the identified structures. For example,
the indicated structures include both hydrated and non-hydrated
forms. Other examples of solvates include the structures in
combination with isopropanol, ethanol, methanol, DMSO, ethyl
acetate, acetic acid, or ethanolamine.
(e) Prodrugs and Metabolites
[0227] In addition to the present formulae and compounds described
herein, the invention also includes prodrugs (generally
pharmaceutically acceptable prodrugs), active metabolic derivatives
(active metabolites), and their pharmaceutically acceptable
salts.
[0228] Prodrugs are compounds or pharmaceutically acceptable salts
thereof which, when metabolized under physiological conditions or
when converted by solvolysis, yield the desired active compound.
Typically, the prodrug is inactive, or less active than the active
compound, but may provide advantageous handling, administration, or
metabolic properties. For example, some prodrugs are esters of the
active compound; during metabolysis, the ester group is cleaved to
yield the active drug. Also, some prodrugs are activated
enzymatically to yield the active compound, or a compound which,
upon further chemical reaction, yields the active compound. A
common example is an alkyl ester of a carboxylic acid.
[0229] As described in The Practice of Medicinal Chemistry, Ch.
31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001),
prodrugs can be conceptually divided into two non-exclusive
categories, bioprecursor prodrugs and carrier prodrugs. Generally,
bioprecursor prodrugs are compounds that are inactive or have low
activity compared to the corresponding active drug compound, that
contain one or more protective groups and are converted to an
active form by metabolism or solvolysis. Both the active drug form
and any released metabolic products should have acceptably low
toxicity. Typically, the formation of active drug compound involves
a metabolic process or reaction that is one of the follow
types:
[0230] Oxidative reactions: Oxidative reactions are exemplified
without limitation to reactions such as oxidation of alcohol,
carbonyl, and acid functions, hydroxylation of aliphatic carbons,
hydroxylation of alicyclic carbon atoms, oxidation of aromatic
carbon atoms, oxidation of carbon-carbon double bonds, oxidation of
nitrogen-containing functional groups, oxidation of silicon,
phosphorus, arsenic, and sulfur, oxidative N-dealkylation,
oxidative O-- and S-dealkylation, oxidative deamination, as well as
other oxidative reactions.
[0231] Reductive reactions: Reductive reactions are exemplified
without limitation to reactions such as reduction of carbonyl
groups, reduction of hydroxyl groups and carbon-carbon double
bonds, reduction of nitrogen-containing functions groups, and other
reduction reactions.
[0232] Reactions without change in the oxidation state: Reactions
without change in the state of oxidation are exemplified without
limitation to reactions such as hydrolysis of esters and ethers,
hydrolytic cleavage of carbon-nitrogen single bonds, hydrolytic
cleavage of non-aromatic heterocycles, hydration and dehydration at
multiple bonds, new atomic linkages resulting from dehydration
reactions, hydrolytic dehalogenation, removal of hydrogen halide
molecule, and other such reactions.
[0233] Carrier prodrugs are drug compounds that contain a transport
moiety, e.g., that improves uptake and/or localized delivery to a
site(s) of action. Desirably for such a carrier prodrug, the
linkage between the drug moiety and the transport moiety is a
covalent bond, the prodrug is inactive or less active than the drug
compound, the prodrug and any release transport moiety are
acceptably non-toxic. For prodrugs where the transport moiety is
intended to enhance uptake, typically the release of the transport
moiety should be rapid. In other cases, it is desirable to utilize
a moiety that provides slow release, e.g., certain polymers or
other moieties, such as cyclodextrins. (See, e.g., Cheng et al.,
U.S. Patent Publ. No. 2004/0077595, Ser. No. 10/656,838,
incorporated herein by reference.) Such carrier prodrugs are often
advantageous for orally administered drugs. Carrier prodrugs can,
for example, be used to improve one or more of the following
properties: increased lipophilicity, increased duration of
pharmacological effects, increased site-specificity, decreased
toxicity and adverse reactions, and/or improvement in drug
formulation (e.g., stability, water solubility, suppression of an
undesirable organoleptic or physiochemical property). For example,
lipophilicity can be increased by esterification of hydroxyl groups
with lipophilic carboxylic acids, or of carboxylic acid groups with
alcohols, e.g., aliphatic alcohols. Wermuth, The Practice of
Medicinal Chemistry, Ch. 31 -32, Ed. Wermuth, Academic Press, San
Diego, Calif., 2001.
[0234] Prodrugs may proceed from prodrug form to active form in a
single step or may have one or more intermediate forms which may
themselves have activity or may be inactive.
[0235] Metabolites, e.g., active metabolites, overlap with prodrugs
as described above, e.g., bioprecursor prodrugs. Thus, such
metabolites are pharmacologically active compounds or compounds
that further metabolize to pharmacologically active compounds that
are derivatives resulting from metabolic process in the body of a
subject or patient. Of these, active metabolites are such
pharmacologically active derivative compounds. For prodrugs, the
prodrug compound is generally inactive or of lower activity than
the metabolic product. For active metabolites, the parent compound
may be either an active compound or may be an inactive prodrug.
[0236] Prodrugs and active metabolites may be identified using
routine techniques known in the art. See, e.g., Bertolini et al.,
1997, J. Med. Chem., 40:2011-2016; Shan et al., 1997, J. Pharm.
Sci. 86(7):756-757; Bagshawe, 1995, Drug. Dev. Res., 34:220-230;
Wermuth, The Practice of Medicinal Chemistry, Ch. 31-32, Academic
Press, San Diego, Calif., 2001.
(f) Pharmaceutically Acceptable Salts
[0237] Compounds can be formulated as or be in the form of
pharmaceutically acceptable salts. Pharmaceutically acceptable
salts are non-toxic salts in the amounts and concentrations at
which they are administered. The preparation of such salts can
facilitate the pharmacological use by altering the physical
characteristics of a compound without preventing it from exerting
its physiological effect. Useful alterations in physical properties
include lowering the melting point to facilitate transmucosal
administration and increasing the solubility to facilitate
administering higher concentrations of the drug.
[0238] Pharmaceutically acceptable salts include acid addition
salts such as those containing sulfate, chloride, hydrochloride,
fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate,
tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate, cyclohexylsulfamate and quinate.
Pharmaceutically acceptable salts can be obtained from acids such
as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid,
sulfamic acid, acetic acid, citric acid, lactic acid, tartaric
acid, malonic acid, methanesulfonic acid, ethanesulfonic acid,
benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic
acid, fumaric acid, and quinic acid.
[0239] Pharmaceutically acceptable salts also include basic
addition salts such as those containing benzathine, chloroprocaine,
choline, diethanolamine, ethylenediamine, meglumine, procaine,
aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium,
alkylamine, and zinc, when acidic functional groups, such as
carboxylic acid or phenol are present. For example, see Remington's
Pharmaceutical Sciences, 19.sup.th ed., Mack Publishing Co.,
Easton, Pa., Vol. 2, p. 1457, 1995. Such salts can be prepared
using the appropriate corresponding bases.
[0240] Pharmaceutically acceptable salts can be prepared by
standard techniques. For example, the free-base form of a compound
can be dissolved in a suitable solvent, such as an aqueous or
aqueous-alcohol solution containing the appropriate acid and then
isolated by evaporating the solution. In another example, a salt
can be prepared by reacting the free base and acid in an organic
solvent.
[0241] Thus, for example, if the particular compound is a base, the
desired pharmaceutically acceptable salt may be prepared by any
suitable method available in the art, for example, treatment of the
free base with an inorganic acid, such as hydrochloric acid,
hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and
the like, or with an organic acid, such as acetic acid, maleic
acid, succinic acid, mandelic acid, fumaric acid, malonic acid,
pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a
pyranosidyl acid, such as glucuronic acid or galacturonic acid, an
alpha-hydroxy acid, such as citric acid or tartaric acid, an amino
acid, such as aspartic acid or glutamic acid, an aromatic acid,
such as benzoic acid or cinnamic acid, a sulfonic acid, such as
p-toluenesulfonic acid or ethanesulfonic acid, or the like.
[0242] Similarly, if the particular compound is an acid, the
desired pharmaceutically acceptable salt may be prepared by any
suitable method, for example, treatment of the free acid with an
inorganic or organic base, such as an amine (primary, secondary or
tertiary), an alkali metal hydroxide or alkaline earth metal
hydroxide, or the like. Illustrative examples of suitable salts
include organic salts derived from amino acids, such as glycine and
arginine, ammonia, primary, secondary, and tertiary amines, and
cyclic amines, such as piperidine, morpholine and piperazine, and
inorganic salts derived from sodium, calcium, potassium, magnesium,
manganese, iron, copper, zinc, aluminum and lithium.
[0243] The pharmaceutically acceptable salt of the different
compounds may be present as a complex. Examples of complexes
include 8-chlorotheophylline complex (analogous to, e.g.,
dimenhydrinate: diphenhydramine 8-chlorotheophylline (1:1) complex;
Dramamine) and various cyclodextrin inclusion complexes.
[0244] Unless specified to the contrary, specification of a
compound herein includes pharmaceutically acceptable salts of such
compound.
(g) Polymorphic Forms
[0245] In the case of agents that are solids, it is understood by
those skilled in the art that the compounds and salts may exist in
different crystal or polymorphic forms, all of which are intended
to be within the scope of the present invention and specified
formulae.
III. Administration
[0246] The methods and compounds will typically be used in therapy
for human patients. However, they may also be used to treat similar
or identical diseases in other vertebrates, e.g., mammals such as
other primates, animals of commercial significance, e.g., sports
animals, farm animals, e.g., bovines, equines, porcines, and
ovines, and pets such as dogs and cats.
[0247] Suitable dosage forms, in part, depend upon the use or the
route of administration, for example, oral, transdermal,
transmucosal, inhalant, or by injection (parenteral). Such dosage
forms should allow the compound to reach target cells. Other
factors are well known in the art, and include considerations such
as toxicity and dosage forms that retard the compound or
composition from exerting its effects. Techniques and formulations
generally may be found in Remington: The Science and Practice of
Pharmacy, 21.sup.st edition, Lippincott, Williams and Wilkins,
Philadelphia, Pa., 2005 (hereby incorporated by reference
herein).
[0248] Compounds of the present invention (i.e. Formula I,
including Formulae Ia-Ic, and all sub-embodiments disclosed herein)
can be formulated as pharmaceutically acceptable salts.
[0249] Carriers or excipients can be used to produce compositions.
The carriers or excipients can be chosen to facilitate
administration of the compound. Examples of carriers include
calcium carbonate, calcium phosphate, various sugars such as
lactose, glucose, or sucrose, or types of starch, cellulose
derivatives, gelatin, vegetable oils, polyethylene glycols and
physiologically compatible solvents. Examples of physiologically
compatible solvents include sterile solutions of water for
injection (WFI), saline solution, and dextrose.
[0250] The compounds can be administered by different routes
including intravenous, intraperitoneal, subcutaneous,
intramuscular, oral, transmucosal, rectal, transdermal, or
inhalant. In some embodiments, oral administration is preferred.
For oral administration, for example, the compounds can be
formulated into conventional oral dosage forms such as capsules,
tablets, and liquid preparations such as syrups, elixirs, and
concentrated drops.
[0251] Pharmaceutical preparations for oral use can be obtained,
for example, by combining the active compounds with solid
excipients, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are, in particular, fillers such as sugars, including lactose,
sucrose, mannitol, or sorbitol; cellulose preparations, for
example, maize starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose (CMC),
and/or polyvinylpyrrolidone (PVP: povidone). If desired,
disintegrating agents may be added, such as the cross-linked
polyvinylpyrrolidone, agar, or alginic acid, or a salt thereof such
as sodium alginate.
[0252] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain, for example, gum arabic, talc,
poly-vinylpyrrolidone, carbopol gel, polyethylene glycol (PEG),
and/or titanium dioxide, lacquer solutions, and suitable organic
solvents or solvent mixtures. Dye-stuffs or pigments may be added
to the tablets or dragee coatings for identification or to
characterize different combinations of active compound doses.
[0253] Pharmaceutical preparations that can be used orally include
push-fit capsules made of gelatin ("gelcaps"), as well as soft,
sealed capsules made of gelatin, and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the active
ingredients in admixture with filler such as lactose, binders such
as starches, and/or lubricants such as talc or magnesium stearate
and, optionally, stabilizers. In soft capsules, the active
compounds may be dissolved or suspended in suitable liquids, such
as fatty oils, liquid paraffin, or liquid polyethylene glycols
(PEGs). In addition, stabilizers may be added.
[0254] Alternatively, injection (parenteral administration) may be
used, e.g., intramuscular, intravenous, intraperitoneal, and/or
subcutaneous. For injection, the compounds of the invention are
formulated in sterile liquid solutions, preferably in
physiologically compatible buffers or solutions, such as saline
solution, Hank's solution, or Ringer's solution. In addition, the
compounds may be formulated in solid form and redissolved or
suspended immediately prior to use. Lyophilized forms can also be
produced.
[0255] Administration can also be by transmucosal, topical,
transdermal, or inhalant means. For transmucosal, topical or
transdermal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants are
generally known in the art, and include, for example, for
transmucosal administration, bile salts and fusidic acid
derivatives. In addition, detergents may be used to facilitate
permeation. Transmucosal administration, for example, may be
through nasal sprays or suppositories (rectal or vaginal).
[0256] The topical compositions of this invention are formulated
preferably as oils, creams, lotions, ointments and the like by
choice of appropriate carriers known in the art. Suitable carriers
include vegetable or mineral oils, white petrolatum (white soft
paraffin), branched chain fats or oils, animal fats and high
molecular weight alcohol (greater than C.sub.12). The preferred
carriers are those in which the active ingredient is soluble.
Emulsifiers, stabilizers, humectants and antioxidants may also be
included as well as agents imparting color or fragrance, if
desired. Creams for topical application are preferably formulated
from a mixture of mineral oil, self-emulsifying beeswax and water
in which mixture the active ingredient, dissolved in a small amount
solvent (e.g., an oil), is admixed. Additionally, administration by
transdermal means may comprise a transdermal patch or dressing such
as a bandage impregnated with an active ingredient and optionally
one or more carriers or diluents known in the art. To be
administered in the form of a transdermal delivery system, the
dosage administration will, of course, be continuous rather than
intermittent throughout the dosage regimen.
[0257] For inhalants, compounds of the invention may be formulated
as dry powder or a suitable solution, suspension, or aerosol.
Powders and solutions may be formulated with suitable additives
known in the art. For example, powders may include a suitable
powder base such as lacatose or starch, and solutions may comprise
propylene glycol, sterile water, ethanol, sodium chloride and other
additives, such as acid, alkali and buffer salts. Such solutions or
suspensions may be administered by inhaling via spray, pump,
atomizer, or nebulizer, and the like. The compounds of the
invention may also be used in combination with other inhaled
therapies, for example corticosteroids such as fluticasone
proprionate, beclomethasone dipropionate, triamcinolone acetonide,
budesonide, and mometasone furoate; beta agonists such as
albuterol, salmeterol, and formoterol; anticholinergic agents such
as ipratroprium-bromide or tiotropium; vasodilators such as
treprostinal and iloprost; enzymes such as DNAase; therapeutic
proteins; immunoglobulin antibodies; an oligonucleotide, such as
single or double stranded DNA or RNA, siRNA; antibiotics such as
tobramycin; muscarinic receptor antagonists; leukotriene
antagonists; cytokine antagonists; protease inhibitors; cromolyn
sodium; nedocril sodium; and sodium cromoglycate.
[0258] The amounts of various compounds to be administered can be
determined by standard procedures taking into account factors such
as the compound EC.sub.50, the biological half-life of the
compound, the age, size, and weight of the patient, and the
disorder associated with the patient. The importance of these and
other factors are well known to those of ordinary skill in the art.
Generally, a dose will be between about 0.01 and 50 mg/kg,
preferably 0.1 and 20 mg/kg of the patient being treated. Multiple
doses may be used.
[0259] The compounds of the invention may also be used in
combination with other therapies for treating the same disease.
Such combination use includes administration of the compounds and
one or more other therapeutics at different times, or
co-administration of the compound and one or more other therapies.
In certain embodiments, dosage may be modified for one or more of
the compounds of the invention or other therapeutics used in
combination, e.g., reduction in the amount dosed relative to a
compound or therapy used alone, by methods well known to those of
ordinary skill in the art.
[0260] It is understood that use in combination includes use with
other therapies, drugs, medical procedures etc., where the other
therapy or procedure may be administered at different times (e.g.
within a short time, such as within hours (e.g. 1, 2, 3, 4-24
hours), or within a longer time (e.g. 1-2 days, 2-4 days, 4-7 days,
1-4 weeks)) than a compound of the present invention, or at the
same time as a compound of the invention. Use in combination also
includes use with a therapy or medical procedure that is
administered once or infrequently, such as surgery, along with a
compound of the invention administered within a short time or
longer time before or after the other therapy or procedure. In
certain embodiments, the present invention provides for delivery of
compounds of the invention and one or more other drug therapeutics
delivered by a different route of administration or by the same
route of administration. The use in combination for any route of
administration includes delivery of compounds of the invention
and-one or more other drug-therapeutics-delivered by the same route
of administration together in any formulation, including
formulations where the two compounds are chemically linked in such
a way that they maintain their therapeutic activity when
administered. In one aspect, the other drug therapy may be
co-administered with one or more compounds of the invention. Use in
combination by co-administration includes administration of
co-formulations or formulations of chemically joined compounds, or
administration of two or more compounds in separate formulations
within a short time of each other (e.g. within an hour, 2 hours, 3
hours, up to 24 hours), administered by the same or different
routes. Co-administration of separate formulations includes
co-administration by delivery via one device, for example the same
inhalant device, the same syringe, etc., or administration from
separate devices within a short time of each other. Co-formulations
of compounds of the invention and one or more additional drug
therapies delivered by the same route includes preparation of the
materials together such that they can be administered by one
device, including the separate compounds combined in one
formulation, or compounds that are modified such that they are
chemically joined, yet still maintain their biological activity.
Such chemically joined compounds may have a linkage that is
substantially maintained in vivo, or the linkage may break down in
vivo, separating the two active components.
IV. Synthesis of Compounds of Formula I
[0261] Compounds with the chemical structure of Formula I can be
prepared in a number of different synthetic routes, including, for
example, the synthetic schemes described herein for groups of
compounds within Formula I. Additional synthetic routes can be
utilized by one skilled in chemical synthesis.
[0262] Certain of the syntheses can utilize key intermediate II in
the synthesis, when Q is O, to afford compounds of Formula Id. Key
intermediate II can be prepared as follows:
Synthesis of Compound II
[0263] One synthetic route for Intermediate II compounds is shown
below in Scheme la. In these compounds, U, V, W, and Y can be C as
in indole, or can be other heteroatoms as specified for Formula I.
In synthetic Scheme la and other synthetic schemes described herein
for groups of compounds, it should be understood that generic
formulae in the schemes (e.g., Formula III in Scheme Ia) describe a
set of compounds, butare referenced in the text description of the
synthesis in the singular. Notably, some compounds such as
Intermediate II may be represented in two tautomeric forms, such as
the enol form shown in Formula II and the keto form shown in
Formula Ia in Scheme Ia, and they may be used interchangeably to
represent the same compound: ##STR11## Step 1--Preparation of
Formula IV,
[0264] Compound IV may be prepared by reacting a commercially
available aromatic amine of Formula III with chloroacetonitrile in
the presence of boron trichloride and a Lewis base (e.g. aluminum
trichloride) with heating to reflux for several hours in an inert
solvent (e.g. benzene) and purification by conventional methods
(e.g. silica gel chromatography) (Sugasawa et. al.; J. Org. Chem.,
44, 1979, 578).
[0265] Step 2--Preparation of Formula V.
[0266] Compound V may be prepared where R is methyl or
trifluoromethyl by reacting a compound of Formula IV with acetic
anhydride or trifluoroacetic anhydride, respectively, and heating
(e.g. 80.degree. C.) for 30 minutes, followed by purification (e.g.
silica gel chromatography) (Sugasawa et. al.; J. Org. Chem., 44,
1979, 578).
Step 3--Preparation of Compound II.
[0267] Key compound II may be prepared by reacting a compound of
Formula V with a base (e.g. sodium hydride or potassium carbonate)
in an inert solvent (e.g. 1,2-dimethoxyethane or acetonitrile) and
stirring with ice-cooling or at room temperature for several
minutes to several hours, followed by purification and isolation by
conventional means (e.g. aqueous work-up and silica gel
chromatography). (Sugasawa et. al.; J. Org. Chem., 44, 1979,
578).
[0268] Compounds of the type of key compound II may also be
prepared in accordance with Scheme Ib as shown below. ##STR12##
Step 1--Preparation of Formula VII:
[0269] Compound VII may be prepared by reacting a commercially
available anthranilic acid or analog of Formula III with
2-chloroacetic acid in the presence of base (e.g. sodium carbonate)
typically at room temperature for 1-4 hours followed by
purification and isolation by conventional means (e.g. aqueous
work-up and recrystallization).
Step 2--Preparation of Formula VIII.
[0270] Compound VIII, where R is methyl, may be prepared by
reacting a compound of Formula VII with sodium acetate in refluxing
acetic anhydride for several hours, followed by purification and
isolation by conventional means (e.g. recrystallization) (Su &
Tsou; J. Am. Chem. Soc., 1960, 82:1187).
Step 3--Preparation of Key Compound II.
[0271] Compound II, where R is methyl, may be prepared from a
compound of Formula VIII by selective deprotection with sodium in
methanol at room temperature typically for 30-60 minutes, followed
by isolation and purification by conventional means (e.g. aqueous
work-up and recrystallization) (Su & Tsou; J. Am. Chem. Soc.,
1960, 8:1187).
[0272] Compounds of Formula Id may be prepared from compound II by
substitution of the 3-hydroxy, followed by removal of the acetyl on
N-1 and substitution of the N-1 as shown in Scheme 2. ##STR13##
Step 1--Preparation of Formula IX.
[0273] Compound IX may be prepared by substituting compound II,
where R is methyl or trifluoromethyl, with an appropriate reagent
(e.g. methyl 2-bromoacetate) containing the R.sup.1, R.sup.3 and
R.sup.4 substituents and appropriate leaving group (e.g. chloro,
bromo, tosyl) in the presence of base (e.g. potassium carbonate) in
an inert solvent (e.g. acetone) typically for 12-18 hours with
heating to reflux, followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography). (Andersen et. al., J. Med. Chem., 1996,
39:3723.)
Step 2--Preparation of Formula X.
[0274] Compound X may be prepared by removal of the N-substituent
of a compound of Formula IX using a base (e.g. potassium hydroxide)
in a solvent (e.g. methanol) typically at room temperature for 2 to
24 hours, followed by isolation and purification by conventional
means (e.g. aqueous work-up and silica gel chromatography). (Naylor
et. al., J. Med. Chem., 1997, 40:2335.)
Step 3--Preparation of Formula Id:
[0275] Compound of Formula Id may be prepared by treating compound
of Formula X with a base (e.g. sodium hydride) in an inert solvent
(e.g. DMF), followed by the addition of R.sup.2L.sub.c, where
L.sub.c is a leaving group (e.g. chloro, bromo), and stirring at
room temperature, typically for 16 to 24 hours, followed by
isolation and purification by conventional means (e.g. aqueous
work-up and silica gel chromatography). (Andersen et. al., J. Med.
Chem., 1996, 39:3723.)
[0276] In one particular embodiment of Formula Id, R.sup.1 is
carboxylic acid and R.sup.3 and R.sup.4 are hydrogen, which may be
prepared from compound II according to Scheme 3. ##STR14## Step
1--Preparation of Formula XI.
[0277] Compound XI may be prepared by substituting compound II,
where R is methyl or trifluoromethyl, with methyl 2-bromoacetate in
the presence of base (e.g. potassium carbonate) in an inert solvent
(e.g. acetone) typically for 12-18 hours with heating to reflux,
followed by isolation and purification by conventional means (e.g.
aqueous work-up and silica gel chromatography). (Andersen et. al.,
J. Med. Chem., 39, 1996, 3723.)
Step 2--Preparation of Formula XII.
[0278] Compound XII may be prepared by removal of the N-substituent
of a compound of Formula XI using a base (e.g. potassium hydroxide)
in a solvent (e.g. methanol) typically at room temperature for 2 to
24 hours, followed by isolation and purification by conventional
means (e.g. aqueous work-up and silica gel chromatography). (Naylor
et. al., J. Med. Chem., 40, 1997, 2335.)
Step 3--Preparation of Formula XIII.
[0279] Compound of Formula XIII may be prepared by treating
compound of Formula XII with a base (e.g. sodium hydride) in an
inert solvent (e.g. DMF), followed by the addition of
R.sup.2L.sub.c, where L.sub.c is a leaving group (e.g. chloro,
bromo), and stirring at room temperature, typically for 16 to 24
hours, followed by isolation and purification by conventional means
(e.g. aqueous work-up and silica gel chromatography). (Andersen et.
al., J. Med. Chem., 1996, 39:723)
Step 4--Preparation of Formula Id:
[0280] Compound of Formula Id wherein R.sup.1 is carboxylic acid
and R.sup.3 and R.sup.4 are hydrogen may be prepared by hydrolysis
of compound of Formula XIII with aqueous base (e.g. sodium
hydroxide), typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
[0281] Compounds of Formula Ie, where Q is S, may be prepared as
shown in Scheme 4: ##STR15## Step 1--Preparation of Formula XV:
[0282] Compound of Formula XV may be prepared by bromination of
compound of Formula XIV with bromine, in an inert solvent (e.g.
DMF), followed by isolation and purification by conventional means
(e.g. aqueous work-up and silica gel chromatography).
Step 2--Preparation of Formula XVI:
[0283] Intermediate XIV may be prepared by treating compound of
Formula XV with an appropriate thiol (e.g. ethyl 2-mercaptoacetate)
and a base (e.g. potassium carbonate), in an inert solvent (e.g.
acetone) at reflux for 18-24 hours, followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography). (Salituro et; al., J. Med. Chem., 35, 1992,
1791.)
Step 3--Preparation of Formula Ie:
[0284] Compound of Formula Ie may be prepared by treating compound
of Formula XVII with a base (e.g. sodium hydride) in an inert
solvent (e.g. DMF), followed by the addition of R.sup.2L.sub.c,
where L.sub.c is a leaving group (e.g. chloro, bromo), and stirring
at room temperature, typically for 16 to 24 hours, followed by
isolation and purification by conventional means (e.g. aqueous
work-up and silica gel chromatography).
[0285] In one particular embodiment of Formula Ib, R.sup.1 is
carboxylic acid and R.sup.3 and R.sup.4 are hydrogen, which may be
prepared according to Scheme 6. ##STR16## Step 1--Preparation of
Formula XVIII.
[0286] Compound XVIII may be prepared by substituting compound of
Formula XVII with ethyl 2-mercaptoacetate in the presence of base
(e.g. potassium carbonate) in an inert solvent (e.g. acetone)
typically for 12-18 hours with heating to reflux, followed by
isolation and purification by conventional means (e.g. aqueous
work-up and silica gel chromatography). (Salituro et. al., J. Med.
Chem., 35, 1992, 1791.)
Step 3--Preparation of Formula XIX:
[0287] Compound of Formula XIII may be prepared by treating
compound of Formula XII with a base (e.g. sodium hydride) in an
inert solvent (e.g. DMF), followed by the addition of
R.sup.2L.sub.c, where L.sub.c is a leaving group (e.g. chloro,
bromo), and stirring at room temperature, typically for 16 to 24
hours, followed by isolation and purification by conventional means
(e.g. aqueous work-up and silica gel chromatography).
Step 4--Preparation of Formula Ie:
[0288] Compound of Formula Ie where R.sup.1 is carboxylic acid and
R.sup.3 and R.sup.4 are hydrogen may be prepared by hydrolysis of
compound of Formula XIX with aqueous base (e.g. sodium hydroxide),
typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
[0289] Compounds of Formula If, where Q is N, may be prepared as
shown in Scheme 7: ##STR17## Step 1--Preparation of Formula
XXI.
[0290] Compound of Formula XXI may be prepared by nitration of
commercially available compound of formula XX with nitric acid, in
a solvent (e.g. acetic anhydride), typically at 0.degree. C. or
colder for 1 to 12 hours, followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography). (Pelkey et. al., Synthesis, 1999, 7:1117.)
Step 2--Preparation of Formula XXII.
[0291] Compound of Formula XXII may be prepared by treating
compound of Formula XXI with a base (e.g. sodium hydride) in an
inert solvent (e.g. DMF), followed by the addition of
R.sup.2L.sub.c, where L.sub.c is a leaving group (e.g. chloro,
bromo), and stirring at room temperature, typically for 16 to 24
hours, followed by isolation and purification by conventional means
(e.g. aqueous work-up and silica gel chromatography).
Step 3--Preparation of Formula XXIII:
[0292] Compound of Formula XXIII may be prepared by treating
compound of Formula XXII with a reducing agent (e.g. hydrogen) in
the presence of a catalyst (e.g. 10% palladium on carbon) in a
solvent (e.g. methanol), at room temperature, typically for 1 to 24
hours, followed by isolation and purification by conventional means
(e.g. aqueous work-up and silica gel chromatography).
Step 4--Preparation of Formula If:
[0293] Compound of Formula If may be prepared by treating compound
of Formula XXIII, with an appropriate reagent (e.g. methyl
2-bromoacetate), containing the R.sup.1, R.sup.3 and R.sup.4
substituents and appropriate leaving group (e.g. chloro, bromo), in
the presence of base (e.g. sodium hydride) in an inert solvent
(e.g. DMF) typically for 12-18 hours with heating, followed by
isolation and purification by conventional means (e.g. aqueous
work-up and silica gel chromatography).
[0294] In one particular embodiment of Formula If, R.sup.1 is
carboxylic acid and R.sup.3 and R.sup.4 are hydrogen, which may be
prepared from intermediate XXIII according to Scheme 8. ##STR18##
Step 1--Preparation of Formula XXIV.
[0295] Compound of Formula XXIV may be prepared by treating
compound of Formula XXIII with methyl 2-bromoacetate in the
presence of base (e.g. sodium hydride) in an inert solvent (e.g.
DMF) typically for 12-18 hours with heating, followed by isolation
and purification by conventional means (e.g. aqueous work-up and
silica gel chromatography).
Step 2--Preparation of Formula If:
[0296] Compound of Formula If wherein R.sup.1 is carboxylic acid
and R.sup.3 and R.sup.4 are hydrogen may be prepared by hydrolysis
of compound of Formula XXIV with aqueous base (e.g. sodium
hydroxide), typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
EXAMPLES
Example 1
Synthesis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid (1)
[0297] Indole acid 1 may be synthesized in seven steps from
commercially available p-anisidine as shown in Scheme 9. ##STR19##
##STR20## Step 1--Preparation of
]-(2-Amino-5-methoxy-phenyl)-2-chloro-ethanone (3)
[0298] Compound 3, 1-(2-Amino-5-methoxy-phenyl)-2-chloro-ethanone,
may be prepared by reacting a commercially available p-anisidine 2
with chloroacetonitrile in the presence of boron trichloride and a
Lewis base (e.g. aluminum trichloride) with heating to reflux for
several hours in an inert solvent (e.g. benzene) and purification
by conventional methods (e.g. silica gel chromatography) (Sugasawa,
et. al.; J. Org. Chem., 1979, 44:578).
Step 2--Preparation of
N-[2-(2-Chloro-acetyl)-4-methoxy-phenyl]-acetamide (4)
[0299] Compound 4,
N-[2-(2-Chloro-acetyl)-4-methoxy-phenyl]-acetamide, may be prepared
by reacting 1-(2-Amino-5-methoxy-phenyl)-2-chloro-ethanone 3 with
acetic anhydride and heating (e.g. 80.degree. C.) for 30 minutes,
followed by purification (e.g. silica gel chromatography) (Sugasawa
et. al.; J. Org. Chem., 1979, 44:578).
Step 3--Preparation of 1-(3-Hydroxy-5-methoxy-indol-1-yl)-ethanone
(5)
[0300] Compound 5, 1-(3-Hydroxy-5-methoxy-indol-1-yl)-ethanone, may
be prepared by reacting
N-[2-(2-Chloro-acetyl)-4-methoxy-phenyl]-acetamide 4 with a base
(e.g. sodium hydride) in an inert solvent (e.g.
1,2-dimethoxyethane) and stirring with ice-cooling or at room
temperature for several minutes to several hours, followed by
purification and isolation by conventional means (e.g. aqueous
work-up and silica gel chromatography). (Sugasawa et. al.; J. Org.
Chem., 1979, 44:578).
Step 4--Preparation of (1-Acetyl-5-methoxy-1H-indol-3-yloxy)-acetic
acid methyl ester (6)
[0301] Compound 6, (1-Acetyl-5-methoxy-1H-indol-3-yloxy)-acetic
acid methyl ester, may be prepared by alkylating
1-(3-Hydroxy-5-methoxy-indol-1-yl)-ethanone 5 with methyl
2-bromoacetate in the presence of base (e.g. potassium carbonate)
in an inert solvent (e.g. acetone) typically for 12-18 hours with
heating to reflux, followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography). (Andersen et. al., J. Med. Chem., 1996,
39:3723.)
Step 5--Preparation of (5-Methoxy-1H-indol-3-yloxy)-acetic acid
methyl ester (7)
[0302] Compound 7, (5-Methoxy-1H-indol-3-yloxy)-acetic acid methyl
ester, may be prepared by removal of the N-acetyl of
(1-Acetyl-5-methoxy-1H-indol-3-yloxy)-acetic acid methyl ester 6
using a base (e.g. potassium hydroxide) in methanol typically at
room temperature for 2 to 24 hours, followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography). (Naylor et. al., J. Med. Chem., 1997,
40:2335.)
Step 6--Preparation of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid methyl ester (8)
[0303] Compound 8,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid methyl ester, may be prepared by treating
(5-Methoxy-1H-indol-3-yloxy)-acetic acid methyl ester 7 with
4-methoxyphenylsulfonyl chloride in a bi-phasic solvent condition
(e.g. toluene and water), in presence of a base (e.g. An aqueous
potassium hydroxide solution), with a phase transfer catalyst (e.g.
tetrabutylammonium hydrogen sulfate), similar to conditions as
described Gribble, et al., J. Org. Chem., 2002, 63: 1001-03.
Step 7--Preparation of
[5-Methoxy-]-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid (I)
[0304] Compound 1,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid, may be prepared by hydrolysis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid methyl ester 8 with aqueous base (e.g. sodium hydroxide),
typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
Example 2
Synthesis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylsulfanyl]-acetic
acid (9)
[0305] Indole acid 9 may be synthesized from commercially available
5-methoxyindole in four steps as shown in Scheme 10. ##STR21## Step
1--Preparation of 3-bromo-5-methoxyindole (11)
[0306] Compound 11, 3-bromo-5-methoxyindole, may be prepared by
bromination of commercially available 5-methoxyindole 10 with
bromine, in an inert solvent (e.g. DMF), followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography).
Step 2--Preparation of (5-Methoxy-1H-indol-3-ylsulfanyl)-acetic
acid ethyl ester (12)
[0307] Compound 12, (5-Methoxy-1H-indol-3-ylsulfanyl)-acetic acid
ethyl ester, may be prepared by reacting 3-bromo-5-methoxyindole 11
with ethyl 2-mercaptoacetate in the presence of base (e.g.
potassium carbonate) in an inert solvent (e.g. acetone) typically
for 12-18 hours with heating to reflux, followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography). (Salituro et. al., J. Med. Chem.,
1992,35:1791.)
Step 3--Preparation of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylsulfanyl]-acetic
acid ethyl ester (13)
[0308] Compound 13,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylsulfanyl]-acetic
acid ethyl ester, may be prepared by treating
(5-Methoxy-1H-indol-3-ylsulfanyl)-acetic acid ethyl ester 12 with
4-methoxyphenylsulfonyl chloride in a bi-phasic solvent condition
(e.g. toluene and water), in presence of a base (e.g. An aqueous
potassium hydroxide solution), with a phase transfer catalyst (e.g.
tetrabutylammonium hydrogen sulfate), similar to conditions as
described Gribble et al, in J. Org. Chem., 2002, 63:1001-03.
Step 4--Preparation of
[5-Methoxy-1-(4-methoxy-benzenesuifonyl)-1H-indol-3-ylsulfanyl]-acetic
acid (9)
[0309] Compound 9,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylsulfanyl]-acetic
acid, may be prepared by hydrolysis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylsulfanyl]-acetic
acid ethyl ester 13 with aqueous base (e.g. sodium hydroxide),
typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
Example 3
Synthesis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamino]-acetic
acid (14)
[0310] Indole acid 14 may be synthesized in five steps from
commercially available 5-methoxyindole as shown in Scheme 11.
##STR22## ##STR23## Step 1--Preparation of 5-methoxy-3-nitroindole
(15)
[0311] Compound 15, 5-methoxy-3-nitroindole, may be prepared by
nitration of commercially available 5-methoxyindole 10 with nitric
acid, in a solvent (e.g. acetic anhydride), typically at 0.degree.
C. or colder for 1 to 12 hours, followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography). (Pelkey et. al., Synthesis, 1999, 7:1117.)
Step 2--Preparation of
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-3-nitro-1H-indole (16)
[0312] Compound 16,
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-3-nitro-1H-indole, may be
prepared by treating 5-methoxy-3-nitroindole 15 with
4-methoxyphenylsulfonyl chloride in a bi-phasic solvent condition
(e.g. toluene and water), in presence of a base (e.g. an aqueous
potassium hydroxide solution), with a phase transfer catalyst (e.g.
tetrabutylammonium hydrogen sulfate), similar to conditions as
described Gribble, et al, in J. Org. Chem., 2002, 63:1001-03.
Step 3--Preparation of
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamine (17)
[0313] Compound 17,
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamine, may be
prepared by treating
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-3-nitro-1H-indole 16 with a
reducing agent (e.g. hydrogen) in the presence of a catalyst (e.g.
10% palladium on carbon) in a solvent (e.g. methanol), at room
temperature, typically for 1 to 24 hours, followed by isolation and
purification by conventional means (e.g. aqueous work-up and silica
gel chromatography).
Step 4--Preparation of
[5-Methoxy-1-(4-methoxy-benzenesuifonyl)-1H-indol-3-ylamino]-acetic
acid methyl ester (18)
[0314] Compound 18,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamino]-acetic
acid methyl ester, may be prepared by treating
5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamine 17, with
an appropriate reagent (e.g. methyl 2-bromoacetate), containing the
R.sup.1, R.sup.3 and R.sup.4 substituents and appropriate leaving
group (e.g. chloro, bromo), in the presence of base (e.g. sodium
hydride) in an inert solvent (e.g. DMF) typically for 12-18 hours
with heating, followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
[0315] Step 5--Preparation of
[5-Methoxy-1-(4-methoxy-benzenesu/fonyl)-1H-indol-3-ylamino]-acetic
acid (14)
[0316] Compound 14,
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamino]-acetic
acid, may be prepared by hydrolysis of
[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ylamino]-acetic
acid methyl ester 18 with aqueous base (e.g. sodium hydroxide),
typically for 6-18 hours, in an inert solvent (e.g.
tetrahydrofuran), followed by isolation and purification by
conventional means (e.g. aqueous work-up and silica gel
chromatography).
Example 4
Synthesis of
[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid (23)
[0317] Indole acid 23 was synthesized in four steps from
commercially available 5-methoxyindole as shown in Scheme 12.
##STR24## ##STR25## Step-1--Preparation of Acetic acid
5-bromo-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl ester (20)
[0318] To a stirring solution of 5-Bromo-1H-indol-3yl ester (19,
685.0 mg, 2.70 mmol) in DMF (1. 5 mL) was added sodium hydride
(77.6 mg, 2.35 mmol) and the reaction mixture was stirred at
25.degree. C. for 1 h. 4-Methoxybenzenesulfonyl chloride (612.8 mg,
2.97 mmol) was introduced and the reaction was stirred overnight
under nitrogen at 25.degree. C. Ethyl acetate was added to the
reaction mixture and was washed with saturated sodium carbonate (X
5), dried over magnesium sulfate and filtered. Concentration under
reduced pressure afforded the crude material, which was purified by
column chromatography (20% ethyl acetate in hexanes) to yield the
desired product as a white solid (20, 425 mg, 37% yield). MS(ESI)
[M+H.sup.+].sup.+=424.2; 426.2.
Step-2--Preparation of
5-Bromo-1-(4-methoxy-benzenesuifonyl)-1H-indol-3-ol (21).
[0319] Acetic acid
5-bromo-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl ester (20, 150
mg, 0.353 mmol) was added to a stirring solution of 50% potassium
hydroxide (2.0 mL) in methanol (6.0 mL). After stirring at
25.degree. C. for 30 min, the reaction mixture was acidified with
1M hydrochloric acid. The organic material was extracted with ethyl
acetate, dried over magnesium sulfate, filtered and concentrated at
reduced pressure to afford
5-bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ol (21, 110.0 mg,
81% yield). MS(ESI) [M-H.sup.+].sup.-=380.0; 382.0
Step-3--Preparation of
[5-Bromo-1-(4-methoxy-benzenesuifonyl)-1H-indol-3-yloxy]-acetic
acid methyl ester (22)
[0320] To a stirring solution of
5-bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-ol (21, 130 mg,
0.340 mmol) in acetonitrile (3.5 mL) in a high pressure reaction
vessel was added potassium carbonate (235 mg, 1.70 mmol) and
bromoacetic acid methyl ester (38.6 .mu.L, 0.408 mmol). The vessel
was flushed with a nitrogen atmosphere, sealed with a Teflon
stopcock and heated to 80.degree. C. for overnight. After the
reaction mixture was cooled to 25.degree. C., ethyl acetate was
added and washed with saturated sodium bicarbonate. The organic
layer was dried over magnesium sulfate, filtered and concentrated
at reduced pressure to obtain a light brown solid. Purification of
the crude material was carried out using biotage chromatography
(30% ethyl acetate in hexanes) which afforded the product as an
off-white solid (22, 72.0 mg, 47% yield). MS(ESI)
[M+H.sup.+].sup.+=454.2; 456.2.
Step-4--Preparation of
[5-Bromo-1-(4-methoxy-benzenesuifonyl)-1H-indol-3-yloxy]-acetic
acid (23)
[0321]
[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic
acid methyl ester (22, 32.0 mg, 0.007 mmol) was dissolved in THF
(1.50 mL) and 1M lithium hydroxide (0.4 mL) was added to this
solution. After stirring for 30 min at 25.degree. C., ethyl acetate
was added and the mixture was acidified with 1M hydrochloric acid.
The organic layer was dried over magnesium sulfate, filtered and
concentrated at reduced pressure to obtain a white solid (23, 28
mg, 90% yield). MS(ESI) [M-H.sup.+].sup.-=438.0; 440.0.
Example 5
Synthesis of
3-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-propionic
acid 24
[0322] ##STR26##
[0323]
3-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-propion-
ic acid 24 was prepared using the same protocol as described in
Example 4, substituting bromoacetic acid methyl ester with
bromopropionic acid methyl ester in step 3. MS(ESI)
[M+H.sup.+].sup.+=452.0; 454.0.
Example 6
Synthesis of
[1-(3,4-dichloro-benzenesulfonyl)-5-methoxy-1H-indol-3-ylsulfanyl]-acetic
acid 27.
[0324] Indole acid 27 was synthesized from commercially available
5-methoxyindole 10 in three steps as shown in Scheme 13. ##STR27##
Step 1: Preparation of (5-Methoxy-1H-indol-3-ylsulfanyl)-acetic
acid methyl ester (25)
[0325] Triiodide synthesis: Into a round bottom flask, KI (5.00 g,
30.1 mmol) was mixed with 12 (5.1 g, 20.0 mmol) in 20 mL water. The
mixture was stirred at room temperature for 24 hours. To a solution
of 5-methoxyindole (10, 200 mg, 1.36 mmol) and thiourea (110 mg,
1.44 mmol) in methanol (10 mL), triiodide, freshly prepared from
the previous day (440 mg, 1.5 mmol) was added over a 20 minute
period, and the combined mixture stirred at room temperature for 40
min. The solvent was reduced to half of its volume and 10 N NaOH (5
mL) was added to the flask and heated at 95.degree. C. for one hour
under an inert atmosphere. The resulting suspension was filtered
hot and the solid rinsed with water. Filtrate was cooled to room
temperature and bromoacetic acid methyl ester (241 mg, 1.6 mmol)
was added. This mixture was stirred vigorously for an hour and the
organic layer was extracted with diethyl ether. The aqueous layer
was acidified with 1 N HCl and extracted with ether. The desired
product was isolated after flash silica column chromatography using
gradient solvent 5-10% EtOAc/hexane. (15 mg, 4.4%)
Step 2. Preparation of
[1-(3,4-dichloro-benzenesulfonyl)-5-methoxy-1H-indol-3-ylsulfanyl]-acetic
acid methyl ester (26)
[0326] To a dry round bottom flask,
(5-Methoxy-1H-indol-3-ylsulfanyl)-acetic acid methyl ester (25, 7.0
mg, 0.027 mmol) was dissolved with CH.sub.2Cl.sub.2 (3.0 mL).
Tetrabutylammonium hydrogen sulfate (2.0 mg) and 50% KOH solution
(3.0 mL) were added next. After about 5 minutes of stirring,
3,4-dichloro-benzenesulfonyl chloride (20 mg, 0.081 mmol) was
added. This reaction was allowed to stir at ambient temperature
overnight. The reaction was extracted with dichloromethane
(2.times.14 mL), washed with water (5 mL), brine (5 mL) and dried
over anhydrous magnesium sulfate. The reactant was filtered and
rotoevaporated to give the desired product 26 as off white
solid.
Step 3: Preparation of
[1-(3,4-dichloro-benzenesulfonyl)-5-methoxy-1H-indol-3-ylsulfanyl]-acetic
acid (27)
[0327] To a solution of (5-Methoxy-1H-indol-3-ylsulfanyl)-acetic
acid methyl ester 26, in THF (4.0 mL) was added an aqueous solution
of potassium hydroxide (1.0 mL of 1M) which was stirred at room
temperature for 4 h. The acid was neutralized with aqueous HCl,
extracted the product with ethyl acetate, dried over anhydrous
magnesium sulfate, evaporated under reduced pressure, and purified
via trituration with tetrabutyl ethyl ether to afford 27 as a white
solid (4.5 mg, 5%). MS(ESI) [M+H.sup.-].sup.+=443.95
Example 7
Synthesis of (5-methoxy-1H-indol-3-ylsulfanyl)-acetic acid 28.
[0328] ##STR28##
[0329] (5-methoxy-1H-indol-3-ylsulfanyl)-acetic acid 28 was
prepared by reacting (5-Methoxy-1H-indol-3-ylsulfanyl)-acetic acid
methyl ester 25 using the same protocol as described in Example 6
step 3 to give 28 as an acid. MS(ESI) [M-H.sup.+].sup.-=238.15
Example 8
Synthesis of
3-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-propionic
acid methyl ester (29)
[0330] ##STR29##
[0331] 3-[5-Bromo-1-(4-methoxy-benzenesulfonyl)-1
H-indol-3-yloxy]-propionic acid methyl ester was prepared using the
same protocol as described in Example 4, substituting bromoacetic
acid methyl ester with bromopropionic acid methyl ester in step 3.
MS(ESI) [M-H.sup.+].sup.-=466.0; 468.0
Example 9
Expression and Purification of PPARs For Use in Biochemical and
Cell Assays Genetic Engineering
[0332] Plasmids encoding the Ligand-binding domains (LBDs) of
PPAR.alpha., PPAR.gamma., and PPAR.delta. were engineered using
common polymerase chain reaction (PCR) methods
(pGal4-PPAR.alpha.-LBD, pGal4-PPAR.gamma.-LBD,
pGal4-PPAR.delta.-LBD). The relevant DNA sequences and encoded
protein sequences used in the assay are shown for each (see below).
Complementary DNA cloned from various human tissues was purchased
from Invitrogen, and these were used as substrates in the PCR
reactions. Specific custom synthetic oligonucleotide primers
(Invitrogen, see below) were designed to initiate the PCR product,
and also to provide the appropriate restriction enzyme cleavage
sites for ligation with the plasmids.
[0333] The plasmids used for ligation with the receptor-encoding
inserts were either pET28 (Novagen) or a derivative of pET28,
pET-BAM6, for expression using E. coli. In each of these cases the
receptor LBD was engineered to include a Histidine tag for
purification using metal affinity chromatography.
Protein Expression and Purification of PPAR's.
[0334] For protein expression, plasmids containing genes of
interest were transformed into E. coli strain BL21(DE3)RIL
(Invitrogen) and transformants selected for growth on LB agar
plates containing appropriate antibiotics. Single colonies were
grown for 4 hrs at 37.degree. C. in 200 ml LB media. For
PPAR.alpha. and PPAR.gamma. all protein expression was performed by
large scale fermentation using a 30 L bioreactor. 400 ml of starter
culture was added to 30 L TB culture and allowed to grow at
37.degree. C. until an OD 600 nm of 2-5 was obtained. The culture
was cooled to 20.degree. C. and 0.5 mM IPTG
(isopropyl-beta-D-thiogalactopyranoside) added, and the culture was
allowed to grow for a further 18 hrs.
[0335] For PPAR.delta. protein expression, single colonies were
grown for 4 hrs at 37.degree. C. in 200 mL LB media. 16.times.1 L
of fresh TB media in 2.8 L flasks were inoculated with 10 mL of
starter culture and grown with constant shaking at 37.degree. C.
Once cultures reached an absorbance of 1.0 at 600 nm, an additive
to improve the solubility of the PPAR.delta. was added to the
culture and 30 min later, 0.5 mM IPTG was added and cultures
allowed to grow for a further 12 to 18 hrs at 20.degree. C. Cells
were harvested by centrifugation and pellets frozen at -80.degree.
C. until ready for lysis/purification.
[0336] For protein purification; all operations were carried out at
4.degree. C. Frozen E. coli cell pellets were resuspended in lysis
buffer and lysed using standard mechanical methods. Soluble
proteins were purified via poly-Histidine tags using immobilized
metal affinity purification (IMAC). For each of the PPAR's
described all have been purified using a 3 step purification
process utilizing; IMAC, size exclusion chromatography and ion
exchange chromatography. For PPAR.alpha. the poly-Histidine tag was
optionally removed using Thrombin (Calbiochem). In the case of
PPAR.delta., during protein purification the solubility improving
additive was present in order to maintain protein stability. During
the final step of purification solubility improving additives were
desalted away before concentration.
[0337] Plasmid Sequence and PCR Primer Information: TABLE-US-00002
PPAR.alpha.: (SEQ ID NO:.sub.----) P332. pET28 PPARA E199-Y468-X
taatacgactcactataggggaattgt
gagcggataacaattcccctctagaaataattttgtttaactttaagaaggagatatacc
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat M G S
S H H H H H H S S G L V P R G S H
atggaaactgcagatctcaaatctctggccaagagaatctacgaggcctacttgaagaac M E T
A D L K S L A K R I Y E A Y L K N
ttcaacatgaacaaggtcaaagcccgggtcatcctctcaggaaaggccagtaacaatcca F N M
N K V K A R V I L S G K A S N N P
ccttttgtcatacatgatatggagacactgtgtatggctgagaagacgctggtggccaag P F V
I H D M E T L C M A E K T L V A K
ctggtggccaatggcatccagaacaaggaggcggaggtccgcatctttcactgctgccag L V A
N G I Q N K E A E V R I F H C C Q
tgcacgtcagtggagaccgtcacggagctcacggaattcgccaaggccatcccaggcttc C T S
V E T V T E L T E F A K A I P G F
gcaaacttggacctgaacgatcaagtgacattgctaaaatacggagtttatgaggccata A N L
D L N D Q V T L L K Y G V Y E A I
ttcgccatgctgtcttctgtgatgaacaaagacgggatgctggtagcgtatggaaatggg F A M
L S S V M N K D G M L V A Y G N G
tttataactcgtgaattcctaaaaagcctaaggaaaccgttctgtgatatcatggaaccc F I T
R E F L K S L R K P F C D I M E P
aagtttgattttgccatgaagttcaatgcactggaactggatgacagtgatatctccctt K F D
F A M K F N A L E L D D S D I S L
tttgtggctgctatcatttgctgtggagatcgtcctggccttctaaacgtaggacacatt F V A
A I I C C G D R P G L L N V G H I
gaaaaaatgcaggagggtattgtacatgtgctcagactccacctgcagagcaaccacccg E K M
Q E G I V H V L R L H L Q S N H P
gacgatatctttctcttcccaaaacttcttcaaaaaatggcagacctccggcagctggtg D D I
F L F P K L L Q K M A D L R Q L V
acggagcatgcgcagctggtgcagatcatcaagaagacggagtcggatgctgcgctgcac T E H
A Q L V Q I I K K T E S D A A L H
ccgctactgcaggagatctacagggacatgtactgagtcgacaagcttgcggccgcactc P L L
Q E I Y R D M Y - gagcaccaccaccaccaccactgagat PCR primers: (SEQ ID
NO:.sub.----) PPARA PPARA-S GCTGACACATATGGAAACTGCAGATCTCAAATC 343
.alpha.: (SEQ ID NO:.sub.----) PPARA-A
GTGACTGTCGACTCAGTACATGTCCCTGTAGA 344 PPAR.gamma.: (SEQ ID
NO:.sub.----) P333. pET28 PPARG E205-Y475-X
taatacgactcactataggggaattgt
gagcggataacaattcccctctagaaataattttgtttaactttaagaaggagatatacc
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat M G S
S H H H H H H S S G L V P R G S H
atggagtccgctgacctccgggccctggcaaaacatttgtatgactcatacataaagtcc M E S
A D L R A L A K H L Y D S Y I K S
ttcccgctgaccaaagcaaaggcgagggcgatcttgacaggaaagacaacagacaaatca F P L
T K A K A R A I L T G K T T D K S
ccattcgttatctatgacatgaattccttaatgatgggagaagataaaatcaagttcaaa P F V
I Y D M N S L M M G E D K I K F K
cacatcacccccctgcaggagcagagcaaagaggtggccatccgcatctttcagggctgc H I T
P L Q E Q S K E V A I R I F Q G C
cagtttcgctccgtggaggctgtgcaggagatcacagagtatgccaaaagcattcctggt Q F R
S V E A V Q E I T E Y A K S I P G
tttgtaaatcttgacttgaacgaccaagtaactctcctcaaatatggagtccacgagatc F V N
L D L N D Q V T L L K Y G V H E I
atttacacaatgctggcctccttgatgaataaagatggggttctcatatccgagggccaa I Y T
M L A S L M N K D G V L I S E G Q
ggcttcatgacaagggagtttctaaagagcctgcgaaagccttttggtgactttatggag G F M
T R E F L K S L R K P F G D F M E
cccaagtttgagtttgctgtgaagttcaatgcactggaattagatgacagcgacttggca P K F
E F A V K F N A L E L D D S D L A
atatttattgctgtcattattctcagtggagaccgcccaggtttgctgaatgtgaagccc I F I
A V I I L S G D R P G L L N V K P
attgaagacattcaagacaacctgctacaagccctggagctccagctgaagctgaaccac I E D
I Q D N L L Q A L E L Q L K L N H
cctgagtcctcacagctgtttgccaagctgctccagaaaatgacagacctcagacagatt P E S
S Q L F A K L L Q K M T D L R Q I
gtcacggaacatgtgcagctactgcaggtgatcaagaagacggagacagacatgagtctt V T E
H V Q L L Q V I K K T E T D M S L
cacccgctcctgcaggagatctacaaggacttgtactaggtcgacaagcttgcggccgca H P L
L Q E I Y K D L Y - ctcgagcaccaccaccaccaccactgagat PCR Primers:
(SEQ ID NO:.sub.----) PPARG PPARG-S
GCTCAGACATATGGAGTCCGCTGACCTCCGGGC 347 (SEQ ID NO:.sub.----) PPARG-A
GTGACTGTCGACCTAGTACAAGTCCTTGTAGA 348 PPAR.delta.: (SEQ ID
NO:.sub.----) P1057. pET BAM6 PPARD G165-Y441-X
taatacgactcactataggggaattgt
gagcggataacaattcccctctagaaataattttgtttaactttaagaaggagatatacc
atgaaaaaaggtcaccaccatcaccatcacggatcccagtacaacccacaggtggccgac M K K
G H H H H H H G S Q Y N P Q V A D
ctgaaggccttctccaagcacatctacaatgcctacctgaaaaacttcaacatgaccaaa L K A
F S K H I Y N A Y L K N F N M T K
aagaaggcccgcagcatcctcaccggcaaagccagccacacggcgccctttgtgatccac K K A
R S I L T G K A S H T A P F V I H
gacatcgagacattgtggcaggcagagaaggggctggtgtggaagcagttggtgaatggc D I E
T L W Q A E K G L V W K Q L V N G
ctgcctccctacaaggagatcagcgtgcacgtcttctaccgctgccagtgcaccacagtg L P P
Y K E I S V H V F Y R C Q C T T V
gagaccgtgcgggagctcactgagttcgccaagagcatccccagcttcagcagcctcttc E T V
R E L T E F A K S I P S F S S L F
ctcaacgaccaggttacccttctcaagtatggcgtgcacgaggccatcttcgccatgctg L N D
Q V T L L K Y G V H E A I F A M L
gcctctatcgtcaacaaggacgggctgctggtagccaacggcagtggctttgtcacccgt A S I
V N K D G L L V A N G S G F V T R
gagttcctgcgcagcctccgcaaacccttcagtgatatcattgagcctaagtttgaattt E F L
R S L R K P F S D I I E P K F E F
gctgtcaagttcaacgccctggaacttgatgacagtgacctggccctattcattgcggcc A V K
F N A L E L D D S D L A L F I A A
atcattctgtgtggagaccggccaggcctcatgaacgttccacgggtggaggctatccag I I L
C G D R P G L M N V P R V E A I Q
gacaccatcctgcgtgccctcgaattccacctgcaggccaaccaccctgatgcccagtac D T I
L R A L E F H L Q A N H P D A Q Y
ctcttccccaagctgctgcagaagatggctgacctgcggcaactggtcaccgagcacgcc L F P
K L L Q K M A D L R Q L V T E H A
cagatgatgcagcggatcaagaagaccgaaaccgagacctcgctgcaccctctgctccag Q M M
Q R I K K T E T E T S L H P L L Q
gagatctacaaggacatgtactaagtcgaccaccaccaccaccaccactgagatccggct E I Y
K D M Y -
ggccctactggccgaaaggaattcgaggccagcagggccaccgctgagcaataactagca
taaccccttggggcctctaaacgggtcttgaggggttttttg PCR Primers: (SEQ ID
NO:.sub.----) PPARD PPARD- GTTGGATCCCAGTACAACCCACAGGTGGC 2313 G165
(SEQ ID NO:.sub.----) PPARB-A GTGACTGTCGACTTAGTACATGTCCTTGTAGA
346
Example 10
Biochemical Screening
[0338] The homogenous Alpha screen assay was used in the agonist
mode to determine the ligand dependent interaction of the PPARs
(.alpha.,.delta.,.gamma.) with the coactivator Biotin-PGC-1 peptide
(biotin-AHX-DGTPPPQEAEEPSLLKKLLLAPANT-CONH.sub.2, (SEQ ID
NO:______) supplied by Wyeth). Compounds 23, 24, 27 and 29 from
Table 1 were serially diluted 1:3 into DMSO for a total of 8
concentration points. Samples were prepared with His-tagged
PPAR-LBD prepared per Example 9. Ni-chelate acceptor beads were
added that bind to the his-tagged PPAR-LBD and streptavidin donor
beads were added that bind to the biotin of the coactivator
(Perkin-Elmer #6760619M) such that agonist activity correlates to
signal from the donor and acceptor beads in close proximity. Each
sample was prepared by mixing 1 .mu.l of compound and 15 .mu.l of
1.33.times. receptor/peptide mix, incubating for 15 minutes at room
temperature, then adding 4 .mu.l of 4.times. beads in assay buffer.
The assay buffer was 50 mM HEPES, pH 7.5, 50 mM KCl, 1 mM DTT and
0.8% BSA. Final concentrations for each sample were 25 nM
biotin-PGC-1 peptide, 20 nM PPAR.gamma. or 10 nM PPAR.alpha. or
.delta., and each bead at 5 .mu.g/ml, with compound added to the
desired concentration resulting in final DMSO of 5%.
WY-14643(PPAR(X), farglitazar (PPAR.gamma.) and bezafibrate
(PPAR.delta.) were assayed as control samples. The samples were
incubated for 1 hour in the dark at room temperature before taking
the reading in the Fusion alpha or Alpha Quest reader. The signal
vs. compound concentration was used to determine the EC.sub.50. The
data was expressed in .mu.Mol/L. The data points from the Fusion
alpha instrument were transferred to Assay Explorer.RTM. (MDL) to
generate a curve and calculate the inflection point of the curve as
EC.sub.50. Compound 27 demonstrated EC.sub.50 of <1 .mu.M with
respect to PPAR.delta. and PPAR.gamma..
Example 11
Co-Transfection Assay
[0339] This assay serves to confirm the observed biochemical
activity (Example 10) on the modulation of intended target
molecule(s) at the cellular level. 293T cells (ATCC) are seeded at
1-2.times.10.sup.6 cells per well of a 6 well plate (Corning 3516)
in 3 ml of growth medium (Dulbecco's eagle medium, Mediatech, with
10% FBS). These are incubated to 80-90% confluent and the medium is
removed by aspirating. These cells are transfected with PPAR LBD
and luciferase such that agonist will result in activation of the
luciferase. Measurement of luciferase activity of transfected cells
treated with test compounds directly correlates with agonist
activity. To 100 .mu.l of serum free growth medium is added 1 .mu.g
of pFR-Luc (Stratagene catalog number 219050), 6 .mu.l Metafectene
(Biontex, Inc.) and 1 mg of the pGal4-PPAR-LBD(.alpha., .gamma. or
.delta. from Example 9). This is mixed by inverting, then incubated
for 15-20 minutes at room temperature, then diluted with 900 .mu.l
of serum free growth medium. This is overlayed onto the 293T cells
and incubated for 4-5 hours at 37.degree. C. in CO.sub.2 incubator.
The transfection medium is removed by aspirating and growth medium
is added and the cells incubated for 24 hours. The cells are then
suspended in 5 ml of growth medium and diluted with an additional
15 ml of growth medium. For each test sample, 95 .mu.l of the
transfected cells are transferred per well of a 96 well culture
plate. Compounds for testing are made up in DMSO at 200.times. the
desired final concentration. This is diluted 10.times. with growth
medium and 5 .mu.l is added to the 95 .mu.l of transfected cells.
The plate is incubated for 24 hours 37.degree. C. in CO.sub.2
incubator. Luciferase reaction mixture is prepared by mixing 1 ml
of lysis buffer, 1 ml of substrate in lysis buffer, and 3 ml of
reaction buffer (Roche Diagnostics Luciferase assay kit #1814036).
For each sample well, the growth medium is replaced with 50 ml of
reaction mixture and the plate shaken for 15-20 minutes, and the
luminescence was measured on a Victor2 V plate reader (Perkin
Elmer). The signal vs. compound concentration is used to determine
the EC.sub.50.
[0340] All patents and other references cited in the specification
are indicative of the level of skill of those skilled in the art to
which the invention pertains, and are incorporated by reference in
their entireties, including any tables and figures, to the same
extent as if each reference had been incorporated by reference in
its entirety individually.
[0341] One skilled in the art would readily appreciate that the
present invention is well adapted to obtain the ends and advantages
mentioned, as well as those inherent therein. The methods,
variances, and compositions described herein as presently
representative of preferred embodiments are exemplary and are not
intended as limitations on the scope of the invention. Changes
therein and other uses will occur to those skilled in the art,
which are encompassed within the spirit of the invention, are
defined by the scope of the claims.
[0342] It will be readily apparent to one skilled in the art that
varying substitutions and modifications may be made to the
invention disclosed herein without departing from the scope and
spirit of the invention. For example, variations can be made to
exemplary compounds of Formula I, Ia, Ib, or Ic to provide
additional active compounds. Thus, such additional embodiments are
within the scope of the present invention and the following
claims.
[0343] The invention illustratively described herein suitably may
be practiced in the absence of any element or elements, limitation
or limitations which is not specifically disclosed herein. Thus,
for example, in each instance herein any of the terms "comprising".
"consisting essentially of" and "consisting of" may be replaced
with either of the other two terms. The terms and expressions which
have been employed are used as terms of description and not of
limitation, and there is no intention that in the use of such terms
and expressions of excluding any equivalents of the features shown
and described or portions thereof, but it is recognized that
various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that although the
present invention has been specifically disclosed by preferred
embodiments and optional features, modification and variation of
the concepts herein disclosed may be resorted to by those skilled
in the art, and that such modifications and variations are
considered to be within the scope of this invention as defined by
the appended claims.
[0344] In addition, where features or aspects of the invention are
described in terms of Markush groups or other grouping of
alternatives, those skilled in the art will recognize that the
invention is also thereby described in terms of any individual
member or subgroup of members of the Markush group or other
group.
[0345] Also, unless indicated to the contrary, where various
numerical values are provided for embodiments, additional
embodiments are described by taking any 2 different values as the
endpoints of a range. Such ranges are also within the scope of the
described invention.
[0346] Thus, additional embodiments are within the scope of the
invention and within the following claims. TABLE-US-00003 SEQ ID
NO:.sub.----: NM_005036 1 gcgccgcctc cttcggcgtt cgccccacgg
accggcaggc ggcggaccgc ggcccaggct 61 gaagctcagg gccctgtctg
ctctgtggac tcaacagttt gtggcaagac aagctcagaa 121 ctgagaagct
gtcaccacag ttctggaggc tgggaagttc aagatcaaag tgccagcaga 181
ttcagtgtca tgtgaggacg tgcttcctgc ttcatagata agagtagctt ggagctcggc
241 ggcacaacca gcaccatctg gtcgcgatgg tggacacgga aagcccactc
tgccccctct 301 ccccactcga ggccggcgat ctagagagcc cgttatctga
agagttcctg caagaaatgg 361 gaaacatcca agagatttcg caatccatcg
gcgaggatag ttctggaagc tttggcttta 421 cggaatacca gtatttagga
agctgtcctg gctcagatgg ctcggtcatc acggacacgc 481 tttcaccagc
ttcgagcccc tcctcggtga cttatcctgt ggtccccggc agcgtggacg 541
agtctcccag tggagcattg aacatcgaat gtagaatctg cggggacaag gcctcaggct
601 atcattacgg agtccacgcg tgtgaaggct gcaagggctt ctttcggcga
acgattcgac 661 tcaagctggt gtatgacaag tgcgaccgca gctgcaagat
ccagaaaaag aacagaaaca 721 aatgccagta ttgtcgattt cacaagtgcc
tttctgtcgg gatgtcacac aacgcgattc 781 gttttggacg aatgccaaga
tctgagaaag caaaactgaa agcagaaatt cttacctgtg 841 aacatgacat
agaagattct gaaactgcag atctcaaatc tctggccaag agaatctacg 901
aggcctactt gaagaacttc aacatgaaca aggtcaaagc ccgggtcatc ctctcaggaa
961 aggccagtaa caatccacct tttgtcatac atgatatgga gacactgtgt
atggctgaga 1021 agacgctggt ggccaagctg gtggccaatg gcatccagaa
caaggaggcg gaggtccgca 1081 tctttcactg ctgccagtgc acgtcagtgg
agaccgtcac ggagctcacg gaattcgcca 1141 aggccatccc aggcttcgca
aacttggacc tgaacgatca agtgacattg ctaaaatacg 1201 gagtttatga
ggccatattc gccatgctgt cttctgtgat gaacaaagac gggatgctgg 1261
tagcgtatgg aaatgggttt ataactcgtg aattcctaaa aagcctaagg aaaccgttct
1321 gtgatatcat ggaacccaag tttgattttg ccatgaagtt caatgcactg
gaactggatg 1381 acagtgatat ctcccttttt gtggctgcta tcatttgctg
tggagatcgt cctggccttc 1441 taaacgtagg acacattgaa aaaatgcagg
agggtattgt acatgtgctc agactccacc 1501 tgcagagcaa ccacccggac
gatatctttc tcttcccaaa acttcttcaa aaaatggcag 1561 acctccggca
gctggtgacg gagcatgcgc agctggtgca gatcatcaag aagacggagt 1621
cggatgctgc gctgcacccg ctactgcagg agatctacag ggacatgtac tgagttcctt
1681 cagatcagcc acaccttttc caggagttct gaagctgaca gcactacaaa
ggagacgggg 1741 gagcagcacg attttgcaca aatatccacc actttaacct
tagagcttgg acagtctgag 1801 ctgtaggtaa ccggcatatt attccatatc
tttgttttaa ccagtacttc taagagcata 1861 gaactcaaat gctgggggta
ggtggctaat ctcaggactg ggaagattac ggcgaattat 1921 gctcaatggt
ctgattttaa ctcacccgat gttaatcaat gcacattgct ttagatcaca 1981
ttcgtgattt accatttaat taactggtaa cctcaaaatt cgtggcctgt cttcccattc
2041 accccgcttt tgactattgt gctcctttat aattctgaaa actaatcagc
actttttaac 2101 aatgtttata atcctataag tctagatgta tccaaaggtg
aagtatgtaa aaagcagcaa 2161 aatatttatt tcaaagactt cacttctgtt
tcctgaatct aaagaaagac aacatgctgc 2221 tttttaatca taggatggag
aattttaaag aactgtttgg gccaggcaca gtcgctcata 2281 cttgtaatcc
cagcactttg ggaggccgag gcgggtggat cacaaggtca gcagatcgag 2341
accatcctgg ccaacatggt gaaaccctgt ctctactaaa aatacaaaaa ttagccgggt
2401 gtggtggcac atgcctgtaa tcccagctac tcgggaagct gaggcaggag
aattgcttga 2461 accagggagt tggaggttgc agtgagctaa gactgcacca
ctgcactcca gcctggtgac 2521 agaacgagac tctgtcttaa aaacaaacaa
acaaaaaaaa aatctgttag ataagctatc 2581 aaaatgcagc tgttgttttg
tttttggctc actgttttcg tggttgtaac taatatgtgg 2641 aaaggcccat
ttccaggttt gcgtagaaga gcccagaaaa cagagtctca agacccccgc 2701
tctggactgt cataagctag cacccgtggt aagcgggacg agacaagctc ccgaagcccg
2761 ccagcttcct gctccactca gctccgtcca gtcaacctga acccacccag
tccagctgtc 2821 tgtgggaatg gtggtgttct tagggacaga ctgacacctt
acttgtcagt gttcctccgg 2881 gccccatttg gcagctcccg tatcttttgt
tatgttgctt ttaaagatat gatgttttat 2941 tgttttaact cttggtgaca
gtagatgctc tctggagcgc agacgaggca catgtgtctt 3001 catagcctgg
gctgggtggg agccagtcac cctgcggatc gagagagggg gtagagtctt 3061
cttcaaatgg cagttttact tcaaatggca gatttcacaa gagttggtta ttttttacaa
3121 tggtttaggt tgttaagtct cctttgtatg taaggtagtt ttttcaacat
ctaaaatttt 3181 tgttttagcc ttcaaaacca acttaccaac ctcagtccag
ctgggaaggc agcgttgatt 3241 atggtagttt gtcaagaata tatggacctg
gaaacacttt ctctctctgt ccacctggta 3301 gataaattgt cctgttgaga
atttttagat ctggactgga actgccagga ccaccgcctc 3361 cagggagtcg
ctgggcacct ggaggtatcg tcgatgcctc tcccccatct ttagaaaatt 3421
tggctcttct gaggtcatta ttattttaag aatgattagg attgataagg gtcccatgac
3481 cagcattatg aaaatgcgag agtgggaagg acacagtgtg agacttccac
tagaaaaaag 3541 tgaaagttag ggttaggaca tcctttttta aaaattacaa
atttagtccg ttttggtttt 3601 tgtaatcagg ctaggcacag tggctcacac
atggaatccc agcactttgg gaggccgagg 3661 tgggaggatc acttgagccc
aggagttcga gaccagccta ggcaacatag caagaccctg 3721 tctgtacaca
aaatttaaaa attagttcat cggggtggca cacatcagta gtcccagcta 3781
ctctgcaggc tgaggtggga ggattgcttg aacccaggag gtcgaggctg cagtgagctg
3841 tgatctcacc actgcattcc agcctgggtg acagagttag attccaccct
ctcccacccc 3901 ggcaaaaaaa aaaaaaaaag atgcaatcaa aggggctgtt
ggccagcaat ggcagcagca 3961 gcggcgggca gtctgcccaa gtgtcttagg
aaccaaaagc aaataaaagt gtttccatat 4021 atgccaccag ccaagtggcc
atcctaattc agaaagaagc tagcctttga gtgtctgtca 4081 tggtgcatcc
gtttcagtat tatttcctaa aatgagaagc ccctgtgtca acaagatcca 4141
ggggctggag cccaatgcca agcctgtgtt gtccccagcg accctgcagc tgctcgctct
4201 gatgtaccct gtgccattca aggagatgtg gtccaggaaa gtgagcctca
tggttttcag 4261 agaagtcatt gttctgttta cattttcata aaacctgttt
aaaatagctc cccgtctcag 4321 gctttcagca gtaacagtga gctgactggc
aagttcgatg ttagctcccg ggacactcag 4381 cagcgatggt gagcattttg
gtttccttaa ggcccagcaa gacttccagg gacatctctg 4441 gtgaagccag
aatggagaca cccgtgacct caggctgaaa gtcactcgac attggtctct 4501
tgtgttgata gggaaggaaa tcaggcattc ctatttcttt aaataacaaa accactaatt
4561 gccactcaat gctggaatat tttgggtcac ctaatcatag atttctcagg
gcatcaatac 4621 tcaaatatag gctgattatg ccccagttca aatgggaact
attaacagag tgcatttctt 4681 gcttgctggg tttcaacaga catcagccaa
aagaacaaaa gagatgtcag gacagattcc 4741 aggagtgtcg gagcacatgt
gtggcacccg ctccctctgg cagcgaatgt aggaagtcgc 4801 caaatttacc
cactcttcaa caagtcattg tttaaacacg gtttttcatt ttctcaactt 4861
ttaatagcaa aaagtgccaa agtcctcaga gacctaacag ccttggtcta ccgtgctgac
4921 cagggtgaag gcacggcgag ggactcctcc cagacgtgcc tcttgtgtgc
cagctggctg 4981 tggctcggga gcagacgcag gcctctccat tgtccagggg
agcctggcgg cgcatccctc 5041 ctctcccacc tcctggcact tccagctggg
tgtcccacat gttggattcc gtccccacca 5101 cacttccaga gaccggagaa
ctgtgcaggg cctaaggccg tttggatgaa ttgtcaaaac 5161 aagatgcttc
cagttacagc ggcaggagcg ggactgggag cacgggctga cggctgctgg 5221
tgcctttctt cccacctcgc ttgcctgttt ccgcttgacc cttcctccag ctccgatgag
5281 aagagtataa agcatcttcc taacgggtgt gtttgctata cgaacataat
ggacgtgaag 5341 tggggcagaa acccagaact cagcattcaa ggatgcccag
gagagctgtc cctgttttaa 5401 agagctgtgt tttgttttgt ttcgcattta
gagagcagac aaggcaccct tctgctgcgc 5461 tgatacgttt cttacactgg
gccattttag acccccaggg aaacagcctt cctggagcgt 5521 tgtctggagg
ttccagggac agggcagcct cccagagccg agcaagagct caaggtacaa 5581
atgagagatt tgctataccg tgagaagtca acaacttagc caccacttcc ccgcaatgga
5641 ccatgtaaca aatacctcag caggccctgc aaaaggccat gctagagctg
aggcgcacag 5701 cctgtggcct ctgtagttag ggcaggtggg atggagactc
cttgagtgca cacacctgag 5761 cctgcccaca cacaggggag cagcatctcg
tatgacgtct ggaaggaact tcggttgtgt 5821 aaagggagcc ttgaagatac
gtgcaaaagg tgctacccca atttggtgaa actgacattg 5881 ggcacgtctt
gggcttagga gaagcggccg atggtcccgg cctgcagtga caaacccccc 5941
tccccgcacc gcccccagca ccccctctcc tcttcacctc ttcctgctgg ccacgaggaa
6001 gccacttcct cagagagacc ctaccagatg cggatggaaa cagatgcacc
aaagcaagcc 6061 ctgatgaaac cgcgacttcc taaggtctgt ctcctctgaa
cttgcacctg ggcctctctg 6121 tgtttggttc caagcacttc ccacctcaaa
ctcccatttt caaaccactg tatctctgcg 6181 cacatctgct acttaccagc
cgcatacatg atggagggtt ttttggtcct gatccagtgg 6241 ccacacctgt
ctttgaaatg tctcactgaa ctccagtttt aaaatagatt cattgcttca 6301
acacagcaag cccaatgcac ccagctaaga ctggcttgac cgacagcctg gcctttggtg
6361 gggggcttcc tggggcctgg ggaaagctgg ccaccttcaa cagctggtac
ctcttcaaca 6421 gtgtggcctt tcaaaatgca gatgccacca ggagaacatg
cccacagctc accacctatg 6481 gatgccatgg ctctgggcag ctttcaaagc
aggttcctgt ggtctcctca gctgtttgag 6541 ggggtaacag caaatcagcc
tccattttaa aatgaaaaca ccagcctcca gatgtagggc 6601 ctgctgggtg
ttgctagccg ctggtcccca ggcacggtgc actttctcca cctcctgcag 6661
cctccctgtt gtttctagac tcttgcacct ggtgagtgca aggataggtg acccaggggc
6721 ctgcagcctt gtcctcagct cccatctcct ggactgccag cctcaccctc
tgcagttagc 6781 atggttggcc tgatgcaggg atcccgaggg attacttttt
agaccttctt tcacattcag 6841 aaaagtagta tagattcagg agaggcaaga
aaattatgct gtccatagaa gtcacccatg 6901 aagactgatg ccaccacctg
aaggctcatg attgttaaaa atgtccacgg gaacctctcg 6961 tccacaggag
gtttgtctca acacttccca tttttacggc attggcattg ccaagcatgg 7021
ggaagtatct gctcttctca tgttaaaagt ggcccagctt ttcttaactc agtccaagct
7081 gacttgttta gctgcactgg aatttcttac caaccaaata tttgcatcga
gcaaaggggg 7141 ctgtgtgcac ctccctaatg gcagcgatga tggctgctgt
cattcaagcc catcttcaga 7201 cgtcacagtc tggaagtgaa atgtccacaa
acatctgtgg cagaaaaggc tatacggacc 7261 acccagttgt gctgcagctt
tacagagcaa ggaagggttg tggcaaataa atgattaacc 7321 tgcctcgact
gtgctgaggg caacaaaggc catctcacca aaggattatt cgatgccatt 7381
aaatcatccc gtgaccttcc tgcttccgag tccatggcct ttgcccaggg catgtactcc
7441 cctgagaggc cttctgccta gaaagatcta tgactgggtt ccaaagttga
ggcctaggtt 7501 tttgctggga tttagatatt ttcaggcacc attttgacag
cattcaggaa aacggttatt 7561 gaccccatag actagggtaa gaataaaggc
aataaatttg gtctgactca gaatatagga 7621 gatccatata tttctctgga
aaccacagtg tacactaaaa tgtgaaattg aaggttttgt 7681 taaaaagaaa
aagataatga gcttcatgct ttgtttaatt acataatgat ttccattacg 7741
ctatttctgt gaaatgcagc aggttcttaa acgttatttc agtggcatgg gctggaagct
7801 tatcacaaaa agccatgtgt gtggccttat cagaacagaa agagacaggc
tggtgcccaa 7861 ggctgctgcc tgctccacct tttgccagct ctggacatct
gaggacgtcc cggcagatct 7921 ggaatggggc cctcaactga ccatttgctt
ctcagaattt cagtttgaga catgagaggt 7981 ataatcagtt acttttctcc
ccccagagaa acccttttgt gaggggagag gagctatggt 8041 atgtggttca
gctgaaacac atacaactgc atccttttgg agtcctttgc caacaaaaac 8101
agaccaacag accagatggt gtccatgttc aatatcatgt cttgatggac gcagctgatg
8161 acctcaaata cttgagtggt ctcatggctg ttagatggat tatttgaaaa
aaaaaaaaaa 8221 aaaagagaga aaaaataatt gatttttaca tcagagatag
caaactaaga cctggggagg 8281 ggggtcagct tttattttat tttatttttt
ttaagtttgc tagttgggtc aaatgtgagg 8341 aggagggagt ctacctgcca
cctcttctct tgcccctctt ctgcccacac atccagcatc 8401 caaaatccat
tcatttaatg aattgataaa gtgccgtgca aactggtgca caaacaggcc 8461
cccagtccac gcagcctggc tcctaggaaa agtggtgacc gggcgtgggg gggcatgccg
8521 cagccctggg acacagtcgg gcaccttccc cggaccccca ggccttggct
gtgcctcaag 8581 tcagagaggg tcagccttca ggccccggag acgagtgact
ggccgatcat ttcacaataa 8641 aatcactcac ttttggcaac ttcacttttt
ttaaggcaca gtcagttcct tttctcatgt 8701 acctcacaaa agatgaagac
catgtagtac tctttttggt aaagttacag tgttcatgtt 8761 aaatatcact
tttttctaca ttgtgtggta aaaagaacta cgttaatagc tatatcttaa 8821
atactgtgat ttgacttttt gaaaaatatc ctaatacaaa tattttacta acttacaatc
8881 actcatttaa taagaaacat ttggattctt ttgaaatcag tgttaattga
ctcatattct 8941 taaaagcctg gctcttgacc ctattggaaa cacaaaggaa
gctgaaatca aacatctaaa 9001 atacactgcg tacacgtgtg cgtgcacaca
cacacacaca cacacacaca cacagctctt 9061 catttctcct gagccatgca
gaatttactt tcaatgtgga aatctgttcc ctttaccaca 9121 ctgtatatgc
acagagcaca agagaggcta tctctagtca cttccaccag cgaggcctta 9181
gactccgtat tagaggccac cgatttcata caacagtgtt tcgctaaaga cccttcacta
9241 ttcttgttta gtaaatagct gtctgctctt cagggaactg ttacctatgg
gttattacca 9301 aagaacgctg gcaattggaa atgtcctgat ggaaattctt
tgcacgtgcc ggttctctgg 9361 catcctccag gtggcccaac ccaaagcaga
aagcagaaac cacagacccc gtgagtctcc 9421 ccataccttg tttccaataa
cttggcaaaa cttcttggtg catattggtt acaccctctg 9481 ggattcataa
tgccattagg ctaaaaccct aagagagagg gttgacagaa acacacgcga 9541
gaatgaggca gatcccagag caaggactgg gcccagactc tccacatgtg ctctactagt
9601 gagtgcctta tactctcagt attttggggc ttacagcttc ttatttgtgc
taaaaaggtg 9661 cagttccaaa gtaggaactg ccacacaggc cccagcatcc
tctctccaac ttcatacctc 9721 tctcctggtg gggggagcgg gcatccagga
cctccggaat caaggatgtg cagagaagag 9781 cgaaagtaat ttttctagtc
acatgaactg attggttcca ggcaattaga aaatggctat 9841 aaaataacct
taattttaaa aaaaaatctt gggtcttcgt tttcctatta ggagactgaa 9901
ctgaccacat gtattgattt atatcctgaa tatatgggaa cttctgtgtt tgggatgtcc
9961 tactgtaaga ctgatgaatg tacagagtta atttcagggt acagttttgc
cttaatggtt 10021 ttaaaaaata aactattttt taaaatttt SEQ ID NO:
.sub.----: NP_005027 1 mvdtesplcp lspleagdle splseeflqe mgniqeisqs
igedssgsfg fteyqylgsc 61 pgsdgsvitd tlspasspss vtypvvpgsv
despsgalni ecricgdkas gyhygvhace 121 gckgffrrti rlklvydkcd
rsckiqkknr nkcqycrfhk clsvgmshna irfgrmprse 181 kaklkaeilt
cehdiedset adlkslakri yeaylknfnm nkvkarvils gkasnnppfv 241
ihdmetlcma ektlvaklva ngiqnkeaev rifhccqcts vetvteltef akaipgfanl
301 dlndqvtllk ygvyeaifam lssvmnkdgm lvaygngfit reflkslrkp
fcdimepkfd 361 famkfnalel ddsdislfva aiiccgdrpg llnvghiekm
qegivhvlrl hlqsnhpddi 421 flfpkllqkm adlrqlvteh aqlvqiikkt
esdaalhpll qeiyrdmy SEQ ID NO:.sub.----: NM_015869 1 actgatgtct
tgactcatgg gtgtattcac aaattctgtt acttcaagtc tttttctttt 61
aacggattga tcttttgcta gatagagaca aaatatcagt gtgaattaca gcaaacccct
121 attccatgct gttatgggtg aaactctggg agattctcct attgacccag
aaagcgattc 181 cttcactgat acactgtctg caaacatatc acaagaaatg
accatggttg acacagagat 241 gccattctgg cccaccaact ttgggatcag
ctccgtggat ctctccgtaa tggaagacca 301 ctcccactcc tttgatatca
agcccttcac tactgttgac ttctccagca tttctactcc 361 acattacgaa
gacattccat tcacaagaac agatccagtg gttgcagatt acaagtatga 421
cctgaaactt caagagtacc aaagtgcaat caaagtggag cctgcatctc caccttatta
481 ttctgagaag actcagctct acaataagcc tcatgaagag ccttccaact
ccctcatggc 541 aattgaatgt cgtgtctgtg gagataaagc ttctggattt
cactatggag ttcatgcttg 601 tgaaggatgc aagggtttct tccggagaac
aatcagattg aagcttatct atgacagatg 661 tgatcttaac tgtcggatcc
acaaaaaaag tagaaataaa tgtcagtact gtcggtttca 721 gaaatgcctt
gcagtgggga tgtctcataa tgccatcagg tttgggcgga tgccacaggc 781
cgagaaggag aagctgttgg cggagatctc cagtgatatc gaccagctga atccagagtc
841 cgctgacctc cgggccctgg caaaacattt gtatgactca tacataaagt
ccttcccgct 901 gaccaaagca aaggcgaggg cgatcttgac aggaaagaca
acagacaaat caccattcgt 961 tatctatgac atgaattcct taatgatggg
agaagataaa atcaagttca aacacatcac 1021 ccccctgcag gagcagagca
aagaggtggc catccgcatc tttcagggct gccagtttcg 1081 ctccgtggag
gctgtgcagg agatcacaga gtatgccaaa agcattcctg gttttgtaaa 1141
tcttgacttg aacgaccaag taactctcct caaatatgga gtccacgaga tcatttacac
1201 aatgctggcc tccttgatga ataaagatgg ggttctcata tccgagggcc
aaggcttcat 1261 gacaagggag tttctaaaga gcctgcgaaa gccttttggt
gactttatgg agcccaagtt 1321 tgagtttgct gtgaagttca atgcactgga
attagatgac agcgacttgg caatatttat 1381 tgctgtcatt attctcagtg
gagaccgccc aggtttgctg aatgtgaagc ccattgaaga 1441 cattcaagac
aacctgctac aagccctgga gctccagctg aagctgaacc accctgagtc 1501
ctcacagctg tttgccaagc tgctccagaa aatgacagac ctcagacaga ttgtcacgga
1561 acacgtgcag ctactgcagg tgatcaagaa gacggagaca gacatgagtc
ttcacccgct 1621 cctgcaggag atctacaagg acttgtacta gcagagagtc
ctgagccact gccaacattt 1681 cccttcttcc agttgcacta ttctgaggga
aaatctgaca cctaagaaat ttactgtgaa 1741 aaagcatttt aaaaagaaaa
ggttttagaa tatgatctat tttatgcata ttgtttataa 1801 agacacattt
acaatttact tttaatatta aaaattacca tattatgaaa aaaaaaaaaa 1861 aaa SEQ
ID NO:.sub.----: NP_056953 1 mgetlgdspi dpesdsftdt lsanisqemt
mvdtempfwp tnfgissvdl svmedhshsf 61 dikpfttvdf ssistphyed
ipftrtdpvv adykydlklq eyqsaikvep asppyysekt 121 qlynkpheep
snslmaiecr vcgdkasgfh ygvhacegck gffrrtirlk liydrcdlnc 181
rihkksrnkc qycrfqkcla vgmshnairf grmpqaekek llaeissdid qlnpesadlr
241 alakhlydsy iksfpltkak arailtgktt dkspfviydm nslmmgedki
kfkhitplqe 301 qskevairif qgcqfrsvea vqeiteyaks ipgfvnldln
dqvtllkygv heiiytmlas 361 lmnkdgvlis egqgfmtref lkslrkpfgd
fmepkfefav kfnaleldds dlaifiavii 421 lsgdrpglln vkpiediqdn
llqaleiqlk lnhpessqlf akllqkmtdl rqivtehvql 481 lqvikktetd
mslhpllqei ykdly SEQ ID NO:.sub.----: NM_006238 1 gttttggcag
gagcgggaga attctgcgga gcctgcggga cggcggcggt ggcgccgtag 61
gcagccggga cagtgttgta cagtgttttg ggcatgcacg tgatactcac acagtggctt
121 ctgctcacca acagatgaag acagatgcac caacgagggt ctggaatggt
ctggagtggt 181 ctggaaagca gggtcagata cccctggaaa actgaagccc
gtggagcagt gatctctaca 241 ggactgcttc aaggctgatg ggaaccaccc
tgtagaggtc catctgcgtt cagacccaga 301 cgatgccaga gctatgactg
ggcctgcagg tgtggcgccg aggggagatc agccatggag 361 cagccacagg
aggaagcccc tgaggtccgg gaagaggagg agaaagagga agtggcagag 421
gcagaaggag ccccagagct caatggggga ccacagcatg cacttccttc cagcagctac
481 acagacctct cccggagctc ctcgccaccc tcactgctgg accaactgca
gatgggctgt 541 gacggggcct catgcggcag cctcaacatg gagtgccggg
tgtgcgggga caaggcatcg 601 ggcttccact acggtgttca tgcatgtgag
gggtgcaagg gcttcttccg tcgtacgatc 661 cgcatgaagc tggagtacga
gaagtgtgag cgcagctgca agattcagaa gaagaaccgc 721 aacaagtgcc
agtactgccg cttccagaag tgcctggcac tgggcatgtc acacaacgct 781
atccgttttg gtcggatgcc ggaggctgag aagaggaagc tggtggcagg gctgactgca
841 aacgagggga gccagtacaa cccacaggtg gccgacctga aggccttctc
caagcacatc 901 tacaatgcct acctgaaaaa cttcaacatg accaaaaaga
aggcccgcag catcctcacc 961 ggcaaagcca gccacacggc gccctttgtg
atccacgaca tcgagacatt gtggcaggca 1021 gagaaggggc tggtgtggaa
gcagttggtg aatggcctgc ctccctacaa ggagatcagc 1081 gtgcacgtct
tctaccgctg ccagtgcacc acagtggaga ccgtgcggga gctcactgag 1141
ttcgccaaga gcatccccag cttcagcagc ctcttcctca acgaccaggt tacccttctc
1201 aagtatggcg tgcacgaggc catcttcgcc atgctggcct ctatcgtcaa
caaggacggg 1261 ctgctggtag ccaacggcag tggctttgtc acccgtgagt
tcctgcgcag cctccgcaaa
1321 cccttcagtg atatcattga gcctaagttt gaatttgctg tcaagttcaa
cgccctggaa 1381 cttgatgaca gtgacctggc cctattcatt gcggccatca
ttctgtgtgg agaccggcca 1441 ggcctcatga acgttccacg ggtggaggct
atccaggaca ccatcctgcg tgccctcgaa 1501 ttccacctgc aggccaacca
ccctgatgcc cagtacctct tccccaagct gctgcagaag 1561 atggctgacc
tgcggcaact ggtcaccgag cacgcccaga tgatgcagcg gatcaagaag 1621
accgaaaccg agacctcgct gcaccctctg ctccaggaga tctacaagga catgtactaa
1681 cggcggcacc caggcctccc tgcagactcc aatggggcca gcactggagg
ggcccaccca 1741 catgactttt ccattgacca gctctcttcc tgtctttgtt
gtctccctct ttctcagttc 1801 ctctttcttt tctaattcct gttgctctgt
ttcttccttt ctgtaggttt ctctcttccc 1861 ttctcccttg ccctcccttt
ctctctccac cccccacgtc tgtcctcctt tcttattctg 1921 tgagatgttt
tgtattattt caccagcagc atagaacagg acctctgctt ttgcacacct 1981
tttccccagg agcagaagag agtggggcct gccctctgcc ccatcattgc acctgcaggc
2041 ttaggtcctc acttctgtct cctgtcttca gagcaaaaga cttgagccat
ccaaagaaac 2101 actaagctct ctgggcctgg gttccaggga aggctaagca
tggcctggac tgactgcagc 2161 cccctatagt catggggtcc ctgctgcaaa
ggacagtggg caggaggccc caggctgaga 2221 gccagatgcc tccccaagac
tgtcattgcc cctccgatgc tgaggccacc cactgaccca 2281 actgatcctg
ctccagcagc acacctcagc cccactgaca cccagtgtcc ttccatcttc 2341
acactggttt gccaggccaa tgttgctgat ggcccctcca gcacacacac ataagcactg
2401 aaatcacttt acctgcaggc tccatgcacc tcccttccct ccctgaggca
ggtgagaacc 2461 cagagagagg ggcctgcagg tgagcaggca gggctgggcc
aggtctccgg ggaggcaggg 2521 gtcctgcagg tcctggtggg tcagcccagc
acctgctccc agtgggagct tcccgggata 2581 aactgagcct gttcattctg
atgtccattt gtcccaatag ctctactgcc ctccccttcc 2641 cctttactca
gcccagctgg ccacctagaa gtctccctgc acagcctcta gtgtccgggg 2701
accttgtggg accagtccca caccgctggt ccctgccctc ccctgctccc aggttgaggt
2761 gcgctcacct cagagcaggg ccaaagcaca gctgggcatg ccatgtctga
gcggcgcaga 2821 gccctccagg cctgcagggg caaggggctg gctggagtct
cagagcacag aggtaggaga 2881 actggggttc aagcccaggc ttcctgggtc
ctgcctggtc ctccctccca aggagccatt 2941 ctgtgtgtga ctctgggtgg
aagtgcccag cccctgcccc tacgggcgct gcagcctccc 3001 ttccatgccc
caggatcact ctctgctggc aggattcttc ccgctcccca cctacccagc 3061
tgatgggggt tggggtgctt cctttcaggc caaggctatg aagggacagc tgctgggacc
3121 cacctccccc tccccggcca catgccgcgt ccctgccccg acccgggtct
ggtgctgagg 3181 atacagctct tctcagtgtc tgaacaatct ccaaaattga
aatgtatatt tttgctagga 3241 gccccagctt cctgtgtttt taatataaat
agtgtacaca gactgacgaa actttaaata 3301 aatgggaatt aaatatttaa
aaaaaaaa SEQ ID NO:.sub.----: NP_006229 1 meqpqeeape vreeeekeev
aeaegapeln ggpqhalpss sytdlsrsss ppslldqlqm 61 gcdgascgsl
nmecrvcgdk asgfhygvha cegckgffrr tirmkleyek cersckiqkk 121
nrnkcqycrf qkclalgmsh nairfgrmpe aekrklvagl tanegsqynp qvadlkafsk
181 hiynaylknf nmtkkkarsi ltgkashtap fvihdietlw qaekglvwkq
lvnglppyke 241 isvhvfyrcq cttvetvrel tefaksipsf sslflndqvt
llkygvheai famlasivnk 301 dgllvangsg fvtreflrsl rkpfsdiiep
kfefavktna lelddsdlal fiaaiilcgd 361 rpglmnvprv eaiqdtilra
lefhlqanhp daqylfpkll qkmadlrqlv tehaqmmqri 421 kktetetslh
pllqeiykdm y
[0347]
Sequence CWU 1
1
13 1 1014 DNA Artificial Sequence Description of Artificial
Sequence Synthetic nucleotide construct 1 taatacgact cactataggg
gaattgtgag cggataacaa ttcccctcta gaaataattt 60 tgtttaactt
taagaaggag atatacc atg ggc agc agc cat cat cat cat cat 114 Met Gly
Ser Ser His His His His His 1 5 cac agc agc ggc ctg gtg ccg cgc ggc
agc cat atg gaa act gca gat 162 His Ser Ser Gly Leu Val Pro Arg Gly
Ser His Met Glu Thr Ala Asp 10 15 20 25 ctc aaa tct ctg gcc aag aga
atc tac gag gcc tac ttg aag aac ttc 210 Leu Lys Ser Leu Ala Lys Arg
Ile Tyr Glu Ala Tyr Leu Lys Asn Phe 30 35 40 aac atg aac aag gtc
aaa gcc cgg gtc atc ctc tca gga aag gcc agt 258 Asn Met Asn Lys Val
Lys Ala Arg Val Ile Leu Ser Gly Lys Ala Ser 45 50 55 aac aat cca
cct ttt gtc ata cat gat atg gag aca ctg tgt atg gct 306 Asn Asn Pro
Pro Phe Val Ile His Asp Met Glu Thr Leu Cys Met Ala 60 65 70 gag
aag acg ctg gtg gcc aag ctg gtg gcc aat ggc atc cag aac aag 354 Glu
Lys Thr Leu Val Ala Lys Leu Val Ala Asn Gly Ile Gln Asn Lys 75 80
85 gag gcg gag gtc cgc atc ttt cac tgc tgc cag tgc acg tca gtg gag
402 Glu Ala Glu Val Arg Ile Phe His Cys Cys Gln Cys Thr Ser Val Glu
90 95 100 105 acc gtc acg gag ctc acg gaa ttc gcc aag gcc atc cca
ggc ttc gca 450 Thr Val Thr Glu Leu Thr Glu Phe Ala Lys Ala Ile Pro
Gly Phe Ala 110 115 120 aac ttg gac ctg aac gat caa gtg aca ttg cta
aaa tac gga gtt tat 498 Asn Leu Asp Leu Asn Asp Gln Val Thr Leu Leu
Lys Tyr Gly Val Tyr 125 130 135 gag gcc ata ttc gcc atg ctg tct tct
gtg atg aac aaa gac ggg atg 546 Glu Ala Ile Phe Ala Met Leu Ser Ser
Val Met Asn Lys Asp Gly Met 140 145 150 ctg gta gcg tat gga aat ggg
ttt ata act cgt gaa ttc cta aaa agc 594 Leu Val Ala Tyr Gly Asn Gly
Phe Ile Thr Arg Glu Phe Leu Lys Ser 155 160 165 cta agg aaa ccg ttc
tgt gat atc atg gaa ccc aag ttt gat ttt gcc 642 Leu Arg Lys Pro Phe
Cys Asp Ile Met Glu Pro Lys Phe Asp Phe Ala 170 175 180 185 atg aag
ttc aat gca ctg gaa ctg gat gac agt gat atc tcc ctt ttt 690 Met Lys
Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp Ile Ser Leu Phe 190 195 200
gtg gct gct atc att tgc tgt gga gat cgt cct ggc ctt cta aac gta 738
Val Ala Ala Ile Ile Cys Cys Gly Asp Arg Pro Gly Leu Leu Asn Val 205
210 215 gga cac att gaa aaa atg cag gag ggt att gta cat gtg ctc aga
ctc 786 Gly His Ile Glu Lys Met Gln Glu Gly Ile Val His Val Leu Arg
Leu 220 225 230 cac ctg cag agc aac cac ccg gac gat atc ttt ctc ttc
cca aaa ctt 834 His Leu Gln Ser Asn His Pro Asp Asp Ile Phe Leu Phe
Pro Lys Leu 235 240 245 ctt caa aaa atg gca gac ctc cgg cag ctg gtg
acg gag cat gcg cag 882 Leu Gln Lys Met Ala Asp Leu Arg Gln Leu Val
Thr Glu His Ala Gln 250 255 260 265 ctg gtg cag atc atc aag aag acg
gag tcg gat gct gcg ctg cac ccg 930 Leu Val Gln Ile Ile Lys Lys Thr
Glu Ser Asp Ala Ala Leu His Pro 270 275 280 cta ctg cag gag atc tac
agg gac atg tac tgagtcgaca agcttgcggc 980 Leu Leu Gln Glu Ile Tyr
Arg Asp Met Tyr 285 290 cgcactcgag caccaccacc accaccactg agat 1014
2 291 PRT Artificial Sequence Description of Artificial Sequence
Synthetic peptide construct 2 Met Gly Ser Ser His His His His His
His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Glu Thr
Ala Asp Leu Lys Ser Leu Ala Lys Arg 20 25 30 Ile Tyr Glu Ala Tyr
Leu Lys Asn Phe Asn Met Asn Lys Val Lys Ala 35 40 45 Arg Val Ile
Leu Ser Gly Lys Ala Ser Asn Asn Pro Pro Phe Val Ile 50 55 60 His
Asp Met Glu Thr Leu Cys Met Ala Glu Lys Thr Leu Val Ala Lys 65 70
75 80 Leu Val Ala Asn Gly Ile Gln Asn Lys Glu Ala Glu Val Arg Ile
Phe 85 90 95 His Cys Cys Gln Cys Thr Ser Val Glu Thr Val Thr Glu
Leu Thr Glu 100 105 110 Phe Ala Lys Ala Ile Pro Gly Phe Ala Asn Leu
Asp Leu Asn Asp Gln 115 120 125 Val Thr Leu Leu Lys Tyr Gly Val Tyr
Glu Ala Ile Phe Ala Met Leu 130 135 140 Ser Ser Val Met Asn Lys Asp
Gly Met Leu Val Ala Tyr Gly Asn Gly 145 150 155 160 Phe Ile Thr Arg
Glu Phe Leu Lys Ser Leu Arg Lys Pro Phe Cys Asp 165 170 175 Ile Met
Glu Pro Lys Phe Asp Phe Ala Met Lys Phe Asn Ala Leu Glu 180 185 190
Leu Asp Asp Ser Asp Ile Ser Leu Phe Val Ala Ala Ile Ile Cys Cys 195
200 205 Gly Asp Arg Pro Gly Leu Leu Asn Val Gly His Ile Glu Lys Met
Gln 210 215 220 Glu Gly Ile Val His Val Leu Arg Leu His Leu Gln Ser
Asn His Pro 225 230 235 240 Asp Asp Ile Phe Leu Phe Pro Lys Leu Leu
Gln Lys Met Ala Asp Leu 245 250 255 Arg Gln Leu Val Thr Glu His Ala
Gln Leu Val Gln Ile Ile Lys Lys 260 265 270 Thr Glu Ser Asp Ala Ala
Leu His Pro Leu Leu Gln Glu Ile Tyr Arg 275 280 285 Asp Met Tyr 290
3 33 DNA Artificial Sequence Description of Artificial Sequence
Synthetic primer 3 gctgacacat atggaaactg cagatctcaa atc 33 4 32 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
primer 4 gtgactgtcg actcagtaca tgtccctgta ga 32 5 1017 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
nucleotide construct 5 taatacgact cactataggg gaattgtgag cggataacaa
ttcccctcta gaaataattt 60 tgtttaactt taagaaggag atatacc atg ggc agc
agc cat cat cat cat cat 114 Met Gly Ser Ser His His His His His 1 5
cac agc agc ggc ctg gtg ccg cgc ggc agc cat atg gag tcc gct gac 162
His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Glu Ser Ala Asp 10
15 20 25 ctc cgg gcc ctg gca aaa cat ttg tat gac tca tac ata aag
tcc ttc 210 Leu Arg Ala Leu Ala Lys His Leu Tyr Asp Ser Tyr Ile Lys
Ser Phe 30 35 40 ccg ctg acc aaa gca aag gcg agg gcg atc ttg aca
gga aag aca aca 258 Pro Leu Thr Lys Ala Lys Ala Arg Ala Ile Leu Thr
Gly Lys Thr Thr 45 50 55 gac aaa tca cca ttc gtt atc tat gac atg
aat tcc tta atg atg gga 306 Asp Lys Ser Pro Phe Val Ile Tyr Asp Met
Asn Ser Leu Met Met Gly 60 65 70 gaa gat aaa atc aag ttc aaa cac
atc acc ccc ctg cag gag cag agc 354 Glu Asp Lys Ile Lys Phe Lys His
Ile Thr Pro Leu Gln Glu Gln Ser 75 80 85 aaa gag gtg gcc atc cgc
atc ttt cag ggc tgc cag ttt cgc tcc gtg 402 Lys Glu Val Ala Ile Arg
Ile Phe Gln Gly Cys Gln Phe Arg Ser Val 90 95 100 105 gag gct gtg
cag gag atc aca gag tat gcc aaa agc att cct ggt ttt 450 Glu Ala Val
Gln Glu Ile Thr Glu Tyr Ala Lys Ser Ile Pro Gly Phe 110 115 120 gta
aat ctt gac ttg aac gac caa gta act ctc ctc aaa tat gga gtc 498 Val
Asn Leu Asp Leu Asn Asp Gln Val Thr Leu Leu Lys Tyr Gly Val 125 130
135 cac gag atc att tac aca atg ctg gcc tcc ttg atg aat aaa gat ggg
546 His Glu Ile Ile Tyr Thr Met Leu Ala Ser Leu Met Asn Lys Asp Gly
140 145 150 gtt ctc ata tcc gag ggc caa ggc ttc atg aca agg gag ttt
cta aag 594 Val Leu Ile Ser Glu Gly Gln Gly Phe Met Thr Arg Glu Phe
Leu Lys 155 160 165 agc ctg cga aag cct ttt ggt gac ttt atg gag ccc
aag ttt gag ttt 642 Ser Leu Arg Lys Pro Phe Gly Asp Phe Met Glu Pro
Lys Phe Glu Phe 170 175 180 185 gct gtg aag ttc aat gca ctg gaa tta
gat gac agc gac ttg gca ata 690 Ala Val Lys Phe Asn Ala Leu Glu Leu
Asp Asp Ser Asp Leu Ala Ile 190 195 200 ttt att gct gtc att att ctc
agt gga gac cgc cca ggt ttg ctg aat 738 Phe Ile Ala Val Ile Ile Leu
Ser Gly Asp Arg Pro Gly Leu Leu Asn 205 210 215 gtg aag ccc att gaa
gac att caa gac aac ctg cta caa gcc ctg gag 786 Val Lys Pro Ile Glu
Asp Ile Gln Asp Asn Leu Leu Gln Ala Leu Glu 220 225 230 ctc cag ctg
aag ctg aac cac cct gag tcc tca cag ctg ttt gcc aag 834 Leu Gln Leu
Lys Leu Asn His Pro Glu Ser Ser Gln Leu Phe Ala Lys 235 240 245 ctg
ctc cag aaa atg aca gac ctc aga cag att gtc acg gaa cat gtg 882 Leu
Leu Gln Lys Met Thr Asp Leu Arg Gln Ile Val Thr Glu His Val 250 255
260 265 cag cta ctg cag gtg atc aag aag acg gag aca gac atg agt ctt
cac 930 Gln Leu Leu Gln Val Ile Lys Lys Thr Glu Thr Asp Met Ser Leu
His 270 275 280 ccg ctc ctg cag gag atc tac aag gac ttg tac
taggtcgaca agcttgcggc 983 Pro Leu Leu Gln Glu Ile Tyr Lys Asp Leu
Tyr 285 290 cgcactcgag caccaccacc accaccactg agat 1017 6 292 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
peptide construct 6 Met Gly Ser Ser His His His His His His Ser Ser
Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Glu Ser Ala Asp Leu
Arg Ala Leu Ala Lys His 20 25 30 Leu Tyr Asp Ser Tyr Ile Lys Ser
Phe Pro Leu Thr Lys Ala Lys Ala 35 40 45 Arg Ala Ile Leu Thr Gly
Lys Thr Thr Asp Lys Ser Pro Phe Val Ile 50 55 60 Tyr Asp Met Asn
Ser Leu Met Met Gly Glu Asp Lys Ile Lys Phe Lys 65 70 75 80 His Ile
Thr Pro Leu Gln Glu Gln Ser Lys Glu Val Ala Ile Arg Ile 85 90 95
Phe Gln Gly Cys Gln Phe Arg Ser Val Glu Ala Val Gln Glu Ile Thr 100
105 110 Glu Tyr Ala Lys Ser Ile Pro Gly Phe Val Asn Leu Asp Leu Asn
Asp 115 120 125 Gln Val Thr Leu Leu Lys Tyr Gly Val His Glu Ile Ile
Tyr Thr Met 130 135 140 Leu Ala Ser Leu Met Asn Lys Asp Gly Val Leu
Ile Ser Glu Gly Gln 145 150 155 160 Gly Phe Met Thr Arg Glu Phe Leu
Lys Ser Leu Arg Lys Pro Phe Gly 165 170 175 Asp Phe Met Glu Pro Lys
Phe Glu Phe Ala Val Lys Phe Asn Ala Leu 180 185 190 Glu Leu Asp Asp
Ser Asp Leu Ala Ile Phe Ile Ala Val Ile Ile Leu 195 200 205 Ser Gly
Asp Arg Pro Gly Leu Leu Asn Val Lys Pro Ile Glu Asp Ile 210 215 220
Gln Asp Asn Leu Leu Gln Ala Leu Glu Leu Gln Leu Lys Leu Asn His 225
230 235 240 Pro Glu Ser Ser Gln Leu Phe Ala Lys Leu Leu Gln Lys Met
Thr Asp 245 250 255 Leu Arg Gln Ile Val Thr Glu His Val Gln Leu Leu
Gln Val Ile Lys 260 265 270 Lys Thr Glu Thr Asp Met Ser Leu His Pro
Leu Leu Gln Glu Ile Tyr 275 280 285 Lys Asp Leu Tyr 290 7 33 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
primer 7 gctcagacat atggagtccg ctgacctccg ggc 33 8 32 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
primer 8 gtgactgtcg acctagtaca agtccttgta ga 32 9 1089 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
nucleotide construct 9 taatacgact cactataggg gaattgtgag cggataacaa
ttcccctcta gaaataattt 60 tgtttaactt taagaaggag atatacc atg aaa aaa
ggt cac cac cat cac cat 114 Met Lys Lys Gly His His His His His 1 5
cac gga tcc cag tac aac cca cag gtg gcc gac ctg aag gcc ttc tcc 162
His Gly Ser Gln Tyr Asn Pro Gln Val Ala Asp Leu Lys Ala Phe Ser 10
15 20 25 aag cac atc tac aat gcc tac ctg aaa aac ttc aac atg acc
aaa aag 210 Lys His Ile Tyr Asn Ala Tyr Leu Lys Asn Phe Asn Met Thr
Lys Lys 30 35 40 aag gcc cgc agc atc ctc acc ggc aaa gcc agc cac
acg gcg ccc ttt 258 Lys Ala Arg Ser Ile Leu Thr Gly Lys Ala Ser His
Thr Ala Pro Phe 45 50 55 gtg atc cac gac atc gag aca ttg tgg cag
gca gag aag ggg ctg gtg 306 Val Ile His Asp Ile Glu Thr Leu Trp Gln
Ala Glu Lys Gly Leu Val 60 65 70 tgg aag cag ttg gtg aat ggc ctg
cct ccc tac aag gag atc agc gtg 354 Trp Lys Gln Leu Val Asn Gly Leu
Pro Pro Tyr Lys Glu Ile Ser Val 75 80 85 cac gtc ttc tac cgc tgc
cag tgc acc aca gtg gag acc gtg cgg gag 402 His Val Phe Tyr Arg Cys
Gln Cys Thr Thr Val Glu Thr Val Arg Glu 90 95 100 105 ctc act gag
ttc gcc aag agc atc ccc agc ttc agc agc ctc ttc ctc 450 Leu Thr Glu
Phe Ala Lys Ser Ile Pro Ser Phe Ser Ser Leu Phe Leu 110 115 120 aac
gac cag gtt acc ctt ctc aag tat ggc gtg cac gag gcc atc ttc 498 Asn
Asp Gln Val Thr Leu Leu Lys Tyr Gly Val His Glu Ala Ile Phe 125 130
135 gcc atg ctg gcc tct atc gtc aac aag gac ggg ctg ctg gta gcc aac
546 Ala Met Leu Ala Ser Ile Val Asn Lys Asp Gly Leu Leu Val Ala Asn
140 145 150 ggc agt ggc ttt gtc acc cgt gag ttc ctg cgc agc ctc cgc
aaa ccc 594 Gly Ser Gly Phe Val Thr Arg Glu Phe Leu Arg Ser Leu Arg
Lys Pro 155 160 165 ttc agt gat atc att gag cct aag ttt gaa ttt gct
gtc aag ttc aac 642 Phe Ser Asp Ile Ile Glu Pro Lys Phe Glu Phe Ala
Val Lys Phe Asn 170 175 180 185 gcc ctg gaa ctt gat gac agt gac ctg
gcc cta ttc att gcg gcc atc 690 Ala Leu Glu Leu Asp Asp Ser Asp Leu
Ala Leu Phe Ile Ala Ala Ile 190 195 200 att ctg tgt gga gac cgg cca
ggc ctc atg aac gtt cca cgg gtg gag 738 Ile Leu Cys Gly Asp Arg Pro
Gly Leu Met Asn Val Pro Arg Val Glu 205 210 215 gct atc cag gac acc
atc ctg cgt gcc ctc gaa ttc cac ctg cag gcc 786 Ala Ile Gln Asp Thr
Ile Leu Arg Ala Leu Glu Phe His Leu Gln Ala 220 225 230 aac cac cct
gat gcc cag tac ctc ttc ccc aag ctg ctg cag aag atg 834 Asn His Pro
Asp Ala Gln Tyr Leu Phe Pro Lys Leu Leu Gln Lys Met 235 240 245 gct
gac ctg cgg caa ctg gtc acc gag cac gcc cag atg atg cag cgg 882 Ala
Asp Leu Arg Gln Leu Val Thr Glu His Ala Gln Met Met Gln Arg 250 255
260 265 atc aag aag acc gaa acc gag acc tcg ctg cac cct ctg ctc cag
gag 930 Ile Lys Lys Thr Glu Thr Glu Thr Ser Leu His Pro Leu Leu Gln
Glu 270 275 280 atc tac aag gac atg tac taagtcgacc accaccacca
ccaccactga 978 Ile Tyr Lys Asp Met Tyr 285 gatccggctg gccctactgg
ccgaaaggaa ttcgaggcca gcagggccac cgctgagcaa 1038 taactagcat
aaccccttgg ggcctctaaa cgggtcttga ggggtttttt g 1089 10 287 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
peptide construct 10 Met Lys Lys Gly His His His His His His Gly
Ser Gln Tyr Asn Pro 1 5 10 15 Gln Val Ala Asp Leu Lys Ala Phe Ser
Lys His Ile Tyr Asn Ala Tyr 20 25 30 Leu Lys Asn Phe Asn Met Thr
Lys Lys Lys Ala Arg Ser Ile Leu Thr 35 40 45 Gly Lys Ala Ser His
Thr Ala Pro Phe Val Ile His Asp Ile Glu Thr 50 55 60 Leu Trp Gln
Ala Glu Lys Gly Leu Val Trp Lys Gln Leu Val Asn Gly 65 70 75 80 Leu
Pro Pro Tyr Lys Glu Ile Ser Val His Val Phe Tyr Arg Cys Gln 85 90
95 Cys Thr Thr Val Glu Thr Val Arg Glu Leu Thr Glu Phe Ala Lys Ser
100 105 110 Ile Pro Ser Phe Ser Ser Leu Phe Leu Asn Asp Gln Val Thr
Leu Leu 115 120 125 Lys Tyr Gly Val His Glu Ala Ile Phe Ala Met Leu
Ala Ser Ile Val 130 135 140 Asn Lys Asp Gly Leu Leu Val Ala Asn Gly
Ser Gly Phe Val Thr Arg 145 150 155 160 Glu Phe Leu Arg Ser Leu Arg
Lys Pro Phe Ser Asp Ile Ile Glu Pro 165
170 175 Lys Phe Glu Phe Ala Val Lys Phe Asn Ala Leu Glu Leu Asp Asp
Ser 180 185 190 Asp Leu Ala Leu Phe Ile Ala Ala Ile Ile Leu Cys Gly
Asp Arg Pro 195 200 205 Gly Leu Met Asn Val Pro Arg Val Glu Ala Ile
Gln Asp Thr Ile Leu 210 215 220 Arg Ala Leu Glu Phe His Leu Gln Ala
Asn His Pro Asp Ala Gln Tyr 225 230 235 240 Leu Phe Pro Lys Leu Leu
Gln Lys Met Ala Asp Leu Arg Gln Leu Val 245 250 255 Thr Glu His Ala
Gln Met Met Gln Arg Ile Lys Lys Thr Glu Thr Glu 260 265 270 Thr Ser
Leu His Pro Leu Leu Gln Glu Ile Tyr Lys Asp Met Tyr 275 280 285 11
29 DNA Artificial Sequence Description of Artificial Sequence
Synthetic primer 11 gttggatccc agtacaaccc acaggtggc 29 12 32 DNA
Artificial Sequence Description of Artificial Sequence Synthetic
primer 12 gtgactgtcg acttagtaca tgtccttgta ga 32 13 25 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
peptide 13 Asp Gly Thr Pro Pro Pro Gln Glu Ala Glu Glu Pro Ser Leu
Leu Lys 1 5 10 15 Lys Leu Leu Leu Ala Pro Ala Asn Thr 20 25
* * * * *